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Abstract  
The accruing data linking the gut microbiota to the development and function of the 
central nervous system has been proposed as a paradigm shift in neuroscience. 
Neuroimmune, neuroendocrine and neural communication pathways exist between host 
and microbe. These pathways are components of the brain-gut-microbiota axis and 
preclinical evidence suggests that the microbiota can recruit this bidirectional 
communication system to modulate brain development, function and behaviour. 
Dysfunctional neuro-immune and neuro-endocrine pathways are implicated in stress-
related psychiatric disorders. To this end, we proposed that the gut microbiota, by 
modulating these pathways, plays an influential role in the pathophysiology of 
depression.  
 
We demonstrated that depression is associated with altered gut microbiota composition 
with decreased richness and diversity. Furthermore, we have shown that transferring the 
gut microbiota from depressed patients to microbiota-depleted rats can induce 
behavioural and physiological features characteristic of depression in the recipient 
animals, including anhedonia and anxiety-like behaviours, as well as alterations in 
tryptophan metabolism. Although we provide evidence that the gut microbiota is altered 
in depression and that this alteration could have a role in prominent features of 
depression, an interventional study based on targeting the gut microbiota in healthy males 
using Lactobacillus rhamnosus (JB-1) was not superior to placebo in modifying self-
reported stress, HPA axis response to an acute stressor, inflammation, cognition or 
neurophysiological measures. 
 
Taken together, these findings have furthered our understanding of the pathophysiology 
of depression. By incorporating the gut microbiota into existing neurobiological models 
of depression a more comprehensive model has been developed. The successful 
translation of this work could lead to stratification based on gut microbiome composition 
and could deliver further diagnostic accuracy to improve patient phenotyping for 
treatment selection in future studies in psychiatric populations.  
 
Furthermore, our findings advance the possibility of targeting the gut microbiome in the 
treatment and prevention of stress related disorders and offer an important future strategy 
in psychiatry. 
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Chapter 1: General Introduction 
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1.1 Epidemiology of Depression  
Depression is a complex, heterogeneous disorder, which accounts for almost 10% of all 
medical disability, making it the leading cause of medical disability in the United States 
and Canada, with an economic burden estimated at $210.5 billion dollars (Greenberg et 
al., 2015, WHO, 2008). In Europe, the economic cost of depression corresponds to 
approximately 1% of the total economy (Sobocki et al., 2006). Worldwide, depressive 
spectrum disorders affect 121 million people and by 2020, the WHO has predicted that 
depression will be second only to cardiovascular disease as the leading causes of total 
disease burden worldwide, measured by disability adjusted life years (Whiteford et al., 
2015, WHO, 2008).  
 
20% of women and 15% of men suffer at least one episode of depression during their 
lifetime (Hirschfeld, 2012, Kessler et al., 2007) and studies indicate that the prevalence 
of depression may be increasing, with an increased lifetime risk for younger cohorts 
(Andrade et al., 2003, Hidaka, 2012). Of those that develop a depressive episode 50% 
will have another episode (Eaton et al., 2008) and the risk of recurrence increases with 
residual symptoms (Nierenberg et al., 2010) and with longer, more frequent, (1985, 
Kessing and Andersen, 2005) and more severe episodes (Kessing, 2004). A large 
(N=7076) prospective epidemiological survey, The Netherlands Mental Health Survey 
and Incidence Study (NEMESIS), found that 50% of depressed participants recovered 
within 3 months, 63% within 6 months, 76% within 12 months, whereas 20% did not 
recover at 24 months (Spijker et al., 2002).  
 
The median age of onset of depression is approximately 30 years (Kessler et al., 2005), 
though up to 50% have had depressive symptoms prior to the identified episode (Horwath 
et al., 1992). The median duration of a depressive episode is approximately 3 months 
(Eaton et al., 2008, Spijker et al., 2002). On average those with a history of depression 
will have on average 5 to 9 episodes (Kessler and Walters, 1998, Kessler et al., 1997). 
The prevalence of depression declines in the community dwelling elderly (>65years) 
(Blazer and Hybels, 2005) and this decline does not appear to be due to increased 
confounding with physical disorders (Kessler et al., 2010). However, not all studies are 
consistent (Forlani et al., 2013).  
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Epidemiological studies have consistently demonstrated a higher lifetime prevalence of 
depression in women. Women have a higher lifetime prevalence of depression in high, 
middle and low income countries (WHO, 2008) and this higher prevalence is due to high 
risk of first onset of depression and not to persistence or recurrence (Kessler, 2003). The 
higher prevalence is not limited to depression, as women have higher rates of other stress-
related disorders (Weich et al., 2001). The higher rates of depression and anxiety in 
women have implications for future generations as maternal depression has negative 
effects on perinatal outcomes (Grigoriadis et al., 2013). Indeed, preclinical studies 
indicate that maternal stress can be transferred to the next generation by a number of 
mechanisms, including epigenetic modification (Franklin et al., 2010, Pena et al., 2013).  
 
However, it is interesting to note that women and men experience depression differently 
(Addis, 2008). Men are more likely to react with anger or self-destructive behaviour, and 
engage in substance abuse with lower levels of impulse control compared to women 
(Winkler et al., 2005). In a secondary analysis of the National Comorbidity Survey 
Replication (Kessler et al., 2003), men reported higher rates of anger, aggression, 
substance use and risk taking compared to women and when this is taken into account 
men and women met criteria for depression in equal proportions 30.6% men and 33.3% 
of women (Martin et al., 2013). 
 
1.2 Symptoms and Classification of Depression 
The DSM-5 criteria for Major Depressive Disorder (MDD) requires, at least 5 of the 
following 9 symptoms, present nearly every day for more than two weeks; depressed 
mood or irritable most of the day, nearly every day, as indicated by either subjective 
report (e.g., feels sad or empty) or observation made by others (e.g., appears tearful), 
decreased interest or pleasure (anhedonia) in most activities, most of each day, significant 
weight change (5%) or change in appetite, change in sleep: insomnia or hypersomnia, 
change in activity: psychomotor agitation or retardation, fatigue or loss of energy, 
guilt/worthlessness: feelings of worthlessness or excessive or inappropriate guilt, 
concentration: diminished ability to think or concentrate, or more indecisiveness, 
suicidality: thoughts of death or suicide, or suicide plan. Mood must represent a change 
from the person's baseline and impair social and occupational/educational function 
(American Psychiatric Association, 2013).  
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The current classification systems separate depression into several categorical subtypes 
including; melancholic, atypical, psychotic, postpartum, and seasonal affective disorder. 
The melancholic subtype is defined as lacking mood reactivity and loss of pleasure with 
at least three of the following: distinct quality of mood, mood worsening in the morning, 
early morning awakening, psychomotor retardation, significant anorexia or weight loss, 
and excessive or inappropriate guilt. The atypical subtype is defined as having mood 
reactivity and at least two of the following: hyperphagia, hypersomnia, leaden paralysis, 
and a longstanding pattern of interpersonal rejection sensitivity (American Psychiatric 
Association, 2013). 
 
1.3 Health implications of Depression  
The adverse consequences of depression are well established, and broadly encompass 
psychiatric and medical co-morbidities. Apart from the negative subjective experience 
and functional disability, chronic or recurrent depression results in an increased mortality 
rate (relative risk =1.5) (Osby et al., 2001). The lifetime completed suicide rate for men 
is 7% and 1% for women (Blair-West et al., 1999, Nordentoft et al., 2011). Depression 
is highly co-morbid with other psychiatric disorders. Nearly half of those meeting 
lifetime criteria for depression also have met criteria for a comorbid anxiety disorder 
(Kessler et al., 2008, Kessler et al., 1996, Regier et al., 1998, Shalev et al., 1998) and 
20% of those with depression have a co-morbid substance use disorder (Conway et al., 
2006, Grant et al., 2004). 
 
1.3.1 Cardiovascular disease  
Depression worsens the prognosis of medical co-morbidities such as cardiovascular 
disease (CVD), diabetes and obesity. Depression is an independent risk factor for cardiac 
morbidity and mortality (Larsen et al., 2013, Versteeg et al., 2013) and the prevalence of 
depression in cardiac disease is 15 – 20% (Celano and Huffman, 2011). The relationship 
between CVD and depression is bidirectional, as depression can increase the risk of CVD 
and CVD can increase the risk of depression (Plante, 2005). Although a direct causal link 
between depression and CVD has not been established, the aetiology is likely to be 
multifactorial, and involves the interaction of the autonomic nervous system, the 
neuroimmune, the neuroendocrine and the vascular systems.  
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Depression is associated with over activity of the Hypothalamic Pituitary Adrenal (HPA) 
axis and Sympathetic Adrenal Medullary (SAM) axes, both of which can result in 
vascular endothelial cell damage (Joynt et al., 2003). Inflammation, linked to endothelial 
dysfunction is the principal pathophysiological process in CVD and can lead to 
atherosclerosis and atherothrombosis (Halaris, 2013, Nymo et al., 2014). Chronic stress 
can result in a pro-inflammatory state, and the increase of pro-inflammatory cytokines 
can result in platelet aggregation and contribute to atherosclerosis (Elsenberg et al., 
2013). Neurovascular dysfunction and hyper permeability of the blood-brain barrier due 
to oxidative stress and neuroinflammation are evident in depression (Najjar et al., 2013a). 
Thus, stress acting via inflammatory pathways could be a common underlying 
mechanism that contributes to CVD and depression (see section 1.4.8).  
 
1.3.2 Diabetes  
20% of people with diabetes have a co-morbid diagnosis of depression (Ali et al., 2006). 
Type 2 diabetes mellitus is a risk factor for the development of depression, with a 15–
24% increased risk compared to people without diabetes (Mezuk et al., 2008, Nouwen et 
al., 2011). A meta-analysis investigating the link between prevalence of depression, 
impaired glucose metabolism, undiagnosed diabetes, previously diagnosed type 2 
diabetes and normal glucose metabolism found individuals with previously diagnosed 
diabetes have an increased risk of depression relative to those with impaired glucose 
metabolism or undiagnosed diabetes (Nouwen et al., 2011). A co-morbid diagnosis of 
depression and diabetes is associated with an increased risk of all-cause mortality (hazard 
ratio = 1.5) (van Dooren et al., 2013) and a number of adverse consequences including; 
lower levels of physical activity (Koopmans et al., 2009), less healthy eating behaviours 
(Egede, 2005) and suboptimal glycemic control (Lustman and Clouse, 2005), lower 
quality of life (Schram et al., 2009) and decreased medication adherence (Makine et al., 
2009). 
 
The role of inflammation in the pathogenesis of type 2 diabetes is now well established 
(Donath, 2014). In a prospective study of community dwelling older adults both high C-
reactive protein (CRP) levels and elevated depressive symptoms were associated with 
risk of diabetes (Au et al., 2014). In a cohort of 1,790 adult participants with newly 
diagnosed type 2 diabetes, CRP, interleukin (IL) 1β, IL-1 receptor antagonist, and 
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monocyte chemotactic protein-1 were significantly associated with depressive symptoms 
in type 2 diabetes (Laake et al., 2014).  
 
1.3.3 Obesity/Metabolic syndrome  
A meta-analysis of 15 studies, indicated that obesity was associated with an increased 
risk of depression and depression was associated with an increased the risk of developing 
obesity (Luppino et al., 2010). A prospective cohort study involving 3054 participants 
found that the atypical subtype of depressive disorder at baseline resulted in an increase 
in adiposity during the 5.5 years of follow-up (Lasserre et al., 2014). Consideration of 
metabolic parameters is important. A meta-analysis of 30,337 men and women aged 15–
105 years, found that the metabolically healthy obese subjects had a slightly increased 
risk of depressive symptoms compared with non-obese, but the risk of depressive 
symptoms was greater in the metabolically unhealthy obese individuals (Jokela et al., 
2013). A prospective study of community dwelling older adults, found that metabolically 
unhealthy obese subjects had an increased risk of depressive symptoms at follow-up 
whereas the metabolically healthy obese did not (Hamer et al., 2012).  
 
Chronic low-grade inflammation has been suggested as a potential mediator linking 
depression, obesity and metabolic syndrome (Kraja et al., 2007, Wellen et al.). The 
English longitudinal study of ageing found that obesity at baseline was associated with 
elevated levels of depressive symptoms at 4 year follow-up and that CRP explained 
approximately 20% of the obesity-related longitudinal change in depression scores (Daly, 
2013). Despite the relationship between depression, obesity and metabolic syndrome, 
studies investigating weight reduction and dietary intervention on depressive symptoms 
are inconsistent. Although it has been suggested that a Mediterranean diet can reduce the 
incidence of depression (Sanchez-Villegas et al., 2009), a large meta-analysis and meta-
regression found no relationship between changes in weight and changes in symptoms of 
depression in lifestyle modification interventions (Fabricatore et al., 2011). Conversely, 
a study using a subgroup of the Reduction of the Metabolic Syndrome in Navarra-Spain 
cohort (RESMENA-S) showed that a six month hypocaloric diet reduced depressive 
symptoms, as measured by the Beck Depression Inventory and reduced body fat and CRP 
levels (Perez-Cornago et al., 2014).  
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1.3.4 Immune Disorders 
As discussed above chronic medical disorders and depression co-occur at high levels 
(Farmer et al., 2008). Similar to all medical disorders, the relationship between disorders 
of the immune system and depression is bidirectional and involves the interaction of 
biological, psychological and sociological factors. Multiple sclerosis, a demyelinating 
disease with CNS inflammation is associated with a range of neuropsychiatric 
manifestations (Feinstein et al., 2013). Lifetime prevalence of major depression in 
multiple sclerosis can be as high as 50% (Feinstein, 2004, Minden and Schiffer, 1990). 
Accumulating evidence from preclinical studies suggests that some aspects of depression 
and fatigue in MS may be linked to inflammatory markers (Gold and Irwin, 2009). 
Similarly, disorders of the immune system that primarily involve systems outside the 
CNS, such as rheumatoid arthritis, sarcoidosis and psoriasis are associated with higher 
levels of depression (Chang et al., 2001, Kurd et al., 2010, Margaretten et al., 2011, 
Soderlin et al., 2000, Zyrianova et al., 2006). Interestingly, patients with psoriasis treated 
with the monoclonal antibody, ustekinumab, reported significant improvements in 
symptoms of depression and anxiety compared to placebo (Langley et al., 2010). For 
further discussion of the relationship between depression and immune dysregulation (see 
section 1.4.2).  
 
1.4 Neurobiology of Depression  
For nearly four decades the prevailing biological theory stated that depression was a 
neurochemical disorder arising from dysfunction of brain monoamine systems including 
the serotonergic, noradrenergic, and/or dopaminergic pathways (Hirschfeld, 2000, 
Schildkraut, 1965). This hypothesis arose from observations that the administration of 
classical antidepressants increased monoaminergic function, whereas monoamine 
depleters such as reserpine altered mood (Davies and Shepherd, 1955, Freis, 1954, Shore 
et al., 1955). Indeed, most currently available antidepressants enhance some aspect of 
monoaminergic function.  
 
The noradrenergic system projects from the brainstem extensively throughout cortical 
and subcortical structures (Rinaman, 2011). Cell bodies containing noradrenaline are 
found within the relatively discrete locus coeruleus and within the lateral tegmental 
nuclei that are more loosely scattered throughout the ventral pons and medulla. 
Noradrenergic neurotransmission in the brain plays a key role in general cognitive 
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processes (Sara, 2009). The actions of noradrenaline are mediated by the family of G 
protein-coupled receptors known as the adrenergic receptors, and levels of extracellular 
noradrenaline are regulated by synaptic clearance via the noradrenaline transporter and 
modulation of  noradrenaline metabolism (Cotecchia, 2010).  
 
The serotonergic system develops early in the course of embryogenesis and has 
widespread projections from the dorsal raphe nuclei in the brainstem to the forebrain 
(Kinast et al., 2013). Serotonin is synthesized from the essential amino acid L-tryptophan 
and the rate limiting step in the pathway is controlled by tryptophan hydroxylase (TPH) 
which converts tryptophan to 5-hydroxytryptophan. Tryptophan is required for protein 
synthesis and is the precursor to a number of other bioactives such as melatonin, 
tryptamine and kynurenines (Ruddick et al., 2006). Preclinical studies have shown 
serotonin is involved in the modulation of anxiety, conditioned fear, stress responses, and 
reward (Asan et al., 2013).  
 
There are 15 subtypes of serotonin (5-HT) receptors, which are also found outside of the 
CNS. Serotonin is produced in the platelets (Berger et al., 2009), with approximately 
95% of the body’s serotonin located within the gastrointestinal tract, primarily 
synthesised by enterochromaffin cells (Gershon and Tack, 2007). The presynaptic 5-
HT1A autoreceptors detect serotonin in the extracellular space and modulate the activity 
of the serotonin neuron (Celada et al., 2004). Meta-analyses of positron emission 
tomography studies reveal widespread reductions of approximately 10% in serotonin 
reuptake sites in major depression, mainly in the midbrain and amygdala (Gryglewski et 
al., 2014) and decreased 5-HT1A binding potential in the raphe, medial temporal lobe, 
and medial prefrontal cortex (Savitz et al., 2009).  Indeed, certain patients with low CSF 
5-hydroxyindoleacetic acid (5-HIAA) are prone to commit suicide (Mann et al., 1996), 
though the lower concentrations of 5-HIAA are not specific to depression, and have also 
been linked to aggressive behaviour (Moore et al., 2002).  
 
Although the monoamine theory has enjoyed considerable support, it is overly simplistic. 
This complex brain disorder requires a systems level approach, encompassing an 
understanding of the interaction of the environment on genes, molecules, cells, circuits 
and physiology. Indeed, depression involves a combination of abnormalities in genetic 
(Hyde et al., 2016, Karg et al., 2011), reward circuitry (Russo and Nestler, 2013), 
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neuroendocrine (Stetler and Miller, 2011), neuroimmune (Dinan, 2009b, Dowlati et al., 
2010), and metabolic systems (Jokela et al., 2014, Perez-Cornago et al., 2014). At the 
cellular level deficits in synaptic plasticity (Duman and Aghajanian, 2012) and impaired 
neurogenesis (Eisch and Petrik, 2012) have been demonstrated. We propose here that the 
microbiome is an additional system that needs to be considered when understanding the 
neurobiology of depression.   
 
1.4.1 Hypothalamic-pituitary-adrenal (HPA) axis in Depression  
Stress can be physical or psychological and has been defined as a state where homeostasis 
is threatened or perceived to be threatened (Bradley and Dinan, 2010). The HPA axis is 
the core endocrine stress system, and when the brain perceives a threat, the HPA, in 
conjunction with the Sympathetic Adrenal Medullary (SAM) axis, is activated. The 
paraventricular nucleus (PVN) in the hypothalamus regulates the neuroendocrine 
response whereas the amygdala regulates the majority of the autonomic and behavioural 
stress reactions in the brain (Kovacs, 2013). At the behavioural level, the HPA functions 
to mobilize adaptive behaviours and peripheral functions while inhibiting biologically 
costly behaviours (e.g. feeding, reproduction, growth) thus priming the body to adapt 
successfully to the environmental perturbation.  
 
At the molecular level corticotropin releasing hormone (CRH) and arginine vasopressin 
(AVP) regulate HPA activity, both of which are synthesized in the PVN. These hormones 
act on the anterior pituitary gland and cause the release of adrenocorticotropic hormone 
(ACTH). ACTH stimulates the release of glucocorticoids (cortisol) from the adrenal 
cortex which bind with specific intracellular receptors called the mineralocorticoid (Type 
I) and glucocorticoid receptors (Type II) which are located in multiple tissues throughout 
the body. The system works as a negative feedback loop, whereby glucocorticoids 
modulate their own secretion by acting at various levels of the HPA axis, such as the 
hippocampus, hypothalamus and pituitary. Cortisol is the main glucocorticoid (GR) in 
humans and high doses of exogenous steroids and high concentrations of endogenous 
glucocorticoids, as occurs in Cushing’s syndrome, can evoke depressive symptoms in 
some individuals (Marques et al., 2009, Pereira et al., 2010). 
 
Stressful life events are strongly associated with depression and the vast majority of first 
episodes are preceded by such triggers (Kendler and Gardner, 2010). A meta-analysis of 
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361 studies, including 18,454 individuals demonstrated that depressed individuals had 
increased cortisol and adrenocorticotropic hormone levels but not corticotropin-releasing 
hormone (Stetler and Miller, 2011). Different subtypes of depression may have different 
HPA axis profiles and this meta-analysis showed that there were cortisol differences 
between sub-groups of depression, with more pronounced differences in older inpatients 
who display melancholic or psychotic forms of depression. However, linking HPA 
profiles to depression sub-groups has been inconsistent. A study from the Netherlands 
Study of Depression and Anxiety cohort (Vreeburg et al., 2009) comprising 308 control 
subjects without psychiatric disorders, 579 persons with remitted major depressive 
disorder (MDD), and 701 persons with a current MDD diagnosis showed a significantly 
higher cortisol awakening response (CAR) in both the remitted and current MDD groups. 
Sub-group analysis revealed no association between CAR and atypical depression, 
though found higher CAR in those with co-morbid anxiety disorders.  
 
Chronic stress exposure may contribute to HPA hyperactivity by disrupting the 
glucocorticoid negative feedback system. Rodent models of chronic stress indicate that 
GRs are down regulated in several stress-sensitive brain regions such as the prefrontal 
cortex (PFC) and hippocampus (Mizoguchi et al., 2003). Early traumatic events, are of 
particular importance as they shape the development of neuroendocrine and neuro-
inflammatory response systems (DeSantis et al., 2011, Franklin et al., 2010, Pena et al., 
2013) and increase the risk of depression later in  life (Banyard et al., 2001, Dube et al., 
2001, Faravelli et al., 2012, Weber et al., 2013). These traumatic events in adulthood do 
not have the same impact on the HPA axis, suggesting that traumatic events during the 
period of brain development may result in persistent changes in the reactivity of the HPA 
axis (Klaassens, 2010, Klaassens et al., 2009). 
 
1.4.2 Cytokine Hypothesis of Depression  
Stress activates the innate immune system (Glaser and Kiecolt-Glaser, 2005). For 
example, stress induces an enhanced expression of proinflammatory factors cytokines 
(IL-1, IL-6, Interferon (IFN)-α, IFN-µ), macrophage migration inhibitory factor (MIF) 
(Bacher et al., 1998) and cyclooxygenase-2 (Madrigal et al., 2003). In clinical studies 
depression is associated with low grade inflammation with most consistent findings for 
elevations in IL-6, Tumour Necrosis Factor-α (TNF-α), and CRP (Dowlati et al., 2010, 
Howren et al., 2009), whereas negative acute-phase proteins (e.g. albumin, retinol 
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binding protein) are decreased (Maes, 1993). Increased levels of peripheral blood 
chemokines and cellular adhesion molecules, stress induced nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and T cells bearing T cell activation 
markers, such as CD2+CD25+, CD3+CD25+, and HLA-DR+ have also been described 
in depression (Maes, 2011). Notwithstanding the fact that meta-analyses consistently 
demonstrate increased peripheral inflammatory biomarkers at the group level in 
depression, it is likely that these biomarkers relate to sub groups of depressed patients, 
making up approximately one third of the total depressed group (Dinan, 2009a, Raison 
and Miller, 2013).  
 
Some studies demonstrate that increased inflammation is a state dependent phenomena, 
with a return of inflammatory biomarkers to control levels post antidepressant treatment 
(Dahl et al., 2014, Hannestad et al., 2011, Miller et al., 2009a, O'Brien et al., 2006). 
Indeed, failure to respond to antidepressant treatment is associated with persistent 
elevations in inflammatory biomarkers (Fitzgerald et al., 2006, Harley et al., 2010, 
O'Brien et al., 2007). In longitudinal studies, raised CRP and IL-6 are associated with the 
development of depressive symptoms (Valkanova et al., 2013). In a prospective study, 
participants in the top third of IL-6 values compared with the bottom third at age 9 years 
were more likely to be depressed at age 18 years (Khandaker et al., 2014).  
 
Several studies demonstrate that depressed patients with suicidal ideation may differ 
from those who are not depressed (Janelidze et al., 2011). A study of 76 depressed 
patients and 48 healthy controls using an inflammatory index composed of IL-6, TNF-α, 
IL-10, and CRP showed a significantly higher inflammatory index score in depressed 
patients with high suicidal ideation compared to depressed patients with lower suicidal 
ideation and controls (O'Donovan et al., 2013). In a post mortem study using quantitative 
reverse transcriptase (RT)-PCR to measure mRNA expression in 34 completed suicide 
victims and 17 comparison subjects, there were higher levels of mRNA expression in the 
orbitofrontal cortex for IL-4 in females and IL-13 in male suicide victims compared to 
those who died by other causes (Tonelli et al., 2008). Although this study should be 
interpreted with caution as protein levels were not measured, other post-mortem studies 
point to evidence of microglial activation in individuals who were depressed and died by 
suicide (Steiner et al., 2008). Cytokines can induce depressive symptoms in non-
depressed individuals (Raison et al., 2005). A meta-analysis of 26 studies investigating 
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the administration of IFN-α in Hepatitis C patients demonstrated a 25% incidence of 
depression (Udina et al., 2012) and this IFN-α induced depressive effect can be prevented 
and treated by antidepressants (Hauser et al., 2002, Kraus et al., 2008).  
 
1.4.3 Sickness behaviour 
Peripheral infection results in the activation of immune, endocrine, autonomic and 
behavioural changes in the host (Dantzer et al., 2008). The adaptive sickness behaviour 
that ensues to conserve energy to combat acute inflammation comprises decreased motor 
activity, social withdrawal, reduced food and water intake, increased slow-wave sleep 
and altered cognition (Dantzer, 2001). Many of these factors are evident in depression 
(including behavioral inhibition, anorexia and weight loss, anhedonia, fatigue, 
hyperalgesia, malaise, anxiety and neurocognitive symptoms), however, whereas 
sickness behaviour is adaptive, the chronic inflammatory processes in depression, result 
in neural tissue damage and consequent functional and cognitive sequelae (Maes et al., 
2012a). 
 
In both human and animal studies cytokines play a vital role in this process (for reviews 
see; (Dantzer and Kelley, 2007, McCusker and Kelley, 2013b). Peripheral or central 
administration of IL-1β or TNF-α to rodents induces the full spectrum of behavioural 
signs of sickness (Yirmiya, 1996) which occurs in a time and dose dependent manner. In 
contrast to IL-1β and TNF-α, IL-6 administered peripherally or centrally has no 
behavioural effect despite its ability to induce a fever response (Dantzer, 2001). Central 
administration of anti-inflammatory cytokines IL-10 or insulin-like growth factor I (IGF-
I), a growth factor that behaves like an anti-inflammatory cytokine in the brain, attenuates 
behavioural signs of sickness induced by centrally injected lipopolysaccharide (LPS) 
(Bluthe et al., 1991). Gram-negative bacteria have an asymmetric outer membrane, in 
which the inner leaflet consists of phospholipid and the outer leaflet is comprised of 
lipopolysaccharide (LPS) (Raetz and Whitfield, 2002). Peripheral administration of LPS 
induces the expression of IL-1β (van Dam et al., 1992) and other pro-inflammatory 
cytokine mRNAs and proteins centrally (Quan et al., 1999). Importantly, this expression 
occurs at doses of LPS that do not cause sepsis. The subclinical low-dose LPS skews 
macrophages into a mild proinflammatory state through cell surface TLR4, IL-1R-
associated kinase-1, and the Toll-interacting protein, and induces activating transcription 
factor 2 through Toll-interacting protein-mediated generation of mitochondrial reactive 
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oxygen species, allowing mild induction of proinflammatory mediators (Maitra et al., 
2012). Indeed, both acute and chronic peripheral administration of LPS acting via TLRs 
increased the transcription of central IFN stimulated genes (Thomson et al., 2014). 
 
Furthermore, peripherally administered LPS stimulates brain 5-HT transporter (SERT) 
activity, and is associated with increased depressive like behaviours and this was 
dependent on IL-1R and p38 MAPK pathways (Zhu et al., 2010). Antidepressants can 
attenuate the effects of LPS (Yirmiya et al., 2001) and inhibit microglial TNF-α, nitric 
oxide production (Tynan et al., 2012) and IL-6 production (Hashioka et al., 2007). In 
humans it has been shown that low-dose endotoxemia can modulate emotional and 
cognitive functioning. In a double-blind, crossover study, 20 healthy male volunteers 
underwent an intravenous injection of Salmonella abortus equi endotoxin or saline in two 
experimental sessions and completed psychological and neuropsychological tests at 1, 3, 
and 9 hours post injection. The Endotoxin increased the circulating levels of TNF-α, 
soluble TNF receptors, IL-6, IL-1 receptor antagonist, and cortisol. After endotoxin 
administration, the subjects showed a transient significant increase in the levels of 
anxiety and depressed mood, verbal and nonverbal memory functions were significantly 
decreased. There were significant positive correlations between cytokine secretion and 
endotoxin-induced anxiety, depressed mood and decreases in memory performance 
(Reichenberg et al., 2001). The endotoxin had no effects on physical sickness symptoms. 
Endotoxin induced increases in IL-6 and TNF-α levels have been shown to be associated 
with feelings of social disconnection, depressed mood (Eisenberger et al., 2010a) and 
memory disturbance (Carroll et al., 2011b, Cohen et al., 2003, Krabbe et al., 2005). 
 
1.4.4 Mechanisms of cytokine effects on the brain  
There are a number of possible mechanisms by which increased levels of cytokines in 
the periphery can reach and affect the brain. These have been summarized by Haroon et 
al and include passage through leaky regions in the BBB such as circumventricular 
organs, active transport through transport molecules, activation of cells lining the 
cerebral vasculature (endothelial cells and perivascular macrophages) binding to 
cytokine receptors associated with the vagus nerve, stimulating the HPA axis at the 
anterior pituitary or hypothalamus and recruitment of activated cells such as 
monocytes/macrophages from the periphery to the brain (Haroon et al., 2012). More 
recently functional lymphatic vessels lining the dural sinuses have been discovered, 
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which serve as an additional route by which immune cells can communicate with the 
CNS (Louveau et al., 2015).  
 
Through activation of the intracellular signalling pathway mitogen-activated protein 
kinase, cytokines can increase the number and function of the reuptake pumps for 
serotonin, noradrenaline, and dopamine, which in turn can reduce the availability of these 
neurotransmitters within the synaptic cleft (Miller et al., 2013). Preclinical studies have 
demonstrated that increased inflammatory cytokines reduce central levels of brain 
derived neurotrophic factor (BDNF) and neurogenesis, leading to depressive-like 
behaviour (Koo and Duman, 2008). However, the relationship between peripheral and 
central inflammatory markers and antidepressants is complex (Warner-Schmidt et al., 
2011) and it remains unclear which pathways are most relevant for cytokine signal 
transmission in stress related disorders such as depression.  
 
There is some evidence, albeit from small studies of short duration, suggesting that anti-
inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDS) and 
cytokine inhibitors reduce depressive symptoms (Kohler et al., 2014). For those 
depressed patients with raised inflammatory markers, this raises the prospect of whether 
reducing the low grade inflammation could reduce depressive symptoms. Although, a 
randomized controlled trial of the monoclonal antibody infliximab, a TNF-α antagonist, 
was not superior to placebo in reducing depressive symptoms overall, in those patients 
with high baseline CRP levels there were greater reductions in depressive symptoms than 
those with low CRP levels (Raison et al., 2013). Another study showed that CRP level 
at baseline differentially predicted treatment outcome with escitalopram or nortriptyline 
(Uher et al., 2014). These studies provide the impetus for stratification of depressed 
patients based on inflammatory profiles to advance personalized medicine. Though 
development of more nuanced profiles of inflammatory proteins and gene expression, as 
well as cellular immune parameters, likely represent the future for predictors and targets 
of response to anti-inflammatory therapies (Miller and Raison, 2015, Miller and Raison, 
2016).  
 
The brain regions most reliably identified as being most affected by administration of 
inflammatory stimuli include the basal ganglia and the dorsal anterior cingulate cortex 
(dACC). The dACC part of the brain’s limbic system is involved in cognitive and 
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emotional processing. Cytokines can induce increases in neural activity most strongly in 
either the subgenual or the dorsal area of the dACC and have been associated with the 
development of mood and anxiety symptoms (Harrison et al., 2009, Miller et al., 2013, 
Slavich et al., 2010). Cytokines can impair basal ganglia functioning by known inhibitory 
effects of cytokines on dopamine signalling in the CNS (Felger and Miller, 2012).  
Reductions in basal ganglia activity have been noted in more posterior regions, where 
they associate with fatigue, and in more ventral regions (such as the nucleus accumbens), 
where they have been associated with the development of anhedonia (Capuron et al., 
2012, Felger et al., 2013).  
 
1.4.5 Microglia 
Microglia are central to the inflammatory process and a source of cytokines (Facci et al., 
2014). These phagocytic innate immune cells account for approximately 10% of cells in 
the brain (Prinz et al., 2014) and contribute to the plasticity of neural circuits by 
modulating synaptic architecture and function (Graeber and Streit, 2010). Microglial 
process motility can be modulated by glutamatergic and GABAergic neurotransmission 
(Fontainhas et al., 2011). Preclinical studies have shown that acute stress results in 
microglia activation and increased levels of proinflammatory cytokines in areas such as 
the hippocampus (Frank et al., 2007) and hypothalamus (Blandino et al., 2009, Sugama 
et al., 2011). 
 
Most studies show increases in activated microglia in response to chronic stress 
(Bollinger et al., 2016, Hinwood et al., 2011, Hinwood et al., 2012, Tynan et al., 2010). 
Preliminary changes in the microenvironment of the microglial may result in a 
susceptibility to a secondary inflammatory stimulus (Perry and Holmes, 2014). This 
concept of microglia priming may be of relevance to depression, which often requires 
multiple environmental “hits” (Fenn et al., 2014). In an environmental two-hit rodent 
model in which the first experimental manipulation targeted pregnant dams, and the 
second manipulation was given to the resulting offspring, exposure to prenatal immune 
challenge and peripubertal stress synergistically induced pathological effects on adult 
behavioural functions and neurochemistry (Giovanoli et al., 2013, Giovanoli et al., 
2015). Thus, early-life stress primes microglia, leading to a potentiated response to 
subsequent stress (Calcia et al., 2016). Interestingly, the microbiota regulates microglia 
maturation and function (Erny et al., 2015). Clinically, microglial activation in the PFC, 
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anterior cingulate cortex (ACC), and insula in medication free depressed patients has 
been demonstrated using translocator protein density measured by distribution volume in 
a positron emission tomography study (Setiawan et al., 2015).  
 
1.4.6 Tryptophan/kynurenine pathway  
Tryptophan/kynurenine metabolism is one of the indirect mechanisms by which either 
cytokines or elevated cortisol can lead to depression. The enzyme indoleamine 2,3-
dioxygenase (IDO) found in macrophages and microglia cells is the first and rate limiting 
step in the kynurenine pathway of tryptophan catabolism. The expression of tryptophan-
2,3-dioxygenase (TDO) can be induced by circulating glucocorticoids (O'Connor et al., 
2009) and has been reported to be regulated by the gut microbiota during colonization 
(El Aidy et al., 2014). Under normal physiological conditions, approximately 99% of 
tryptophan is metabolized to kynurenine in the liver by TDO. However proinflammatory 
cytokines such as IFN-γ, CRP, IL-1, IL-6 and TNF-α can induce IDO resulting in the 
metabolism of tryptophan to kynurenine. Kynurenine pathway metabolites such as 
hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA) and quinolinic acid are 
neurotoxic while kynurenic acid is neuroprotective (Stone, 2000). Additionally, this 
process diverts tryptophan from the synthesis of serotonin, and could potentially result 
in decreased availability of serotonin (Halaris, 2013).  
 
1.4.7 Compartmentalization of Central Kynurenine pathways  
In the brain, kynurenine metabolism occurs in all cells, though the two kynurenine 
pathway branches are physically segregated into distinct cell types. Astrocytes contain 
kynurenine aminotransferases (KATs), not kynurenine 3-monooxygenase (KMO) and 
therefore cannot produce 3-hydroxykynurenine (3-HK) from KYN (Guidetti et al., 
2007). The end result of the metabolic pathway in astrocytes is Kynurenic acid (KYNA) 
(Gramsbergen et al., 1997), whereas, in microglia due to the enzymatic machinery, it is 
quinolinic acid (Alberati-Giani et al., 1996). Tryptophan and 3-HK can also cross the 
BBB and tryptophan’s conversion to kynurenine and 3-HK in the peripheral circulation 
can therefore contribute significantly to CNS levels, due to the low levels of brain IDO 
and TDO (Schwarcz 2012).  
 
The kynurenine pathway has important implications for depression, as kynurenine can 
cross the BBB to increase central levels. Indeed, most of the CNS kynurenine is drawn 
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from the periphery and when metabolized further, as outlined above could result in excess 
production of  neurotoxic metabolites (Myint and Kim, 2013). Metabolites, such as 3-
hydroxykynurenine and quinolinic acid can directly or indirectly modulate several 
neurotransmitter systems, such as glutamatergic, GABAergic, dopaminergic and 
noradrenergic neurotransmissions, which in turn induce changes in neuronal-glial 
network (Myint and Kim, 2014). It has been postulated that depression may be related to 
an imbalance between quinolinic acid and kynurenic acid in the brain, with a relative 
abundance of quinolinic acid resulting in enhanced glutamatergic activity and symptoms 
of depression (Schwarcz and Stone, 2016). 
 
There is an association between cerebrospinal fluid levels of kynurenine and quinolinic 
acid, and the development of depression during treatment with IFN-α (Raison et al., 
2010b). Moreover, increased quinolinic acid has been found in activated microglia in the 
ACC of suicide victims who were depressed. However, a recent study with 1042 subjects 
with current major depressive disorder from the Netherlands Study of Depression and 
Anxiety (NESDA) cohort, found that tryptophan/kynurenine did not mediate the 
relationship between CRP, IL-6 and depressive symptoms (Quak et al., 2014).  
 
1.4.8 Stress, HPA axis and Inflammation  
Inflammatory pathways interact with the HPA axis (Leonard, 2000). In pre-clinical 
studies, administration of cytokines induces the production of CRH, ACTH and cortisol 
(Miller et al., 2009a). In a clinical study of malignant melanoma patients, the first IFN-α 
dose induced the acute ACTH and cortisol response and correlated with the development 
of depressive symptoms (Capuron et al., 2003). In addition, in the same study, all subjects 
exhibited significant increases in kynurenine, and the kynurenine/tryptophan ratio during 
IFN-α therapy. In the antidepressant free patients, decreases in tryptophan correlated with 
depressive, anxious, and cognitive symptoms suggesting that reduced tryptophan 
availability plays a role in IFN-α induced depressive symptoms. Chronic IFN-α 
administration is associated with flattening of the diurnal curve and increased evening 
cortisol concentration, which correlate with the development of depression and fatigue 
(Raison et al., 2010a, Raison et al., 2010b). 
 
Stress, both acute and chronic, activates peripheral inflammatory pathways such as NF-
κfB in humans. The Trier Social Stress Test (TSST) has been an important test in 
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determining the relationship between acute stress and inflammation. The TSST is a 
fifteen minute psychosocial stress protocol involving five minutes of anticipatory stress, 
five minutes of public speaking and five minutes of mental arithmetic performed in front 
of a panel of evaluators. The TSST is associated with a significant increase in the DNA 
binding of the inflammatory transcription factor NF-κB in peripheral blood mononuclear 
cells (PBMCs) compared with subjects who were spectators of the task (Bierhaus et al., 
2003). Early life traumatic events are associated with an exaggerated inflammatory 
response to the TSST. In adult subjects who were not depressed though had a history of 
early life traumatic events, there was an increased IL-6 response to acute stress 
(Carpenter et al., 2010). There was also an increase in NF-κβ B DNA binding in PBMCs 
and IL-6 levels in depressed male patients with a history of early life stress compared to 
healthy controls (Pace et al., 2006). The socially evaluated cold pressor test (SECPT) is 
a combined psychological (social-evaluative threat) and physiological (cold pressor) 
acute stressor procedure (Schwabe et al., 2008) which also activates the sympathetic 
nervous system (SNS) and the HPA axis, and has been useful in elucidating the stress 
response in humans (Minkley et al., 2014). 
 
It is important to note, that in the context of chronic stress or depression, the immune 
system can become glucocorticoid (GR) resistant (Camilleri et al., 2008, Cohen et al., 
2012). This GR resistance may account for the discrepancy between HPA activation and 
elevated inflammatory markers found in depression. Indeed, using a social defeat rodent 
model, GR resistance has been hypothesized as an adaptive mechanism that allows the 
inflammatory component of wound healing to occur in the presence of high levels of 
corticosterone (Avitsur et al., 2001).  
 
A study using data from 776 subjects from the Netherlands Study of Depression and 
Anxiety, including 111 chronic depressed subjects with melancholic depression, 122 
with atypical depression and 543 controls found higher saliva cortisol awakening curves 
(area under the curve with respect to the ground (AUCg) and higher diurnal slope) in 
melancholic depression compared with atypical depression and controls. In the same 
study subjects with atypical depression had significantly higher levels of CRP, IL-6, 
TNF-α, body mass index (BMI), waist circumference and triglycerides, and lower high-
density lipid cholesterol than persons with melancholic depression and controls (Lamers 
et al., 2013). However, it is unclear why increased levels of cytokines in the melancholic 
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group are associated with higher saliva cortisol awakening curves, as cytokines are potent 
activators of the HPA axis (Dunn, 2000, Miller et al., 2009b). 
 
1.5 Current treatment options and limitations in Depression  
As discussed above, the pharmacologic therapy for treatment of depression has focused 
on modulating concentrations of brain monoamines, namely noradrenaline, serotonin, 
and dopamine. As is common in drug discovery in psychiatry (Ban, 2006), the 
monoamine oxidase inhibitors (MAOIs) and the Tricyclic antidepressants (TCAs) were 
discovered by serendipity. Iproniazid, a non-selective, irreversible monoamine oxidase 
inhibitor (MAOI) of the hydrazine class was reported to produce euphoria and 
hyperactive behaviour in some patients treated for tuberculosis. MAOIs inhibit the 
breakdown of serotonin into 5-hydroxyindoleacetic acid (5-HIAA). However, the 
irreversible MAOIs had serious side effects, and their use was problematic because of 
the strict diet people needed to follow in order to prevent hypertensive reactions induced 
by food rich in tyramine, the so called “cheese reaction” (Youdim et al., 2006).  
 
The discovery of the TCAs is also interesting. Chlorpromazine was first synthesized in 
1951 by Paul Charpentier, in the laboratories of Rhône-Poulenc, as an antihistamine and 
possible potentiator of general anaesthesia (Charpentier P et al., 1952). The French 
surgeon Henri Laborit, used the new drug to lower body temperature before general 
anaesthesia and noted it sedative properties (Laborit et al., 1952). Jean Delay and Pierre 
Deniker, tested it on agitated psychotic patients and it was noted to decrease psychotic 
symptoms (Delay et al., 1952). Imipramine, the first Tricyclic antidepressant (TCA) was 
derived from chlorpromazine, but instead of reducing psychotic symptoms, it was noted 
to cause hypomanic symptoms in some of the schizophrenia patients (Kuhn, 1957). 
 
TCAs block the serotonin transporter (SERT) and the noradrenaline transporter (NET) 
(Gillman, 2007). The selective serotonin reuptake inhibitors (SSRIs) were first 
discovered in 1972 (Carlsson et al., 1972) and fluoxetine was introduced clinically in 
1987. As mentioned the serotonin transporter (SERT) reuptakes 5-HT from the synaptic 
cleft into the presynaptic neuron, and SSRI antidepressants act by inhibiting the SERT, 
resulting in an increase in 5-HT in the extracellular space. A recent X-ray 
crystallographic study has further defined the structure of the human SERT (Coleman et 
al., 2016).  
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Acutely depleting tryptophan the precursor of serotonin, induces depressive symptoms 
in 50-60% of selective SSRI treated, and recovered depressed patients (Booij et al., 
2002). An extensive meta-analysis of 5HT depletion carried out in 2007, demonstrated 
that acute tryptophan depletion (ATD) resulted in a moderate decrease in mood in drug-
free patients with MDD in remission and induced relapse in patients with MDD in 
remission who used serotonergic antidepressants (Ruhe et al., 2007). Mood in healthy 
controls was unaffected, apart from those with a family history of MDD. Although, a 
meta-analysis of 24 studies involving 744 patients and 793 controls demonstrated a 
significant decrease in tryptophan in MDD patients, with unmedicated patients showing 
a greater decrease compared to medicated patients (Ogawa et al., 2014) , though there is 
insufficient evidence for tryptophan as an augmenting strategy in the treatment of 
depression (Sarris et al., 2016).  
 
The serotonin-noradrenaline reuptake inhibitors (SNRIs), such as venlafaxine and 
duloxetine, enhance monoaminergic function by inhibiting neuronal reuptake of 
serotonin and noradrenaline to prolong its concentration and time in the synaptic cleft. 
Whereas bupropion inhibits neuronal reuptake of noradrenaline and dopamine. Other 
antidepressants enhance noradrenaline and serotonin release by blocking presynaptic α2 
receptors (eg, mirtazapine) or blocking serotonin-2 receptors (eg, trazodone). 
Agomelatine has agonist properties at M1 and M2 receptors and antagonist properties at 
5HT2C receptors (Pringle et al., 2015) and has been shown to be superior to placebo in 
the treatment of depression (Taylor et al., 2014). See Table 1.1 for mode of action of 
Antidepressants.  
 
Antidepressants are effective for certain groups, and can reduce risk of relapse (Geddes 
et al., 2003). However, a significant percentage of depressed patients either do not 
respond or partially respond to treatment (Fava, 2003). The landmark STAR*D 
pragmatic effectiveness trial found that 30% of patients met criteria for remission during 
first line treatment with a selective serotonin reuptake inhibitor (citalopram) and 30% of 
patients did not respond after four treatment levels (Huynh and McIntyre, 2008, Trivedi 
et al., 2006). However, as this trial did not contain a placebo group, remission rates that 
would have occurred without treatment cannot be accounted for and considering placebo 
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rates in depression studies are approximately 30% (Walsh et al., 2002) suggests that 
response rates could be even lower.  
Apart from suboptimal efficacy, currently available antidepressants are also limited by 
slow onset of therapeutic effect (Machado-Vieira et al., 2008) and side effects (Anderson 
and Tomenson, 1995, Andrews et al., 2015). The glutamatergic system has received 
recent focus (Caddy et al., 2014, Duman, 2014, Swanson et al., 2005). Several studies 
have demonstrated rapid antidepressant effects with the N-methyl-D-aspartate glutamate 
receptor (NMDAR) antagonist ketamine (Allen et al., 2015, Murrough et al., 2013, Price 
et al., 2014). However, use of ketamine is restricted by dissociative and psychotomimetic 
adverse effects. A study using the low-trapping NMDA channel blocker lanicemine 
demonstrated rapid antidepressant effects with less dissociative and psychotomimetic 
adverse effects though with reduced efficacy compared to ketamine (Sanacora et al., 
2013). Recent evidence suggest that the antidepressant properties of ketamine may be 
mediated via metabolites acting through AMPARs (α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid receptors) rather than inhibition of NMDAR  (Zanos et al., 
2016). Moreover, hallucinogens, such as psilocybin have recently been shown to be 
efficacious in treatment resistant depression (Carhart-Harris et al., Carhart-Harris et al., 
2016). Additionally, antidepressant exploration has extended to cholinergic and opioid 
systems (Papakostas and Ionescu, 2015).  
 
There is an imperative need for the development of conceptually novel therapeutic 
strategies for treating depression, with safe side effect profiles and limited abuse 
potential. This advance in therapeutics will be contingent on further elucidating the 
pathophysiological mechanisms underlying depression. Concurrently, identification of 
clinically useful biomarkers to facilitate selection of the most appropriate treatment 
option and to monitor the impact of treatment will undoubtedly improve patient outcomes 
(Gururajan et al., 2016a). 
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Table 1.1 Antidepressants  
Antidepressant 
Class 
Drugs Mode of Action 
SSRIs Citalopram, Escitalopram, 
Fluoxetine, Paroxetine, 
Sertraline 
Enhance monoaminergic transmission by selectively 
preventing the reuptake of serotonin  
SNRIs Duloxetine, Venlafaxine Enhance monoaminergic transmission by selectively 
preventing the reuptake of serotonin & noradrenaline 
NaSSA Mirtazepine Increases noradrenergic & serotonergic neurotransmission 
by inhibition of presynaptic α2 and 5-HT2C receptors 
NDRI Bupropion Inhibits reuptake of noradrenaline & dopamine 
SARI Trazodone Inhibits the serotonin transporter & 5-HT2A and 5-HT2C 
receptor antagonism 
TCAs Amitriptyline, 
Clomipramine, Imipramine, 
Lofepramine, Nortriptyline, 
Trimipramine 
Enhance monoaminergic transmission by non-selectively 
inhibiting the reuptake of serotonin & noradrenaline 
MAOIs Irreversible: phenelzine, 
tranylcypromine 
Reversible: moclobemide  
Enhance monoaminergic transmission by selectively 
preventing the breakdown of monoamines by inhibiting 
the monoamine oxidase enzyme 
Melatonergic 
agonist 
Agomelatine Agonist at M1 & M2 receptors and 5HT2C antagonist  
 
SSRI: selective serotonin reuptake inhibitor, SNRI: serotonin-noradrenaline reuptake inhibitor, NaSSA: 
noradrenergic and specific serotonergic antidepressant, NDRI: noradrenergic–dopamine reuptake 
inhibitor, SARI: serotonin antagonist and reuptake inhibitor, TCA: tricyclic antidepressant, MAOI: 
monoamine oxidase inhibitors 
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1.6 Structure of the Gut Microbiota  
Emerging evidence, mainly from animal studies, indicates that some of the same 
pathways, discussed above, that are dysregulated in depression are modulated by the 
microbes that inhabit the gut – the gut microbiota. Indeed, many of the proposed targets 
of current and novel antidepressants and anxiolytics can potentially be manipulated via 
the gut microbiota. It is increasingly recognized that the gut microbiota might influence 
the core symptoms of stress-related psychiatric disorders and that it might be a tractable 
target for symptom alleviation. 
 
The mutualistic co-evolution of microbes and the human body, composed of more than 
90% microbial cells and 10 million microbial genes has led to the collective being 
described as a “superorganism” (Nicholson et al., 2005). The most heavily colonized area 
of the human body is the gut, with bacterial concentrations ranging from 101 - 103 cells 
per gram in the upper intestines to 1011 - 1012 bacteria per gram in the colon (Derrien and 
van Hylckama Vlieg, 2015, O'Hara and Shanahan, 2006). Although the functional 
significance of the microbiome has yet to be fully determined (Franzosa et al., 2014), it 
is clear that an interlinked symbiotic relationship exists between host and microbe (Ley 
et al., 2008b). In terms of bacterial phyla found in the gut, Firmicutes (species such as 
Lactobacillus, Clostridium, Enterococcus) and Bacteroidetes  (species such as 
Bacteroides) account for the majority (Dethlefsen et al., 2007), though the other phyla 
such as Actinobacteria (Bifidobacteria), Proteobacteria (Escherichia coli), 
Fusobacteria, Verrucomicrobia and Cyanobacteria are also present (Eckburg et al., 
2005, Qin et al., 2010).  
 
Differences exist between the microbiota composition between the gut lumen and the 
microbiota composition which lies in close proximity to the mucus layer. For instance, 
gram negative Proteobacteria and Akkermansia muciniphila (Verrucomicrobia), which 
use mucus as a carbon and nitrogen source, adhere and reside within the mucus layer 
(van Passel et al., 2011). This gradient can be differentially regulated by factors such as 
stress (Johansson et al., 2014, Johansson et al., 2011, Rozee et al., 1982, Swidsinski et 
al., 2005).  
 
Studies using different, but complementary, gut-microbiota directed interventions (Germ 
Free (GF) rodents, antibiotics, probiotics, gastrointestinal infection studies, and fecal 
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microbiota transplantation studies) have all suggested a number of possible brain-gut 
signalling pathways under the influence of the gut microbiota and capable of modulating 
brain and behaviour (Collins and Bercik, 2013, Cryan and Dinan, 2012b, Cryan and 
Dinan, 2015a, Dinan and Cryan, 2013, Grenham et al., 2011, Mayer et al., 2014, McVey 
Neufeld et al., 2013, Rhee et al., 2009).  
 
1.7 Development of the Gut Microbiota across the lifespan  
The developmental trajectory of the gut microbiota is compatible with concepts in 
psychiatry of the early-life period as a vulnerable phase for the subsequent emergence of 
psychopathology in adulthood (O'Mahony et al., 2015b). In the initial days of life, the 
gut microbiota is unstable and of low diversity, shifting in composition over the first few 
years to resemble an adult like profile by age three (Voreades et al., 2014). The effect of 
mode of delivery and the implications for CNS host development has attracted recent 
attention (Adlerberth and Wold, 2009, Clarke et al., 2014a, Dominguez-Bello et al., 
2010). Vaginally delivered infants are colonized by the fecal and vaginal bacteria of the 
mother, most notably Lactobacilli, whereas infants delivered by Caesarean section (C-
section) are colonized by other bacteria from the skin of the mother and from 
environmental sources including health-care workers, air, medical equipment and other 
newborns (Borre et al., 2014). Other factors such as gestational age (Barrett et al., 2013), 
feeding mode (Khanna et al., 2014, Koenig et al., 2011), antibiotic use, (Persaud et al., 
2014) and exposure to family members and pets (Dominguez-Bello et al., 2010, Fujimura 
et al., 2010, Marques et al., 2010, Penders et al., 2006) also influence the trajectory of 
microbiota acquisition. The relative importance of these factors in determining the 
eventual stable microbiota profile has not been fully elucidated.  
 
A critical function of the microbiota is to prime the development of the neuroimmune 
system (Chistiakov et al., 2014, Francino, 2014, Olszak et al., 2012, Round and 
Mazmanian, 2009). The luminal surface of the gut is a key interface in this process 
(O'Hara and Shanahan, 2006). Alterations in the gut microbiota signature early in life can 
predispose to immune disorders (Penders et al., 2007). Interestingly, emerging evidence 
suggests that infants integrate an initial microbiome profile prior to birth, and that both 
prenatal and postnatal maternal transmission is pivotal in shaping the structure of the 
microbiome (Funkhouser and Bordenstein, 2013, Gilbert, 2014, Jimenez et al., 2008, 
Mueller et al., 2015, Prince et al., 2014, Rautava et al., 2012). This challenge to the 
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prevailing sterile womb paradigm brings into focus the possible role of maternal 
microbiome transmission in the modulation of immune activation associated with 
maternal stress and the implications of this on fetal programming (Howerton and Bale, 
2012).  
 
Thus, it is plausible that subtle alterations in microbiota acquisition and maintenance, 
perhaps as early as the prenatal phase by influencing neuroimmune signalling pathways, 
may act as additional vulnerability factors that predispose to stress related disorders in 
adulthood. However, the precise microbiota signatures have yet to be determined. This 
concept is an extension of the hygiene hypothesis first proposed in the late 1980’s 
(Strachan, 1989) and more recently reconceptualised as  the “old friends hypothesis” 
(Rook et al., 2003, Williamson et al., 2015). This proposes that encountering less 
microbial biodiversity may contribute to the increase in chronic inflammatory disorders 
including subtypes of depression (Guarner et al., 2006, Hidaka, 2012, Klerman and 
Weissman, 1989, Rook and Lowry, 2008, Rook et al., 2013, Rook et al., 2014, Stein et 
al., 2016, 1992).  
 
The gut microbiota patterns change as we age. There is a decrease in microbial diversity 
during this period and, in conjunction with diet, is associated with a poorer health status 
in this group (Claesson et al., 2011, Claesson et al., 2012). Furthermore, aging is 
characterized by chronic low-grade inflammation (termed "inflammaging") as evidenced 
by increased circulating levels of TNF-α, IL-6 and CRP; known to affect mood and 
cognition (Frasca and Blomberg, 2015). The fact that the gut microbiota are key 
regulators of immune function and inflammatory responses, it is likely that a change in 
the composition of the gut microbiota during ageing plays a role in the gradual activation 
of the immune system and consequently inflammaging (Prenderville et al., 2015). The 
ELDERMET consortium demonstrated that the elderly have a distinct microbiota profile, 
characterised by greater inter-individual variation compared to younger adults (Claesson 
et al., 2011). Of note, differences in microbiota composition were more pronounced 
between frail elderly subjects and healthy elderly subjects. Moreover, certain gut 
microbiota signatures were linked to measures of frailty, co-morbidity, nutritional status, 
and markers of inflammation (Claesson et al., 2012).  
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1.8 Factors which influence composition and stability: diet, exercise, antibiotics 
As mentioned above, a multitude of factors influence the composition of the microbiota, 
including genetics (Hufeldt et al., 2010), diet (David et al., 2014, De Filippo et al., 2010, 
Turnbaugh et al., 2009b), medication (Davey et al., 2012), geography (Yatsunenko et al., 
2012), antibiotic use (Blaser, 2011) and stool consistency (Falony et al., 2016). Although 
the composition of the gut microbiota, in the absence of insults remains relatively stable 
during adulthood, there are significant interpersonal differences (Hamady and Knight, 
2009, Lozupone et al., 2012a). Two recent population-based cohort studies investigating 
the gut microbiota have confirmed this remarkably high degree of inter-individual 
variation (Falony et al., 2016). Consequently, there are multiple possible configurations 
for a healthy microbiome and it is also likely that some stable configurations are 
associated with disease (Relman, 2015). This concept of an entire ecosystem as a 
potential pathogen is a somewhat unfamiliar concept in clinical psychiatry. It is important 
also to appreciate that the functional output of multiple microbiome configurations may 
in fact be equivalent, given that concepts of redundancy and pleiotropy can also be 
applied to specific microbial members of the overall consortium.  
 
It is important to state that the relevant features of dysbiosis that might be implicated in 
stress-related disorders have yet to be fully determined. However, like any ecosystem, 
diversity and stability brings resilience and these are some of the key indices for the 
overall health of a particular gut microbiome. For example, a deficiency in 
Christensenellaceae has been associated with obesity and a C. minuta amendment was 
sufficient to reduced weight gain in an animal study (Goodrich et al., 2014). Thus, obesity 
for example, has been associated with a reduced diversity (Turnbaugh et al., 2009a). 
Recently, a Mediterranean diet, suggested as protective for depression, has been 
associated with beneficial microbiome-related metabolomic profiles (De Filippis et al., 
2015) and there is increasing awareness of the role of a healthy diet in reducing the risk 
of depression (Opie et al., 2015).  
 
Indeed, diet is one of the most important modifiable determinants of human health which 
can profoundly alter the composition of the gut microbiota (Ley et al., 2008a). Human 
gut microbiomes are less diverse that those of wild apes and have become more 
specialized for animal-based diets (Moeller et al., 2014). The composition of the gut 
microbiome can change rapidly and converting from a low-fat, plant polysaccharide-rich 
36 
 
diet to a high-fat, high-sugar "Western" diet shifted the structure of the microbiota within 
a single day (Turnbaugh et al., 2009b). Even during the course of a day, the gut 
microbiota, in both mice and humans, exhibits diurnal oscillations that are influenced by 
feeding rhythms, leading to time-specific compositional and functional profiles. Ablation 
of host molecular clock components or induction of jet lag leads to aberrant microbiota 
diurnal fluctuations and dysbiosis, driven by impaired feeding rhythmicity (Thaiss et al.).  
Exercise is another factor in the relationship between the gut microbiota, host immunity 
and host metabolism. GF mice show reduced levels of exercise and have lower liver, 
muscle, brown adipose and epididymal fat pad weight. In addition this study showed that 
the antioxidant enzyme system was altered in the GF group (Cerdá et al., 2016, Hsu et 
al., 2015). A human study investigating the gut microbiota in athletes from the Irish 
international rugby squad found a higher level of microbiota diversity, representing 22 
distinct phyla, compared to 11 in the low BMI control group and to 9 in the high BMI 
control group (Clarke et al., 2014b). This diversity was positively correlated with a diet 
rich in protein and creatine kinase. In addition athletes had lower levels of inflammatory 
markers and better metabolic profiles compared to the controls. Akkermansia muciniphila 
a mucin-degrading bacteria that resides in the mucus layer, shown in previous studies to 
be inversely correlated with obesity (Everard et al., 2013, Karlsson et al., 2012) was 
significantly higher in the athletes in the low body mass index (BMI) group compared 
with the high BMI group. This study highlights the complex interconnected relationship 
between diet, gut microbiota, exercise and the metabolic and immune system.  
 
Antibiotics alter the composition of the gut microbiota (Dethlefsen and Relman, 2011) 
and repeated antibiotic exposure in the second or third trimester or in the first 2 years of 
life is associated with early childhood obesity (Bailey et al., 2014, Mueller et al., 2014). 
Furthermore, recurrent antibiotic exposure is associated with increased risk for 
depression (Lurie et al., 2015).  
 
1.9 From Brain-Gut axis to Brain-Gut-Microbiota axis  
A recurring question surrounding the impact of the gut microbiome on the CNS and a 
possible impediment to integration of this research in psychiatry pertains to the 
uncertainty surrounding the mechanisms through which this influence can be exerted. 
The prevailing view currently is that the microbiome recruits the scaffolding provided by 
the brain-gut axis, a bidirectional communication pathway between the gut and brain 
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(Cryan and Dinan, 2012b). Studies using different but complementary approaches, such 
as, germ-free (GF) rodents, antibiotics, probiotics, gastrointestinal infection studies, and 
fecal microbiota transplantation studies have shown that the gut microbiota acting via the 
brain-gut axis contributes to the regulation of brain and behaviour (Cryan and Dinan, 
2015b, Dinan and Cryan, 2013, Mayer et al., 2014). There are several putative 
mechanisms by which the gut microbiota can achieve this; via modulation of the immune 
system (Erny et al., 2015), the HPA axis (Sudo et al., 2004), tryptophan metabolism 
(O'Mahony et al., 2015a), the production of bacterial metabolites (Tan et al., 2014) and 
via the vagus nerve (Bravo et al., 2011) (see Figure 1.1). Interestingly, the epigenetic 
factors that play a role in shaping stress-related behaviours could arise as a consequence 
of host-microbe interactions (Dalton et al., 2014, Stilling et al., 2014a, Stilling et al., 
2014b).  
 
1.10 Signalling pathways of the Brain-Gut-Microbiota axis 
1.10.1 HPA axis  
GF mice exhibit reduced levels of anxiety but increased levels of neuroendocrine 
responses to stress (Sudo et al., 2004). It is evident that the microbiota are required for 
the normal development of the HPA axis and that there is a certain period in early life 
where colonisation must occur to ensure normal development of the HPA axis (Cryan 
and Dinan, 2012a). In a resistant stress animal model, GF mice had higher ACTH and 
corticosterone responses than specific pathogen free (SPF) mice. This exaggerated HPA 
stress response was partly corrected by reconstitution with SPF feces at an early stage 
but not at a later stage of development and completely corrected by reconstitution with 
Bifidobacterium infantis (Sudo et al., 2004).  
 
1.10.2 Toll-like receptors (TLRs)  
TLRs are evolutionarily conserved type I transmembrane proteins that function as pattern 
recognition receptors (PRRs) that recognize microbial components (McCusker and 
Kelley, 2013a, Mogensen, 2009, Palsson-McDermott and O'Neill, 2007) and play an 
important role in the host defence system (Jeong and Lee, 2011). TLRs recognize 
microbe-associated molecular patterns (MAMPs) which are shared by many 
microorganisms. TLRs are expressed by a number of immune cells, including dendritic 
cells (DCs), macrophages, neutrophils, T cells, and B cells but are also found on non-
immune cells, such as epithelial and endothelial cells (Hopkins and Sriskandan, 2005). 
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Without the microbiota certain TLR’s are not expressed fully in the gut, affecting the 
proper functioning of the immune and neuroendocrine systems (O'Hara and Shanahan, 
2006). 
 
TLR2 recognizes lipoproteins and peptidoglycans from Gram positive bacteria whereas 
TLR4 mediates responses to lipopolysaccharide (LPS) primarily from Gram negative 
bacteria (Marteau and Shanahan, 2003b). It is well established that administration of LPS 
can result in behavioural changes including depressed mood, fatigue, cognitive 
dysfunction and feelings of social isolation (Eisenberger et al., 2010b, O'Connor et al., 
2008, Reichenberg et al., 2001). TLR signalling consists of at least two distinct pathways: 
a Myeloid differentiation primary response gene 88 (MYD88) dependent pathway that 
leads to the production of inflammatory cytokines, and a MyD88-independent pathway 
associated with the stimulation of IFN-β and the maturation of dendritic cells (Takeda 
and Akira, 2005). The TLR4 pathway consists of both pathways whereas the TLR2 
pathway consists of only the MyD88-dependent pathway (Leclercq et al., 2014a).  
 
Activation of TLRs initiates signal transduction pathways and triggers the expression of 
genes that control innate immune responses and further guide development of antigen-
specific acquired immunity (Akira and Takeda, 2004). Thus, TLRs might serve as a 
molecular channel between microbiota alterations and immune homeostasis (Rogier et 
al., 2015). As well as playing a role in maintaining intestinal barrier function (Cario et 
al., 2004, Rakoff-Nahoum et al., 2004), TLRs also promote epithelial cell proliferation, 
secretion of IgA into the gut lumen and expression of antimicrobial peptides (Abreu, 
2010). Dysregulation of this process, or excessive TLR activation, can result in chronic 
inflammatory and over-exuberant repair responses. Recent evidence suggests that the 
TLR3 synthetic agonist, Poly(I:C) not only decreases epithelial resistance in the small 
intestine but also promoted thinning of the mucosal layer (Moyano-Porcile et al., 2015). 
 
A study investigating the role of inflammatory pathways and gut-derived bacterial 
products in alcohol dependence syndrome, a disorder commonly co-morbid with 
depression (Regier et al., 1990), demonstrated that LPS and peptidoglycans (PGN) cross 
the gut barrier and activate TLR4 and TLR2 in PBMCs (Leclercq et al., 2014a). Chronic 
alcohol consumption inhibited the NF-kB pathway, but activated protein kinase/activator 
protein 1 pathway. IL-8 and IL-1ß were positively correlated with alcohol consumption, 
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whilst short term alcohol withdrawal was associated with the recovery of LPS but not 
PGN dependent receptors. The same group also demonstrated that increased intestinal 
permeability occurred in a sub group of alcohol-dependent subjects which was associated 
with higher depression and anxiety scores as well as an altered gut microbiota profile 
(Leclercq et al., 2014b). A study showed that depressed patients had significantly 
elevated expression of TLR4 RNA and protein, NF-κB RNA and 16S rDNA compared 
to healthy controls, which the authors suggested may be related to bacterial translocation 
or to the presence of various damage-associated molecular patterns (Keri et al., 2014).  
 
1.10.3 Short Chain Fatty Acids (SCFAs)  
The microbiota produce several bioactive metabolic products, including polysaccharides, 
lycosylceramides, nucleic acids, structural proteins, and SCFAs (Olle, 2013, Russell et 
al., 2013). SCFAs (butyrate, acetate and propionate) are neurohormonal signalling 
molecules produced by certain classes of bacteria such as Bacteroides, Bifidobacterium, 
Propionibacterium, Eubacterium, Lactobacillus, Clostridium, Roseburia, and Prevotella 
(Macfarlane and Macfarlane, 2012). SCFAs are transported by monocarboxylate 
transporters, which notably are expressed at the BBB (Steele, 1986, Vijay and Morris, 
2014). Indeed, a preclinical imaging study demonstrated that microbiota-derived acetate 
can cross the BBB where it can subsequently alter hypothalamic gene expression (Frost 
et al., 2014). Furthermore, butyrate, has been shown to reduce depression and anxiety-
related behaviours (Schroeder et al., 2007, Wei et al., 2015). 
 
 
SCFAs are also pivotal in the maintenance of the intestinal barrier (Peng et al., 2007, 
Ploger et al., 2012, Suzuki et al., 2008). Butyrate has also been shown to facilitate the 
association between transcription factors and the claudin-1 promoter (Wang et al., 
2012a), increase AMP-activated protein kinase (AMPK) activity (Peng et al., 2009) and 
to reduce bacterial translocation (Lewis et al., 2010). Interestingly, given the importance 
of butyrate in the maintenance of the intestinal barrier, IBS has been associated with a 
reduction in butyrate producing gut micro-organisms. It has, however, proven difficult 
thus far to demarcate the CNS consequences of SCFA-mediated effects on intestinal 
barrier function from a direct action in the brain. It is also notable that there is still 
considerable debate surrounding the ability of physiological levels of SCFAs to impact 
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substantially on relevant behaviours via central mechanisms, albeit that higher doses do 
have clear behavioural consequences (Macfabe, 2012, MacFabe et al., 2007).  
 
Other mechanisms by which the microbiota may signal to the underlying mucosa, or 
mucosal immune system, include delivery to an underlying subset of dendritic cells via 
small intestine goblet cells (Artis, 2008, McDole et al., 2012). It has also been postulated 
that bacterial components can cross the intestinal barrier in small lipoprotein vesicles 
called exosomes which contain protein, nucleic acids, sugars and lipids. These exosomes 
can then transfer from dendritic cells to T cells in the draining lymph nodes and enter the 
circulation (Smythies and Smythies, 2014b). Consequently, T cells may receive 
epigenetic material from gut bacteria, either by direct endocytosis, or via afferent 
exosomes (Smythies and Smythies, 2014a). More recently, identification of “neuropods” 
as a pathway by which bacteria can communicate via intestinal enterochromaffin cells to 
the nervous system provides further insight into pathways responsible for gut to brain 
communication (Bohorquez et al., 2015). 
 
1.10.4 Neuroactives  
Certain bacteria can produce neuroactive metabolites, including neurotransmitters and 
neuromodulators (Lyte, 2011, 2013, Wikoff et al., 2009). The gut microbiome also 
appears to have a role in developmental programming of the brain, specifically, synapse 
maturation and synaptogenesis (Diaz Heijtz et al., 2011). Synaptophysin, a marker of 
synaptogenesis, and PSD 95, a marker of excitatory synapse maturation, were decreased 
in the striatum in GF animals compared to SPF animals. This suggests that the microbiota 
may programme certain brain circuits when colonized by maternal microbiota, though 
the authors point out that exposure to gut microbiota metabolites during embryogenesis 
may also be a possible mechanism. 
 
1.10.4.1 GABA  
γ-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter in the CNS and 
implicated in the pathophysiology of depression and anxiety disorders. (Kumar et al., 
2013, Olivier et al., 2013). Certain strains of Lactobacillus and Bifidobacteria can  
produce GABA by metabolizing dietary glutamate (Barrett et al., 2012) although this is 
not viewed as a source of central GABA. Indeed, Lactobacillus rhamnosus was shown 
to reduce anxiety and depression related behaviour in mice and increase GABA levels in 
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the hippocampus (Bravo et al., 2011). Interestingly, in vagotomised mice, these effects 
were not found, further supporting the concept that the vagus nerve is an important neural 
signalling pathway between the microbiota and brain. A recent preclinical magnetic 
resonance spectroscopy study adds further evidence to support the concept that oral 
Lactobacillus rhamnosus can increase central GABA levels (Janik et al., 2015). 
 
1.10.4.2 BDNF 
A key regulator of synaptic plasticity and neurogenesis in the brain is the neurotrophin, 
BDNF (Monteggia et al., 2004). Several studies have demonstrated that clinical 
depression is associated with reduced peripheral levels of BDNF (Allen et al., 2015, 
Bocchio-Chiavetto et al., 2010, Bus et al., 2015, Molendijk et al., 2014). In GF rodents 
levels of BDNF were reduced in the cortex and hippocampus in GF mice (Sudo et al., 
2004). In a study by Clarke and colleagues (2013) this finding was replicated, but in male 
mice only (Clarke et al., 2013). However, not all studies are consistent. (Neufeld et al., 
2011) confirmed a decrease level of anxiety like behaviour in GF animals, but found an 
increase in BDNF mRNA in female mice. In addition there was a decrease in the 
NMDAR subunit NR2B mRNA expression in the amygdala and decreased serotonin 
receptor 1A in the hippocampus (Neufeld et al., 2011).  
 
1.10.5 Tryptophan metabolites with a focus on serotonin, kynurenine pathway 
metabolites and indoles 
Serotonin is a critical signalling molecule in the brain-gut-microbiota axis (O'Mahony et 
al., 2015a) and is involved in a wide range of physiological functions. In the 
gastrointestinal tract it plays an important role in secretion, sensing and signalling (Mawe 
and Hoffman, 2013). The largest reserve of 5-HT is located in enterochromaffin cells 
(Berger et al., 2009). Emerging evidence also suggests that the serotonergic system may 
be under the influence of gut microbiota, especially, but not limited to, periods prior to 
the emergence of a stable adult-like gut microbiota (Clarke et al., 2013, Desbonnet et al., 
2008, El Aidy et al., 2012). A metabolomics study demonstrated that the gut microbiota 
has a significant impact on blood metabolites and showed a 2.8 fold increase in plasma 
serotonin levels when GF mice are colonized by gut microbiota (Wikoff et al., 2009). 
 
Mucosal 5-HT has been demonstrated to play a direct role in the regulation of intestinal 
permeability. 5-hydroxytryptophan (5-HTP), a precursor of 5HT, significantly decreased 
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intestinal permeability in healthy control subjects and this was associated with a 
redistribution of ZO-1. Whilst in IBS patients 5-HTP resulted in a further decrease in 
occludin expression (Keszthelyi et al., 2014). The gut microbiota itself is also an 
important, but frequently overlooked, regulator of 5-HT synthesis and secretion. For 
example, colonic tryptophan hydroxylase 1 (Tph1) mRNA and protein were increased in 
humanized germ-free and conventionally raised mice. Bacterial metabolites have also 
been demonstrated to influence Tph1 transcription in a human enterochromaffin cell 
model (Reigstad et al., 2015). Others have demonstrated that distinct microbial 
metabolites produced by spore forming bacteria increase colonic and blood 5-HT in 
chromaffin cell cultures (Yano et al., 2015). 
 
Figure 1.1 The brain-gut-microbiota axis. Postulated signalling pathways between the 
gut microbiota, the intestinal barrier and the brain.  
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Figure 1.2: Potential neuropsychiatric consequences of a dysregulated intestinal barrier. 
Activation of brain-gut-microbiota Axis signalling pathways via a compromised 
intestinal barrier with potential effects on mood, anxiety, cognition and social interaction. 
 
1.11 Stress and the Gut Microbiota 
Stressful life events, particularly early life events are associated with the development of 
depression later in life (Bremner et al., 2003, Heim et al., 2000). The HPA is the core 
endocrine stress system and the interaction between stress, the HPA and the immune 
system is well established (Baes et al., 2014, Hueston and Deak, 2014). Evidence 
suggests the gut microbiota mediates this interaction. Stress can reshape gut microbiota 
composition (Galley et al., 2014a, Galley et al., 2014b, O'Mahony et al., 2009, Wang 
and Wu, 2005). For example, early life maternal separation resulted in a significant 
decrease in fecal Lactobacillus numbers on day 3 post separation which was correlated 
with stress related behaviours in rhesus monkeys (Bailey and Coe, 1999). In a mouse 
model of social disruption, stress altered the gut microbial profile and increased the levels 
of the pro-inflammatory cytokine IL-6 (Bailey et al., 2011).  
 
As previously mentioned, the most influential effect of the gut microbiota may occur 
early in life during critical neurodevelopmental stages (Borre et al., 2014). Preclinical 
evidence suggests that the gut microbiota signature acquired and maintained during these 
pivotal stages may affect stress reactivity. GF rodents demonstrate abnormal behavioural 
and neuroendocrine responses to stress (Crumeyrolle-Arias et al., 2014, Moloney et al., 
2014, Nishino et al., 2013, Sudo et al., 2004) and the normal development of the HPA 
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axis is contingent on microbiota colonisation at specific neurodevelopmental time points 
(Sudo et al., 2004). The expression of anxiety-like behaviour in a mouse model of early 
life stress is partially dependent on the gut microbiota (De Palma et al., 2015). 
Furthermore, using an olfactory bulbectomy model of chronic depression, elevated 
central CRH expression occurred concomitantly with changes in the gut microbiota (Park 
et al., 2013). Collectively, these preclinical studies, establish a relationship between the 
gut microbiota, stress, and depressive and anxiety-related behaviours. 
 
Recent evidence suggests that prenatal stress also impacts the gut microbiota with 
implications for physiological outcomes in the offspring (Golubeva et al., 2015). In a 
mouse model of prenatal stress, maternal stress decreased the abundance of vaginal 
Lactobacillus, resulting in decreased transmission of this bacterium to offspring, which 
corresponded with changes in metabolite profiles involved in energy balance, and with 
disruptions of amino acid profiles in the developing brain (Jasarevic et al., 2015a, 
Jasarevic et al., 2015b). Clinical studies examining the relationship between prenatal 
stress and the gut microbiota are starting to emerge but are far from definitive. In one 
such study, infants of mother’s with high self-reported stress and high salivary cortisol 
concentrations during pregnancy had significantly higher relative abundances of 
Proteobacterial groups known to contain pathogens and lower relative abundances of 
lactic acid bacteria (Lactobacillus) and Bifidobacteria (Zijlmans et al., 2015). It is 
currently unclear whether this effect was mediated via maternal microbial transmission 
or through cortisol-specific effects on the developing gastrointestinal tract. Whatever the 
mechanism, those infants with altered microbiota composition, exhibited a higher level 
of maternally reported infant gastrointestinal symptoms and allergic reactions, 
highlighting the functional consequences of aberrant colonisation patterns.  
 
1.12 Fecal Microbiota Transplantation (FMT)  
A number of studies have shown that it is possible to transfer characteristics from donor 
to recipient via fecal microbiota transplantation. For example, the transfer of microbiota 
from obese mice to lean mice can result in weight gain and obesity associated metabolic 
profiles (Ridaura et al., 2013). Furthermore, transfer of the human maternal gut 
microbiota in pregnancy to GF rodents, induces metabolic changes such as greater 
adiposity and insulin insensitivity, resembling the metabolic changes that occur in 
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pregnancy (Koren et al., 2012). This has been extended beyond metabolic system, as 
phenotype transfer via microbiota has also been demonstrated for behaviour.  
 
When the microbiota from BALB/c mice was transferred into adult GF NIH Swiss mice, 
the result was a decrease in exploratory behaviour and when the NIH Swiss microbiota 
was transferred into the BALB/c GF mice there was an increase in exploratory behaviour, 
associated with an increase in hippocampal BDNF levels (Bercik et al., 2011b). Thus, 
the anxiety-like behavioural phenotype could be transferred via the microbiota, 
independent of the autonomic nervous system, gastrointestinal specific neurotransmitters 
or inflammation. The reverse situation has also been demonstrated, as restoration of 
normal gut microbiota normalised anxiety like behaviour in GF mice (Clarke et al., 
2013). More recently, it has been shown that mice that received an obesity associated 
microbiota exhibit more anxiety-like behaviours associated with increased evidence of 
neuroinflammation compared to controls (Bruce-Keller et al., 2015).  
 
1.13 Stress and Intestinal Permeability  
Stress can impact on the developmental trajectory of the intestinal barrier (Lennon et al., 
2013, Smith et al., 2010) and has been associated with an increase in gut permeability 
(Soderholm et al., 2002). The effects of stress on intestinal permeability are complex and 
likely involve both the gut and the brain. Corticotrophin releasing hormone (CRH) and 
its receptors, CRF R1 and CRF R2, play a key role in stress-induced gut permeability 
dysfunction (Overman et al., 2012, Rodino-Janeiro et al., 2015, Taché and Million, 
2015). In response to an acute stressor, colonic paracellular permeability increases and 
has been associated with the development of visceral hypersensitivity (Ait-Belgnaoui et 
al., 2005). Early life stress has also been demonstrated to enhance plasma corticosterone 
in rat pups and is associated with an increase in intestinal permeability and bacterial 
translocation to liver and spleen. This effect appeared to predominate in the colon 
(Moussaoui et al., 2014). Human studies further confirm that acute-stress paradigms can 
affect intestinal permeability. In a public speaking based stressor, small intestinal 
permeability was significantly increased, however, this was only observed in those 
subjects who also responded with a significant elevation of cortisol. In a different acute 
stress model using a cold pain stressor, albumin permeability increased, though in 
females only (Alonso et al., 2012).  
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Of note, stress-induced changes in the HPA axis and autonomic nervous system display 
sensitivity to probiotic intervention (L. helveticus R0052 and Bifidobacterium longum 
R0175); (Ait-Belgnaoui et al., 2014). Moreover, L. helveticus R0052 and B. longum 
R0175 also restored colonic TJ integrity in stressed mice (Ait-Belgnaoui et al., 2014). 
Probiotics have also been demonstrated to influence bacterial adhesion and translocation 
to mesenteric lymph nodes in response to stress (Zareie et al., 2006). L. farciminis in 
particular not only suppresses stress-induced changes in permeability, HPA axis activity, 
endotoxaemia and neuroinflammation (Ait-Belgnaoui et al., 2012), but also beneficially 
influences the mucus barrier (Da Silva et al., 2014).  
 
1.14 Leaky gut hypothesis  
A dysfunctional intestinal barrier could permit a microbiota-driven proinflammatory 
state with implications for the brain (see Figure 1.2). The sequence of this process is not 
yet clear. An increase in gut permeability could precede mucosal inflammation to induce 
the inflammatory response and thus culminate in a feed forward cycle between 
inflammatory responses and barrier dysfunction. This could subsequently maintain and 
exacerbate the low grade inflammatory response. Alternatively, systemic inflammation 
could increase intestinal barrier permeability and thus allow translocation of commensal 
bacteria with further implications for systemic inflammation. Irrespective of the 
sequence, both processes could engage the gut microbiota.  
 
The source of the low grade inflammation which has been consistently demonstrated in 
sub groups of depressed patients has not been isolated to a particular source (Berk et al., 
2013, Dinan, 2009b, Jokela et al., 2015, Raison and Miller, 2013). The concept that a 
dysfunctional intestinal barrier, or “leaky gut” could permit a microbiota-driven 
proinflammatory state has gained traction (Julio-Pieper et al., 2014, Kelly et al., 2015, 
Maes, 2008, Maes et al., 2008). Under normal conditions, immune cells are separated 
from gram negative bacteria in the gut. However, a permeable intestinal barrier could 
allow certain gram negative bacteria such as Enterobacteriaceae to translocate and 
activate inflammatory pathways (Berg and Garlington, 1979, Lucas and Maes, 2013, 
Wiest and Garcia-Tsao, 2005).  
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Higher IgA and IgM-mediated immune responses directed against LPS of certain 
commensal gram negative gut bacteria have been shown in depressed patients (Maes et 
al., 2008, Maes et al., 2012c, Maes et al., 2013). The implication being that the presence 
of such responses may have occurred subsequent to disruption of the intestinal barrier. 
Moreover, bacterial DNA has been detected in whole serum from depressed patients who 
also displayed increased TLR4 expression on peripheral mononuclear blood cells 
compared to healthy controls, which may be related to bacterial translocation (Keri et al., 
2014). 
 
1.15 Microbiota and the Blood Brain Barrier  
Structural similarities exist between the intestinal, the placental and the BBB (Doran et 
al., 2013). The BBB is a complex neurovascular unit (Bauer et al., 2014) consisting of 
CNS endothelial cells which separate the lumen of blood vessels from the CNS 
parenchyma. Tight Junctions, astrocytes and pericytes seal the capillary endothelial cells 
of the BBB (Daneman and Rescigno, 2009). The TJ transmembrane proteins claudins, 
tricellulin and occludin restrict paracellular diffusion of water-soluble substances from 
blood to the brain (Hawkins and Davis, 2005). Preclinical evidence from GF mice 
suggests that the microbiota can modulate the BBB. Exposure of GF adult mice to the 
fecal microbiota from pathogen-free donors decreased BBB permeability and increased 
the expression of TJ proteins (Braniste et al., 2014). Moreover, monocolonization of the 
intestine of GF adult mice with SCFA producing bacterial strains normalised BBB 
permeability whilst sodium butyrate was associated with increased expression of 
occludin in the frontal cortex and hippocampus (Braniste et al., 2014). This study 
strengthens the hypothesis that the BBB may also be vulnerable to changes in the gut 
microbiota (Frohlich et al., 2016).  
 
1.16 Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease  
Irritable bowel syndrome (IBS) is a stress related functional brain-gut-microbiota axis  
disorder associated with an altered gut microbiota profile (Carroll et al., 2011a, Collins, 
2014, De Palma et al., 2014, Jeffery et al., 2012b, Rajilic-Stojanovic et al., 2015, Simrén, 
2014) and increased intestinal permeability (Camilleri et al., 2012, Dunlop et al., 2006, 
Rao et al., 2011). Moreover, a significant proportion of IBS patients also suffer from 
depressive and anxiety symptoms (Lucas et al., 2014, Singh et al., 2012) and this 
increases with the frequency and severity of gastrointestinal symptoms (Pinto-Sanchez 
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et al., 2015). In addition, alterations in brain circuits involved in attention, emotion, pain 
(Blankstein et al., 2010, Labus et al., 2009, Tillisch et al., 2013a) together with deficits 
in hippocampal-mediated visuospatial memory (Kennedy et al., 2014a, Kennedy et al., 
2012) have been noted the disorder. In particular, an altered Firmicutes: Bacteroidetes 
ratio has been linked to IBS and an association between Firmicutes, Proteobacteria and 
IBS symptom scores has been demonstrated (Rajilic-Stojanovic et al., 2011).  
 
Traditionally, there have been a number of different diagnosis methods which are now 
unified within the Rome framework, at least for research purposes (Soares, 2014). A 
recent meta-analysis of clinical studies to identify and assess the various diagnostic tests 
indicated that a combination of intestinal permeability, Rome I criteria and fecal 
calprotectin (see Table 1.2 for brief description of Intestinal Permeability markers) 
provided the highest positive likelihood ratio for predicting IBS (Sood et al., 2015). 
Although not captured in this meta-analysis, and not part of routine clinical practice, the 
addition of gut microbiota profiling may deliver further diagnostic accuracy (Casen et 
al., 2015). For example, IBS subtypes have been stratified according to their microbiota 
profiles, specifically those with an increased Firmicutes: Bacteroidetes ratio (Jeffery et 
al., 2012a). Furthermore, depression was the most robust clinical discriminator between 
a high Firmicutes: Bacteroidetes ratio in IBS patients relative to IBS patients with a 
healthy-like microbiota signature (Jeffery et al., 2012a). In addition, the order 
Actinomycetales and the family Actinomycetaceae were inversely associated with 
clinically significant depression (Jeffery et al., 2012a).   
 
Although the microbiota varies along the length of the gastrointestinal tract, the majority 
of studies use fecal microbiota sampling as a representative of global changes, however 
site specific changes may influence the ensuing immune consequences. For example 
mucosal jejunal tissue from diarrhoea-predominant IBS patients is also associated with 
increased activation of mucosal B lymphocytes, plasma cells and mucosal IgG 
production. (Vicario et al., 2014). Of note in this study, humoral activity markers 
positively correlated with depressive symptoms (Vicario et al., 2014). Further studies 
need to be conducted to disentangle the contributing role of an exaggerated or aberrant 
immune response, changes in intestinal permeability and psychiatric co-morbidities in 
IBS. However, individuals with a pre-existing psychological disorders are known to be 
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at an increased risk of developing post-infectious IBS (PI-IBS) in particular (Thabane 
and Marshall, 2009).  
 
Variations in several genes associated with bacterial recognition, the inflammatory 
response and epithelial integrity including TLR9, IL-6 and cadherin 1 genes have been 
identified as risk factors for the development of PI-IBS. A longitudinal study which 
examined the rate of IBS development following an accidental outbreak of E. coli 
0157:H7 into a town’s (Walkerton) water supply identified an increased rate of IBS two 
years after the outbreak (Marshall, 2009). A subsequent study further identified a modest 
increase in intestinal permeability amongst this IBS cohort (Marshall et al., 2004). An 
association between this outbreak and depression was also identified (Garg et al., 2006). 
Similarly, an outbreak of shiga toxin-producing E. coli O104 in Germany increased self-
reported depressive and anxiety symptoms measured six months after the infection 
(Lowe et al., 2014).  
 
Inflammatory bowel disease (IBD), a gastrointestinal disorder with overt inflammation 
is also associated with intestinal barrier dysfunction (Antoni et al., 2014, Laukoetter et 
al., 2008, Marchiando et al., 2010) increased intestinal permeability (Gerova et al., 2011) 
immune dysregulation and an altered gut microbiota (Sartor and Mazmanian, 2012). IBD 
is also associated with a higher prevalence of anxiety and depressive disorders (Walker 
et al., 2008). Moreover, stress can adversely affect the course of IBD (Mawdsley and 
Rampton, 2005, Mittermaier et al., 2004). Both Crohn’s disease and Ulcerative colitis 
exhibit alterations in the expression of the TJ proteins, claudin and occludin (Heller et 
al., 2005, Zeissig et al., 2007). Interestingly, recent preclinical evidence suggests that 
chronic intestinal inflammation alters hippocampal neurogenesis (Zonis et al., 2015) 
which itself has recently been reported to be under the influence of the gut microbiota 
(Ogbonnaya et al., 2015)  
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Table 1.2: Markers of Intestinal Permeability 
Permeability Test Sample  Measures Clinical/Preclinical Representative citation 
Challenge Tests     
Lactulose/mannitol urine small intestine permeability  clinical & preclinical (Vanuytsel et al., 2014) 
Lactulose/L-rhamnose urine small intestine permeability  clinical & preclinical (Keszthelyi et al., 2014) 
Sucrose urine gastric permeability  clinical & preclinical (Mujagic et al., 2014) 
Sucralose  urine colonic permeability   clinical & preclinical (Anderson et al., 2004) 
Polyethylene glycols urine entire intestine permeability   clinical & preclinical (Rao et al., 2011) 
 51Cr-EDTA urine entire intestine permeability   clinical & preclinical (Leclercq et al., 2014b) 
     
Circulating Markers     
Zonulin plasma small intestine epithelial cell damage clinical & preclinical (Fasano, 2011) 
Intestinal Fatty acid binding protein (I-
FABP) 
plasma small intestine permeability clinical & preclinical (Derikx et al., 2009) 
Citrulline plasma small intestine epithelial cell damage clinical & preclinical (Crenn et al., 2000) 
αGlutathione S-transferase (αGST) plasma epithelial cell damage clinical & preclinical (McMonagle et al., 2006) 
Claudin-3 urine epithelial cell damage clinical & preclinical (Patel et al., 2012a) 
Lipopolysacharide (LPS) Binding Protein 
(LBP) 
plasma indirect evidence of permeability deficit clinical & preclinical (Pasternak et al., 2010) 
Endotoxin core antibodies (EndoCAb) plasma entire intestine permeability clinical & preclinical (Ammori et al., 2003) 
D-Lactate  plasma entire intestine permeability clinical & preclinical (Poeze et al., 1998) 
Fluorescein isothiocyanate–dextran (FITC-
Dextran 4) 
plasma entire intestine permeability   preclinical (Moussaoui et al., 2014) 
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Fecal Markers     
Calprotectin faeces nonspecific marker of gut inflammation clinical & preclinical (de Magistris et al., 2010) 
Zonulin faeces marker of intestinal permeability clinical (Lamprecht et al., 2012) 
     
Ex-Vivo     
Ussing chamber  ex vivo 
biopsies 
epithelial ion transport clinical & preclinical (Piche et al., 2009) 
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1.17 Gut Microbiota in Depression: State of Knowledge  
To date three clinical studies have investigated the microbiota composition in depressed 
patients. In the first study, a significant increase in the order Bacteroidales and a 
decrease in Lachnospiraceae family was demonstrated in the depressed group 
(Naseribafrouei et al., 2014). At the genus level there was an increase in Oscillibacter 
and Alistipes species. There were no differences in species richness or diversity between 
the groups. In the second study the depressed group had increased levels of 
Enterobacteriaceae and Alistipes and reduced levels of Fecalibacterium which 
negatively correlated with severity of depressive symptoms. They also found no 
significant differences in richness (Jiang et al., 2015). The most recent study, sequenced 
the fecal sample from 58 depressed (39 drug free) and 63 healthy controls. At the 
phylum level they found an increase in Actinobacteria and a decrease in Bacteroidetes 
in the depressed group. Using random forests classifier, 29 operational taxonomic units 
(OTUs) were overrepresented in the depressed subjects and 25 OTUs were 
overrepresented in healthy control subjects. There were no significant differences in 
alpha diversity (shannon, simpson, phylogenetic diversity, observed species) while beta 
diversity, measured by unweighted unifrac, separated the groups to account for 19% of 
the difference.  
 
In the preclincal arm of the study they compared GF to SPF mice and found that the GF 
mice exhibited reduced anxiety-like behaviour in the open field test (OFT) and 
decreased depressive like behaviour in the forced swim test (FST). Preparing an FMT 
from a pooled sample of 5 antidepressant free male donors and 5 matched controls they 
found no differences in the OFT, FST or tail suspension test (TST), whereas at two 
weeks post FMT the mice that received the depressed FMT displayed an increase in 
depressive and anxiety-like behaviour. Then using multiplex shotgun metagenomic 
analysis on caecal samples they identified several carbohydrate metabolites that were 
increased in the mice that received the depressed FMT (α-glucose, β-glucose, fructose 
and succinate) relative to control mice and this was verified in fecal, serum and 
hippocampal samples. Dysregulation of amino acid metabolism was also evident in the 
mice that received the depressed FMT. However, this finding, unlike the carbohydrate 
metabolites, was not consistent across different samples (Zheng et al., 2016a).  
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1.18 Psychobiotics  
Although diet may be a key factor shaping the gut microbiota, it may prove difficult as 
a first-line option in a population which may not be sufficiently motivated to radically 
alter eating habits. Consequently, alternative options need to be considered. A probiotic 
is defined as a live bacteria which when administered in adequate amounts confers a 
health benefit on the host (Petschow et al., 2013, WHO, 2001). Previous probiotic health 
claims have been exaggerated (Hoffmann et al., 2013, Sanders, 2003, Shanahan, 2002) 
and only certain probiotics are viable in the gastro-intestinal tract (Fredua-Agyeman and 
Gaisford, 2015). Other strains demonstrate beneficial effects on the intestinal barrier 
across the lifespan via a number of mechanisms and mediators (Eutamene and Bueno, 
2007, Mennigen and Bruewer, 2009) (see Table 1.3).  
 
Some of the strongest evidence for the clinical role of probiotics comes from studies in 
patients with the brain-gut disorder, IBS (Orel and Kamhi Trop, 2014, Whelan and 
Quigley, 2013). A number of probiotics and commensal organisms, primarily lactic acid 
bacteria, have been shown to ameliorate certain IBS symptoms (Clarke et al., 2012, 
Didari et al., 2015, Hoveyda et al., 2009, Ortiz-Lucas et al., 2013, Yoon et al., 2013). 
Some of these beneficial effects may, at least, relate to the anti-inflammatory effects of 
particular organisms (O'Mahony et al., 2005). Moreover, probiotics in accordance with 
preclinical evidence can improve intestinal barrier function under pathological 
conditions in human populations. In a randomized single blind placebo controlled study 
a fermented milk drink containing Streptococcus thermophilus, L. bulgaricus, 
L.acidophilus and B.longum decreased small intestinal permeability, though colonic 
permeability was unaltered (Zeng et al., 2008).  
 
The term “psychobiotics” has been recently conceived to encompass the sub-types of 
probiotics predominately lactobacillus and bifidobacteria species, that may be capable 
of modulating the brain-gut-microbiota axis to have a beneficial effect on mood, anxiety 
and cognition (Dinan et al., 2013). A growing number of studies (see Table 1.4) with 
healthy individuals suggest that prolonged pre and probiotic consumption can positively 
affect aspects of mood and anxiety in healthy controls (Messaoudi et al., 2011, 
Mohammadi et al., 2015a, Steenbergen et al., 2015b), modulate HPA axis function 
(Messaoudi et al., 2011, Schmidt et al., 2015) and alter functional brain activity (Tillisch 
et al., 2013a). However, a recent systematic review indicated that the impact of 
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probiotic supplementation on gut microbiota structure in healthy controls was minimal 
(Kristensen et al., 2016).  
 
Logan and Katzman initially proposed an augmenting role for probiotics in the 
treatment of depression (Logan, 2015, Logan and Katzman, 2005). Ten years later, the 
first clinical trial was conducted. This randomized placebo controlled trial (n = 40) of a 
multispecies probiotic, showed that 8 weeks of L. acidophilus, L. casei and B. bifidum 
reduced Beck depression scores compared to placebo (Akkasheh et al., 2016). 
Although, diet was recorded in this study, microbiota analysis was not reported.  
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Table 1.3: Preclinical studies of Probiotics & Intestinal barrier 
Probiotic Effects Reference 
VSL#3  normalization of colonic physiologic function and barrier integrity reduction in mucosal secretion of TNFα 
and IFNγ & an improvement in histologic disease.  
Decreased ileal paracellular permeability, decrease claudin-2 and increase occludin in a mouse model of 
ileitis 
(Corridoni et al., 2012) 
VSL#3 (protein soluble 
factor) 
enhanced barrier function and resistance to Salmonella invasion (Madsen et al., 2001) 
VSL#3   Prevented the increase in epithelial permeability in DSS induced acute colitis & prevented the decreased 
expression & redistribution of the occludin, zonula occludens-1, and claudin-1, -3, -4, and -5 
(Mennigen et al., 2009) 
VSL#3  VSL#3 can attenuate intestinal barrier damage and reduced bacterial translocation in a LPS induced mouse 
model of sepsis 
(Ewaschuk et al., 2007) 
Lactobacillus rhamnosus 
& L. acidophilus  
attenuated the damage caused by Shigella dysenteriae (Moorthy et al., 2009) 
Lactobacillus plantarum   prevented the rearrangement of claudin-1, occludin, JAM-1 and ZO-1 proteins induced by Escherichia coli (Qin et al., 2009) 
Lactobacillus reuteri reduced levels of colonic mucosal adherent and translocated bacteria and attenuated the development of the 
colitis in interleukin IL-10 gene deficient mice 
(Madsen et al., 1999) 
Lactobacillus rhamnosus 
GG culture supernatant 
(LGG-s)  
pretreatment significantly inhibited alcohol-induced intestinal permeability, endotoxemia and subsequently 
liver injury  
(Wang et al., 2012b) 
Lactobacillus rhamnosus 
OLL2838 (live & heat-
killed) 
Administration to DSS-treated animals protected against the increase in mucosal permeability associated 
with DSS-induced colitis.  
Increased expression of ZO-1 and myosin light-chain kinase in intestinal epithelial cells isolated from mice 
of the heat-killed OLL2838 group 
(Miyauchi et al., 2009) 
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Lactobacillus casei DN-
114 001 (lysate - Lc) 
increased the numbers of CD4(+)FoxP3(+) Tregs in mesenteric lymph nodes,  
decreased the production of TNFα and IFNγ, and anti-inflammatory IL-10 in peyer's patches and large 
intestine  
changed the gut microbiota composition in an DSS colitis BALB/c model  
Lc also resulted in a significant protection against increased intestinal permeability and barrier dysfunction 
shown by preserved ZO-1 expression  
Lc treatment prevented LPS induced TNFα expression in RAW 264.7 cell line by down-regulating the NF-
κβ B signalling pathway 
(Zakostelska et al., 2011) 
Lactobacillus brevis 
SBC8803 polyphosphate 
(poly P) 
 
 
suppressed the oxidant-induced intestinal permeability in the mouse small intestine and its protective effect 
was prevented by pharmacological inhibitors of p38 MAPK and integrins  
 
daily intrarectal administration of poly P improved the inflammatory profile and survival rate when 
administered to DSS mice. 
(Segawa et al., 2011) 
Lactobacillus rhamnosus 
GG, soluble secretory 
proteins p40 and p75 
prevented hydrogen peroxide induced redistribution of occludin, ZO-1, E-cadherin, and beta-catenin from 
the intercellular junctions 
(Seth et al., 2008) 
 
Lactobacillus plantarum 
DSM 2648  
 
 
Lactobacillus plantarum 
MB452 
 
 
 
attenuated the negative effect of enteropathic Escherichia coli (EPEC) O127:H6 (E2348/69) on 
transepithelial electrical resistance and adherence to intestinal cells. 
  
 
19 TJ related genes had altered expression levels including those encoding occludin and its associated 
plaque proteins that anchor it to the cytoskeleton.  
 
L. plantarum MB452 altered tubulin and proteasome gene expression levels 
(Anderson et al., 2010a) 
 
 
(Anderson et al., 2010b) 
Lactobacillus 
acidophilus protects TJ 
from aspirin damage in 
HT-29 cells  
 protects TJ from aspirin damage in HT-29 cells (Montalto et al., 2004) 
Lactobacillus rhamnosus 
GG (LGG) - modified 
lipoteichoic acid (LTA)  
correlated with a significant down-regulation of TRL2 expression and downstream proinflammatory 
cytokine expression in DSS mouse model 
(Claes et al., 2010) 
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Lactobacillus plantarum 
299v 
1 week of pretreatment the drinking water abolished E. coli-induced increase in permeability (Mangell et al., 2002) 
Lactobacillus helveticus 
and Lactobacillus 
rhamnosus  
Administration one week prior to and concurrently with Citrobacter rodentium attenuated C. rodentium 
induced barrier dysfunction, epithelial hyperplasia, and binding of the pathogen to host colonocytes 
(Rodrigues et al., 2012) 
Lactobacillus rhamnosus 
LOCK0900, L. 
rhamnosus LOCK0908 
and L. casei LOCK0919 
Colonization of GF mice enhanced the integrity of gut mucosa and ameliorated allergic sensitization (Kozakova et al., 2015) 
Lactobacillus fermentum 
AGR1487 - cell surface 
structures & supernatant  
live and deadAGR1487 decreased TEER across Caco-2 cells.  
only live AGR1487 increased the rate of passage of mannitol 
(Sengupta et al., 2015) 
Lactobacillus rhamnosus 
GG (live or heat-killed) 
 
Enteral administration accelerated intestinal barrier maturation and induced claudin 3 (Patel et al., 2012a) 
Lactobacillus helveticus 
R0052 & 
Bifidobacterium longum 
R0175  
reversed the increased intestinal permeability and depressive like behaviours post MI. (Arseneault-Breard et al., 2012) 
Bifidobacterium lactis 
CNCM I-2494  
prevented the increase in intestinal permeability induced by PRS and restored occludin and JAM-A 
expressions to control levels 
(Agostini et al., 2012) 
Bifidobacteria infantis  In T84 cells increased TEER, decreased claudin-2, and increased ZO-1 and occludin expression, associated 
with enhanced levels of phospho-ERK and decreased levels of phospho-p38.  
 
prevented TNFα & IFNγ induced decrease in TEER & rearrangement of TJ proteins.  
 
Oral administration acutely reduced colonic permeability in mice whereas long-term BiCM treatment in IL-
10-deficient mice attenuated inflammation, normalized colonic permeability & decreased colonic and 
splenic IFN-gamma secretion 
(Ewaschuk et al., 2008) 
Bacteroides 
thetaiotaomicron  
modulated the expression of genes involved in several important intestinal functions, including nutrient 
absorption, mucosal barrier fortification, xenobiotic metabolism, angiogenesis, and postnatal intestinal 
maturation 
(Hooper et al., 2001) 
Escherichia coli Nissle 
1917  
altered the expression, and distribution of ZO-2 protein (Zyrek et al., 2007) 
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Escherichia coli Nissle 
1917  
Colonization of GF mice resulted in an up-regulation of ZO-1 in intestinal epithelial cells at both mRNA 
and protein levels 
(Ukena et al., 2007) 
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Table 1.4: Probiotics & Clinical Stress Studies 
Probiotic Duration N Subjects Design Clinical Measures Biological 
Measures 
Results Reference 
Lactobacillus 
casei Shirota 
(milk drink) 
21 days 124 
 
Healthy 
 
(average 
age was 
61.8 yrs) 
 
randomized 
double blind 
placebo 
controlled 
Mood: Profile of Mood 
States (POMS), at 
baseline, 10 days & 20 
days 
 
Cognition: 
Episodic memory 
Semantic memory 
Verbal fluency 
N/a no general effect on mood of taking the 
probiotic 
 
small improvement in mood when post hoc 
analysis of the lowest tertile mood scores were 
considered 
 
decreased performance on semantic memory  
(Benton et 
al., 2007) 
L. helveticus 
R0052 & B. 
Longum 
R0175 
30 days 30 Healthy double blind 
placebo 
controlled 
Hopkins Symptoms 
Checklist (HSCL-90) 
 
Hospital Anxiety & 
Depression Scale 
(HADS) 
 
Perceived Stress Scale 
(PSS) 
 
Coping Checklist 
(CCL) 
24 hour 
urinary 
free 
cortisol 
(UFC) 
HSCL-90 scale (global severity index, 
somatisation, depression, and anger–hostility), 
the HADS (HADS global score, and HADS 
anxiety) & by the CCL (problem solving) 
 
Decrease in UFC 
 
 
 
 
(Messaoud
i et al., 
2011) 
Lactobacillus 
casei Shirota  
60 days 35 
 
Chronic 
Fatigue 
Syndrom
e 
Randomized 
double blind 
placebo 
controlled 
Beck Anxiety & 
Depression Inventories 
 
 
Fecal  Decrease in Anxiety symptoms 
 
Increase in Lactobacillus and Bifidobacteria in 
Fecal samples 
(Rao et al., 
2009) 
Clostridium 
Butyricum 
14 days 
(twice 
daily) 
30 
CFS 
 
20 
Healt
hy 
contr
ols 
pre-op 
laryngect
omy 
Randomized, 
placebo 
controlled 
Hamilton Anxiety 
Scale 
Serum 
CRF 
 
Heart rate 
(HR) 
reduced anxiety levels from 19.8 to 10.2  
 
attenuated the increase in CRF & HR pre op 
(Yang et 
al., 2014) 
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Bifidobacteri
um animalis, 
Streptococcus 
thermophiles, 
Lactobacillus 
bulgaricus, & 
Lactobacillusl
actis 
(fermented 
milk) 
28 days 12 Healthy 
Females 
Randomized 
placebo 
controlled 
parallel-arm 
design 
 fMRI: 
emotional 
faces 
attention 
task 
reduced task related response of a distributed 
functional network containing affective, 
viscerosensory and somatosensory cortices 
 
independent of self reposted GI symptoms 
(Tillisch et 
al., 2013a) 
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1.19 Prebiotics  
A prebiotic effect is defined as the selective stimulation of growth and/or activity(ies) of 
one or a limited number of microbial genus(era)/species in the gut microbiota that 
confer(s) health benefits to the host (Gibson, 2004, Roberfroid et al., 2010). Preclinical 
and clinical studies demonstrate that certain prebiotics alter the gut microbiota, can 
reduce low grade inflammation and improve metabolic function (Bindels et al., 2015, da 
Silva et al., 2013, Dewulf et al., 2013, Everard et al., 2011, Greiner and Backhed, 2011). 
Evidence also suggests that prebiotic galacto-oligosaccharides (GOS) can improve 
intestinal barrier function in a rats (Zhong et al., 2009). Moreover, mice treated with 
prebiotics exhibit improvements in intestinal permeability, TJ integrity, decreased 
plasma LPS and cytokine levels in addition to decreased hepatic expression of 
inflammatory and oxidative stress markers (Cani et al., 2009).  
 
Prebiotics have also been shown to influence brain neurochemistry and behaviour. GOS, 
for example, increased hippocampal neurotrophin levels and the expression N-methyl-d-
aspartate receptor subunits in the rat frontal cortex (Savignac et al., 2013). Behaviourally, 
a combination of GOS and polydextrose attenuated anxiety like behaviour rats and 
induced alterations in the gut microbiota composition (Mika et al., 2014). In the context 
of IBS, GOS also appeared to influence the gut microbiota and improved anxiety scores 
(Silk et al., 2009). Furthermore, in healthy adults, administration of GOS significantly 
decreased the cortisol awakening response and decreased attentional vigilance to 
negative versus positive information in a dot-probe task compared to placebo (Schmidt 
et al., 2015).  
 
1.20 Minocycline  
As discussed above antibiotics have a profound impact on the gut microbiota (Dethlefsen 
and Relman, 2011). One potential effect of microbiota disruption, is the alteration of its 
metabolizing capabilities. Alteration of the microbiota, could potentially modulate the 
efficacy or toxicity of certain drugs, though little is known about these interactions. 
Although there is a shift towards more targeted narrow spectrum antibiotics, which 
minimize the disruption to the gut microbiota, (“microbiome sparing”), the broad 
spectrum antibiotic minocycline has received much attention recently due to its 
neuroprotective effects (Borre et al., 2012, Plane et al., 2010, Stirling et al., 2005, Stock 
et al., 2013). This second generation tetracycline antibiotic targets aerobic and anaerobic 
62 
 
gram positive and gram negative bacteria, and as it is highly lipophilic with a 
bioavailability of 95%, has good penetration into the central nervous system. 
Minocycline is commonly used in the treatment of acne vulgaris (Garner et al., 2012) 
and occasionally used in the treatment of sexually transmitted diseases (Rosen et al., 
2009). 
 
There are several mechanisms proposed to account for minocycline’s neuroprotective 
effects. Minocycline can suppress microglial activation, reduce the expression of pro-
inflammatory cytokines (IL 1ß, IL 6, IL 2, TNFα, IFN-γ), matrix metalloproteinases, and 
up-regulate the anti-inflammatory cytokine IL-10 (Hinwood et al., 2013, Soczynska et 
al., 2012, Tikka et al., 2001). It can inhibit free radical generation (Lin et al., 2003) and 
may indirectly modulate glutamatergic transmission (Chaves et al., 2009, Jin et al., 
2012). Minocycline has also been investigated in animal models of depression. 
Minocycline reduced immobility and increased climbing in the forced swim test (FST) 
(Molina-Hernandez et al., 2008). It resulted in less escape failures and shorter latency to 
escape in a learned helplessness model (Arakawa et al., 2012). In LPS experiments, 
minocycline attenuated the LPS induced expression of pro-inflammatory cytokines 
(Henry et al., 2008) and attenuated LPS associated increases in the duration of 
immobility in the FST and TST (O'Connor et al., 2009). Another tetracycline antibiotic, 
doxycycline, similar to imipramine prevented and reduced LPS alteration in the FST, and 
also prevented and reversed LPS induced increase in IL 1ß and reversed LPS induced 
alterations in nitrite content and oxidative stress parameters in the striatum, hippocampus 
and PFC (Ferreira Mello et al., 2013).  
 
The majority of clinical studies investigating minocycline in psychiatry have involved its 
evaluation as an augmenting agent in the treatment of the negative symptoms in 
schizophrenia (Chaudhry et al., 2012, Levkovitz et al., 2010, Liu et al., 2014), though 
several studies have been conducted in depressed patients. A case report showed mild 
nonspecific inflammation without lymphocytic infiltration and lipofuscin granule 
accumulation within the neurovascular endothelium in a brain biopsy of a depressed 
patient with recurrent treatment resistant depression. After a nine month course of 
intravenous immunoglobulin and a concurrent six month course of intravenous 
minocycline, a repeat Single-photon emission computed tomography (SPECT) scan 
showed normalization of frontal lobe hypoperfusion with a reduction in depression and 
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anxiety symptoms as measured by the Montgomery-Asberg depression rating scale and 
the Beck depression and anxiety inventory (Najjar et al., 2013b).   
 
In an open label study involving 25 patients diagnosed with unipolar psychotic 
depression, minocycline in combination with SSRIs for six weeks resulted in significant 
reductions in depression scores in the Hamilton Rating Scale for Depression and the Brief 
Psychiatric Rating Scale (BPRS) (Miyaoka et al., 2012). A number of ongoing trials are 
investigating minocycline’s effect in unipolar (NCT01574742), bipolar (NCT01403663, 
NCT01514422) and old age depression (NCT 01659320). One such trial is a trial of 
minocycline and aspirin in the depressed phase of bipolar (Savitz et al., 2012). Another 
ongoing trial is investing the effect of minocycline in patients that have relapsed into 
depression after successful treatment with intravenous ketamine (NCT01809340).  
 
An intriguing additional possible mechanism whereby minocycline could exert beneficial 
effects in neuropsychiatric disorders could be via modulation of the gut microbiota. In a 
preclinical study, stressed mice treated with minocycline, exhibited increases in the 
relative abundances of Akkermansia and Blautia species compatible with beneficial 
effects of attenuated inflammation and an increase in Lachnospiracea consistent with 
changes of caspase-1 deficiency (Wong et al., 2016).   
 
1.21 Primary hypothesis and aims of thesis  
 
We hypothesise that the gut microbiota may have a causal role in symptom generation in 
depression and that targeting the gut microbiota with psychobiotics might represent a 
viable strategy for altering mood and cognitive processes. This hypothesis will be tested 
via the following objectives: 
1. To determine the composition, richness and diversity of the gut microbiota in 
depressed patients compared to healthy controls and its relationship to: immune 
activity (plasma cytokines), HPA-axis function, tryptophan metabolism, 
intestinal permeability and SCFAs.  
2. To determine a potential causal role for the gut microbiota, the behavioral & 
physiological effects of a Fecal Microbiota Transplantation from depressed 
patients and health controls to a microbiota depleted antibiotic rat model will be 
assessed. 
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3. To determine the effect of a putative psychobiotic, Lactobacillus Rhamnosus, on 
mood, stress response, cognition and relevant brain activity patterns in healthy 
males. 
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Chapter 2: Gut Microbiota & Physiological 
profiles in Depression 
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2.1 Abstract  
Background: Major Depressive Disorder (MDD) is a common, often recurrent, 
heterogeneous disorder responsible for significant disability and economic burden 
worldwide. The biological mechanisms underlying the pathophysiology of MDD involve 
immune, endocrine and neurotransmitter dysregulation. Pre-clinical findings suggest that 
the complex and dynamic gut microbiota can modulate brain development, function and 
behaviour by recruiting the same neuroimmune, neuroendocrine and neural pathways of 
the brain-gut-axis which are dysfunctional in MDD. We tested the hypothesis that an 
altered gut microbiota, contributing to a dysregulated brain-gut-microbiota axis, could 
contribute to the pathophysiology of MDD. 
Methods: Thirty four patients with major depression and 33 matched healthy controls 
were recruited. Cytokines, CRP, Salivary Cortisol and plasma Lipopolysaccharide 
binding protein (LBP) were determined by ELISA. Plasma tryptophan and kynurenine 
were determined by High Performance Liquid Chromatography (HPLC). Fecal samples 
were collected for 16s rRNA sequencing. Fecal Short chain fatty acids (SCFAs) were 
determined by Gas Chromatography. Fecal metabolites were analysed using Gas 
Chromatography Mass Spectometry (GC-MS). 
Results: Depression is associated with altered gut microbiota composition and decreased 
gut microbiota richness and diversity. In parallel, patients with depression showed 
significantly higher levels of IL-6 (p = 0.01), IL-8 (p = 0.02), TNF-α (p = 0.02), CRP (p 
= 0.001) and a Kynurenine/tryptophan ratio (p = 0.05) compared to healthy controls. 
There was a greater cortisol output as measured by the Area under the Curve with respect 
to ground (AUCg) (p = 0.05) in the depressed group. There were no significant 
differences in LBP levels or fecal SCFAs. A Principal Component Analysis (PCA) model 
of fecal metabolites did not reveal distinct clusters.  
Conclusions: We confirm that depression is associated with HPA axis, immune system 
and tryptophan dysregulation. Moreover, we show that depression is characterised by 
alterations in the gut microbiota at the family and genus level. Given that the metabolic 
output of this altered composition was not compromised and gut barrier function 
remained intact, further exploration of alternative mechanisms explaining the 
contribution of an altered gut microbiota profile to the pathophysiology of depression is 
warranted.  
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2.2 Introduction  
Depression is a common, often recurrent (Eaton et al., 2008) heterogeneous disorder 
responsible for significant disability worldwide (WHO, 2008). The complex aetiology 
involves dysregulated neuroendocrine (Stetler and Miller, 2011) neuroimmune (Dowlati 
et al., 2010), metabolic (Jokela et al., 2014) and neurotransmitter systems (Berton and 
Nestler, 2006). Current pharmacological interventions are suboptimal (Fava, 2003) and 
there has been little progress in the identification of biomarkers.  
 
Accumulating evidence from preclinical studies suggests that the gut microbiota can 
modulate brain activity and behaviour via neuroendocrine, neuroimmune, neural and 
humoral pathways (Cryan and Dinan, 2012a, Dinan and Cryan, 2013). This emerging 
link between the gut microbiota and the central nervous system suggests that gut 
microbiota modification may have translational applications in the treatment of 
neuropsychiatric disorders (Cryan and Dinan, 2015b, Desbonnet et al., 2014, Hsiao et 
al., 2013). 
 
Data from animal studies provides evidence that the gut microbiota may impact on the 
neurobiological features of depression (Park et al., 2013), such as low-grade immune 
activation (Bailey et al., 2011), hypothalamic-pituitary-adrenal axis (HPA) activity 
(Sudo et al., 2004), altered tryptophan metabolism (Clarke et al., 2013, El Aidy et al., 
2012, O'Mahony et al., 2015a, Yano et al., 2015), neurotrophic factors (Bercik et al., 
2011b), and neurogenesis (Mohle et al., 2016, Ogbonnaya et al., 2015). 
 
Different lactobacillus and bifidobacteria species have been shown to modulate 
depression and stress-related behaviours in animal models (Bravo et al., 2011, Desbonnet 
et al., 2010, Savignac et al., 2015b). Furthermore, a growing number of small studies 
suggest pre- and probiotic consumption can positively affect aspects of mood and anxiety 
(Akkasheh et al., 2016, Messaoudi et al., 2011, Steenbergen et al., 2015b), modulate 
HPA function (Messaoudi et al., 2011, Schmidt et al., 2015) and alter brain activity 
(Tillisch et al., 2013a). However, there are a paucity of clinical studies in well 
phenotyped pathological populations (Jiang et al., 2015, Naseribafrouei et al., 2014, 
Zheng et al., 2016a). 
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We investigated alterations in the gut microbiota composition in patients with depression 
compared to healthy controls with respect to signature physiological alterations in HPA 
axis function, immune activation and tryptophan metabolism. We aimed to identify the 
functional consequences of the gut microbiota alterations in depression by determining 
levels of fecal short chain fatty acids. We then assessed gut permeability as a potential 
mechanism by which gut bacteria may influence brain function (Julio-Pieper et al., 2014, 
Kelly et al., 2015).  
 
2.3 Methods 
Subjects 
Approval of the study protocol was granted by the Cork University Hospital ethics 
committee (Protocol Number: APC045) and written informed consent was obtained from 
all subjects. Thirty four depressed patients were recruited from outpatient and inpatient 
psychiatric clinics by a psychiatrist (JK). The Diagnostic and Statistical Manual of 
Mental Disorders (DSM IV) was used to confirm major depressive disorder diagnosis. 
Thirty three healthy subjects, screened using the Mini International Neuropsychiatric 
Interview (MINI), and matched for gender, age and ethnicity were recruited from 
advertisements directed at staff at Cork University Hospital and University College Cork. 
Inclusion criteria were as follows: age between 18 and 65 years, Hamilton depression 
score greater than 17. All patients had been prescribed antidepressant medication before 
referral to the secondary care service. Exclusion criteria were as follows: the use of 
probiotics, antibiotics use in the previous 4 weeks, active infections, glucocorticoids, 
nonsteroidal anti-inflammatory drugs, diabetes, inflammatory bowel disease, irritable 
bowel syndrome, recent gastrointestinal surgery, arthritis, pregnancy, and active alcohol 
or substance abuse or dependency. Inpatients were excluded if admission was greater 
than one week. 
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Clinical Measures 
Anxiety Beck Anxiety Inventory (Beck et al., 1988) 
 Perceived Stress Scale (Levenstein et al., 1993) 
Mood Hamilton rating scale for Depression (HAMD 17) (Hamilton, 1960) 
 Beck Depression Inventory (Beck et al., 1961) 
Traumatic 
Events 
Early Life events scale 
Recent Life events scale 
 
Sleep Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989) 
Exercise International Physical Activity Questionnaire 
(IPAQ) short version 
(Craig et al., 2003)  
 
Diet The Food Frequency Questionnaire (FFQ) (Harrington et al., 2010) 
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Microbiota analysis 
Fecal samples were collected in a plastic containers containing an anaerobic generator 
AnaeroGen Compact Oxoid sachet. The fecal sample was transported to the laboratory 
and opened in an anaerobic hood. For the preparation of the fecal sample for inoculation, 
1g of fecal sample was place into a stool collection tube and 10 mls of reduced PBS 
containing 15% (v/v) glycerol was added. Fecal slurry was prepared by vortexing each 
tube until the mixture was homogenous. The sample was frozen at -80oC in cryovials in 
1ml aliquots until further use. DNA was either extracted from fresh samples within 24 
hours or from frozen samples using QIAamp DNA Stool Mini Kit (Qiagen, Hilden, 
Germany). DNA was extracted from 21 frozen fecal samples and 43 from fresh samples. 
This has been shown to have little impact on the integrity of the microbiota (Fouhy et al., 
2015) and the Chao1, Simpson, Shannon, phylogenetic diversity and observed species 
between samples extracted from fresh and frozen were compared, and no significant 
differences were observed. Extracted DNA was prepared for sequencing on the Illumina 
Miseq platform using the Illumina recommended protocol: DNA was amplified using 
16S Amplicon primers selected from (Klindworth et al., 2012). Forward Primer = 5' 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 
Reverse Primer = 5' 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC. The PCR product was purified of free primers and primer-dimer species using 
AMPure XP beads. Amplicons were tagged using the Illumina Nextera XT Index kit, and 
purified again using AMPure XP beads. The amplicons were quantified using Qubit 
fluorometric analysis and then normalised before pooling and sequencing. 300bp paired-
end reads were combined using FLASH. Quality filtering removed reads with a quality 
score of <20 using QIIME. Filtered sample read numbers ranged from 28,057-895,372, 
with a mean read number of 157,030. Removal of chimeras and clustering of reads into 
operational taxonomic units (OTUs) was performed with USEARCH v7 (64-bit) with a 
lower threshold of 97% identity. OTUs were then aligned with PyNAST, and taxonomy 
was assigned using BLAST against the SILVA SSURef database release 111. The 
observation data were rarefied using QIIME to remove skew caused by samples 
containing very low or very high numbers of reads; a subsampling depth of 60,000 was 
chosen as optimal to maintain the maximum of both observed diversity and sample 
numbers. This left 23 test and 25 control samples. The Benjamini-Hochberg procedure 
was used to correct for multiple comparisons where appropriate with a FDR-adjusted p-
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value ≤ 0.1 considered significant (Thissen et al., 2002). Statistical tests were performed 
using R using the Mann-Whitney U test with continuity correction. Using QIIME, Alpha 
diversity was calculated for Chao1, Simpson, Shannon, observed species and Faith’s 
phylogenetic diversity. Beta diversity was calculated for Bray Curtis (R2 = 0.03444, p = 
0.014), weighted (R2 = 0.05515, p = 0.018) and unweighted unifrac (R2 = 0.05515, p = 
0.018) using the multivariate ANOVA method "adonis" adapted in QIIME from the R 
"Vegan" package.  
 
SCFA analysis 
A modified version of the method used by (Zhao et al., 2006) was used to analyse SCFA 
from human fecal samples: 1g of sample was mixed with 5mls of sterile distilled water 
and vortex for 3 minutes. The pH of the suspension was adjusted to 2-3 with 5M HCL 
and allowed to sit at room temperature for 10 minutes with occasional shaking. The 
samples were centrifuged at 4600rpm for 30 minutes. The supernatant was filtered 
through a 0.2um filter and 900ul of the sample was removed in duplicate into sterile 
eppendorfs. 100ul of 3.0mM-2-ethylbutyric acid (Sigma) was added as an internal 
standard to each sample. This was centrifuged for 3 minutes at full speed and transferred 
to a clear glass vial. Standard solutions containing 10.0, 8.0, 6.0, 4.0, 2.0, 1.0 and 0.5 
mmol/l of acetic acid, propionic acid, isobutyric acid and butyric acid (Sigma), 
respectively, were used for calibration. The concentration of SCFA was measured using 
a Varian 3800 GC flame ionisation system, fitted with a ZB-FFAP column (30m x 
0.32mmx 0.25 mm; Sigma). Helium was used as a carrier gas at a flow rate of 1.3 ml/min. 
The initial oven temperature was 50oC and held for 0.5 min, raised to 140oC at a rate of 
10C/min and held for 0.5 min for a total of 10 minutes and finally held at 240oC at a rate 
of 20oC /min and held for 5 minutes to give a total run time of 20 minutes. The 
temperature of the detector and injector were set at 250oC and 240oC, respectively Peaks 
were integrated by using the Varian Star Chromatography Workstation version 6.0 
software. Standards were included in each run to maintain calibration. 
 
Metabolomic analysis   
Fecal water was prepared from the fecal matter of 20 depression samples and 18 healthy 
controls. 200-400 mg of fecal material was placed into sterile 2 ml microcentrifuge tubes. 
Sterile PBS was added. 400 mg required 800 µl PBS. A slurry was produced by vigorous 
manual shaking and then centrifuged at 16000g for 30 mins. The supernatant was 
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centrifuged in 2ml microcentrifuge tubes at 16000 g for 30 mins. The supernatant was 
filtered through a VectaSpin Micro centrifuge filters 0.2 µm at recommended top speed 
10,000 g until clear. The fecal water was stored at –20°C. All samples have been 
derivatized with methyl chloroformate (MCF). MCF converts amino and nonamino 
organic acids into volatile carbamates and esters. Although limited to compounds 
presenting amino and/or carboxyl groups, these include most metabolites of the central 
carbon metabolism, which are key intermediate of the cell metabolism. The samples were 
randomised and analysed by Gas Chromatography Mass Spectometry (GC-MS). A 
mixed pooled sample (QC sample) was created by taking a small aliquot from each 
sample. Every four-to-five samples, this QC sample was analysed. Testing of matrix 
effects was performed by spiking/dilution of QC samples. The raw GC-MS data was 
processed by software developed by MS-Omics and collaborators.  
 
Salivary Cortisol analysis 
Participants were instructed to collect three saliva samples using Salivettes (Sarstedt AG 
and Co, Numbrecht, Germany) at the following time points: (t 0) upon wakening, 30 
minutes post wakening (t +30hr), and 150 minutes post wakening (t + 150). As it is not 
yet established if variable waking times affect the cortisol awakening response, we took 
the approach which is common in the literature (Hinkelmann et al., 2013) and did not 
require that participants wake at a specific time, but followed their normal routine as 
closely as possible. Waking times were recorded for analysis to determine any group 
differences. Salivettes were centrifuged at 1000 g for 5 min and aliquoted and stored 
initially at -35oC then transferred to - 80oC until analysis. Cortisol concentrations were 
determined using the Cortisol Enzyme Immunoassay Kit as per manufacturers’ 
instruction (Enzo®, Life Sciences). Assay detection limit was 0.16 nmol/L. Inter and 
intra-assay % C.Vs were 11.24% and 8.2% respectively. 
 
Kynurenine/Tryptophan analysis 
Plasma samples were spiked with internal standard (3-Nitro l-tyrosine) prior to being 
deproteinised by the addition of 20 μl of 4M perchloric acid to 200 μl of sample. Samples 
were centrifuged at 21000g on a Hettich Mikro 22R centrifuge (AGB, Dublin, Ireland) 
for 20 minutes at 4°C and 100 μl of supernatant transferred to a HPLC vial for analysis 
on the HPLC system (UV and FLD detection). All samples were injected onto a reversed 
phase Luna 3 μm C18 (2) 150 × 2 mm column (Phenomenex), which was protected by 
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Krudkatcher disposable pre-column filters (Phenomenex) and SecurityGuard cartridges 
(Phenomenex). The mobile phase consisted of 50 mM acetic acid, 100 mM zinc acetate 
with 3% (v/v) acetonitrile and was filtered through Millipore 0.45 μm HV Durapore 
membrane filters (AGB) and vacuum degassed prior to use. Compounds were eluted 
isocratically over a 30-minute runtime at a flow rate of 0.3 mls/min after a 20 μl injection. 
The column was maintained at a temperature of 30°C and samples/standards were kept 
at 8°C in the cooled autoinjector prior to injection. The fluorescent detector was set at an 
excitation wavelength of 254 nm and an emission wavelength of 404 nm. The UV 
detector was set to 330 nm. L-tryptophan and kynurenine were identified by their 
characteristic retention times as determined by standard injections which were run at 
regular intervals during the sample analysis. Analyte: Internal standard peak height 
rations were measured and compared with standard injections and results were expressed 
as ng/ml of plasma. 
 
Cytokine sampling & analysis 
10ml of whole blood was collected in heparinized tubes. Samples were centrifuged 
immediately at 1,000 x g for 15 minutes and then aliquoted. Samples were frozen initially 
at -35oC and then transferred to -80oC until analysis. Plasma levels of IL-6, IL-8, TNF-
α, and CRP were assayed in duplicate using high sensitivity commercially available 
electrochemiluminescence MULTI-SPOT® Meso Scale Discovery kits (MSD, 
Rockville, MD, 75USA) as per manufacturer’s instructions. The median lower limits of 
detection for each cytokine are; IL-6; 0.06 pg/ml, IL-8; 0.04 pg/ml, TNF-α 0.04 pg/ml 
and CRP; 0.1 ng/ml. 
 
Lipopolysaccharide Binding Protein (LBP) 
10ml of whole blood was collected in heparinized tubes. Samples were centrifuged 
immediately at 1,000 x g for 15 minutes and then aliquoted. Samples were frozen initially 
at -35oC and then transferred to -80oC until analysis. LBP concentrations were 
determined using the Enzyme Immunoassay Kit for free human LBP as per 
manufacturers’ instruction (Enzo®, Life Sciences). Sensitivity: Range 5-50ng/ml.  
 
Statistical Analysis. Data that were normally distributed according to Shapiro-Wilk test 
were analyzed using unpaired t tests. Outliers were removed by Grubbs' test. Data that 
were not normally distributed were transformed by square root transformation. 
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Microbiota data were analyzed using non parametric tests. Benjamini-Hochberg 
procedure was used to correct for multiple comparisons with a FDR-adjusted p-value ≤ 
0.1 considered significant. Statistical procedures were carried out using IBM SPSS 20.0. 
Graphs were generated using GraphPad Prism 5. Macronutrient data was generated using 
Diet Plan 6.  
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2.4 Results 
Demographic data and health indicators 
Other than education level, employment status, smoking and alcohol consumption, there 
were no differences between the groups (Table 2.1). Clinical characteristics of the 
depressed patients are presented in (Table 2.2). 
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Table 2.1: Comparison of group demographics and health indicators 
  Controls (n=33) Depression 
(n=34) 
p-value 
      
Age mean (s.d.) 45.8 (11.9) 45.8 (11.5) 0.98 
Sex:   Male (%)  19 (57.6) 21 (61.8) 0.73 
           Female (%) 14 (42.4) 13 (32.8)   
        
Education, degree level (%) 26 (78.8) 8 (23.5) <0.001*** 
Relationship status (% yes) 23 (69.7) 20 (58.8) 0.35 
Employed (% yes) 31 (93.9) 16 (47.1) <0.001*** 
        
Alcohol units/week mean, (s.d) 9.24 (8.3) 5.29 (5.9) 0.03* 
1st degree relative with alcohol use disorder 4 (12.1) 12 (35.3) 0.03* 
Smoking (%)       
Current  3 (9.1) 13 (38.2)   
Ex 19 (57.6) 3 (8.8)   
Never 11 (33.3) 18 (52.9) <0.001*** 
        
BMI mean (s.d.) 24.58 (2.7) 26.2 (4.5) 0.07 
        
Dyslipidaemia (%) 4 (12.1) 7 (20.6) 0.51 
HTN (%) 3 (9.1) 3 (8.8) 0.97 
        
Physical Activity (IPAQ)        
Low (%) 7 (21.2) 13 (38.2)   
Moderate (%) 16 (48.5) 14 (41.2)   
High (%) 10 (30.3) 6 (17.6) 0.23 
Metabolic Equivalent Task Units (MET) 
median, range 
1386 (7287) 693 (7722) 0.1 
Hours sitting per day mean, (s.d) 6.03 (2.730) 5.97 (2.456) 0.92 
Data are presented as mean and S.D, or median and range. BMI, body mass index; HTN, 
Hypertension; IPAQ, International Physical Activity Questionnaire. *p<0.05 vs control. 
**p<0.01 vs control; ***p<0.001 vs control. 
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Table 2.2: Comparison of group clinical characteristics 
  Controls (n=33) Depression 
(n=34) 
p- value 
Diagnosis       
Depression (%) NA 29 (85.3)   
BPAD II (%) NA 5 (14.7)   
        
Co-morbid Anxiety Disorder (%) NA 4 (11.7)   
Ex-Alcohol abuse (%) NA 8 (23.5)   
Ex-Substance abuse (%) NA 3 (8.8)   
Ex-Alcohol & Substance abuse (%) NA 2 (5.8)   
        
        
HAMD 17 median (range)  NA 19.5 (14)   
Beck Depression mean, (s.d)  NA 32.4 (9.92)   
Duration of Depressive sx (months) median, 
(range) 
NA 3.0 (72)   
Number of Depressive episodes median 
(range) 
NA 1.0 (8)   
Positive Family History of Depression (%) 2 (6.1) 21 (61.8) <0.001*** 
        
Beck Anxiety median, (range) NA 25.5 (45)   
Perceived Stress Scale (PSS) mean, (s.d) 7.5 (4.9) 27.7 (6.0) <0.001*** 
Pittsburgh Sleep Quality Index (PSQI) 
mean, (s.d) 
2.8 (1.8) 11.7 (4.3) <0 .001*** 
Data are presented as mean and S.D, or median and range. *p<0.05 vs control. **p<0.01 
vs control; ***p<0.001 vs control. 
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Figure 2.1: Life Events and Medication.  
(A) The depressed group (n = 34) experienced significantly more parental upheaval (χ2 
(1) = 5.35, p = 0.02), traumatic sexual experiences (χ2 (1) = 4.24, p = 0.04) and violence 
(χ2 (1) = 4.70, p = 0.03) prior to the age of 17 years and (B) more relationship upheaval 
(χ2 (1) = 7.76, p = 0.01) and illness/injury (χ2 (1) = 4.24, p = 0.04) in the last 3 years 
compared to the control group (n = 33). (C) Percentage of depressed subjects prescribed 
psychotropic medication. 
 
Daily Macronutrient Consumption similar in depressed patients and controls 
We assessed Daily Macronutrient Consumption using a food frequency questionnaire 
(Table 2.3). Apart from Trans fats (t (61) = 2.06, p = 0.05) there were no significant 
differences in diet between the groups. Total fats were not significantly different between 
the groups (t (61) = 1.19, p = 0.24).  
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Table 2.3. Daily Macronutrient Consumption.  
Macronutrient Controls (s.d.), N=33 Depression (s.d.), N=30 p 
Quantity (g) 2330.53 (1130.1) 2304.9 (1210.67) 0.93 
Total Nitrogen (g) 13.36 (4.46) 14.07 (6.59) 0.62 
Protein (g) 82.5 (27.61) 87.47 (41.18) 0.57 
Fat (g) 75.49 (31.54) 87.70 (50.66) 0.25 
CHOm (available carbs) (g) 296.33 (166.6) 288.62 (135.65) 0.84 
Energy kcal 2202.09 (827.96) 2234.51 (1064.75)  0.89 
        
Starch (g) 107.55 (44.03) 114.96 (38.75)  0.49 
Total Sugar (g) 157.35 (80.71) 151.48 (107.07) 0.81 
Non Milk Extrinsic Sugars 
(g) 
23.85 (median), 22.88 (IQR) 29.1 (median), 28.9 (IQR) 0.43  
Glucose (g) 28.45 (17.31) 27.78 (21.24) 0.89 
Fructose (g) 51.31 (39.36) 48.11 (40.65) 0.75 
Sucrose (g) 60.27 (39.62) 59.58 (38.20) 0.94 
Maltose (g) 2.07 (1.39) 2.41 (1.53) 0.36 
Lactose (g) 11.65 (median), 9.75 (IQR) 8.45 (median), 20.7 (IQR) 0.55  
Non-starch polysaccharides 
(g) 
26.96 (12.53) 24.91 (12.43) 0.52 
Fibre (AOAC method) (g) 34.2 (16.21) 31.53 (16.32) 0.52 
        
Sat.fats (g) 28.96 (14.89) 35.63 (22.19) 0.17 
MonoUfats (g) 25.08 (10.24) 29.37 (16.62) 0.22 
PolyUfats (g) 14.17 (6.13) 14.57 (8.96) 0.48 
Transfats (g) 1.66 (0.87) 2.31 (1.53) 0.05 
Cholesterol (mg) 259.85 (122.43) 294.92 (132.50) 0.28 
        
Calories from Protein 329.93 (110.36) 350.58 (164.89) 0.56 
Calories from Carbs 1021.16 (367.96) 1082.58 (508.87) 0.59 
Calories from Fat 679.43 (283.91) 789.19 (455.72) 0.25 
Calories from Fiber 68.41 (32.47) 63.19 (32.65) 0.53 
        
Percentage Protein 14.99 (3.23) 15.6 (3.12) 0.46 
Percentage Carbs 47.53 (9.16) 47.55 (7.90) 1.00 
Percentage Fat 30.43 (7.81) 33.52 (7.75) 0.12 
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Percentage Fiber 3.32 (1.41) 2.83 (1.12) 0.14 
 
Macronutrient Controls (s.d.), N=33  Depression (s.d.), N=30   p 
Sodium (mg) 2385.9 (942.86) 2552.3 (1180.20) 0.55 
Potassium (mg) 4355.22 (1610.90) 4253.87 (2077.0) 0.83 
Calcium (mg) 1002.78 (482.24) 1043.96 (753.06) 0.78 
Magnesium (mg) 398.21 (181.9) 352 (180.99) 0.32 
Phosphorus (mg) 1615.75 (626.24) 1603.32 (862.58) 0.95 
Iron (mg) 13.28 (5.12) 12.45 (5.59) 0.54 
Copper (mg) 1.99 (0.93) 1.87 (1.00) 0.64 
Zinc (mg) 10.44 (3.68) 11.24 (4.75) 0.45 
Chloride (mg) 4021.12 (2483.31) 4231.58 (2423.71) 0.74 
Manganese (mg) 4.23 (1.82) 3.95 (1.98) 0.58 
Selenium (ug) 49.91 (21.40) 47.53 (26.33) 0.70 
Seleno Protein P  (mg/ml 
serum) 
3.61 (1.50) 2.85 (1.55) 0.05 
Iodine (ug) 187.77 (100) 174.41 (117.77) 0.63 
Retinol (ug) 337.87 (193.81) 340.48 (204.72) 0.96 
Carotene (ug) 3566.22 (2037.85) 3488.56 (2136.80) 0.89 
Vitamin D (ug) 2.87 (1.57) 2.38 (1.57) 0.24 
Vitamin E (mg) 12.95 (6.14) 11.64 (7.32) 0.45 
Thiamin (mg) 1.62 (0.72) 1.5 (0.59) 0.48 
Riboflavin (mg) 1.85 (0.89) 1.79 (1.01) 0.80 
Niacin (mg) 21.05 (6.18) 20.66 (9.43) 0.85 
        
Tryptophan divided by 60 
(mg) 
16.59 (5.76) 17.06 (7.76) 0.78 
Vit.B6 (mg) 2.26 (0.8) 2.22 (0.9) 0.83 
Vit.B12 (ug) 4.96 (2.78) 6.1 (4.59) 0.24 
Folate (ug) 286.12 (142.64) 241.96 (108.96) 0.21 
Pantothen (mg) 5.97 (2.8) 5.92 (3.1) 0.95 
Biotin (ug) 43.98 (21.1) 40.1 (25.40 0.51 
Vitamin C (mg) 154.51 (131.48) 142.19 (111.64) 0.69 
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Proinflammatory profile in depression 
The depressed group had increased levels of IL-6 (t (62) = 2.69, p = 0.009), IL-8 (t (61) 
= 2.37, p = 0.021), TNF-α, (t (49) = 2.36, p = 0.022) and CRP (t (45) = 3.6, p = 0.001) 
compared to the healthy controls (Figure 2.2A-D).  
 
Activated Kynurenine pathway in depression 
The kynurenine/tryptophan ratio was significantly higher in the depressed group 
compared to the controls (t (61) = 2.01, p =0.049) (Figure 2.2E). There were no 
significant differences in tryptophan (t (58) = 0.92, p=0.362), kynurenine (t (63) = 1.00, 
p=0.320), kynurenic acid (t (45) = 0.38, p=0.70), or the kynurenic acid/kynurenine ratio 
(t (44) = 0.40, p=0.685). 
 
Altered HPA axis in depression 
AUCg analysis showed that patients with depression exhibited a greater total cortisol 
output (t (50) = 2.06, p = 0.045) (Figure 2.2F) but no difference in the delta cortisol 
response (t (50) = - 0.40, p = 0.69) or AUCi (t (50) = -0.67, p = 0.51). There were no 
significant differences between baseline cortisol levels upon wakening (t (50) = 1.88, p 
= 0.06), 30 minutes post wakening (t (50) = 1.28, p = 0.206), or 150 minutes post 
wakening (t (50) = 1.73, p = 0.09) (Figure 2.2G). Although there was no significant 
baseline difference between groups, when controlling for baseline cortisol values there 
was not a significantly elevated AUCg between groups. 
 
No alterations in intestinal permeability in depression  
There were no significant differences in plasma LBP levels (Depression versus Healthy 
controls, 39 ± 2.7, vs. 36 ± 2.1; t (63) = 1.05, p = 0.30) between the groups (data not 
shown).  
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Figure 2.2: Altered Inflammatory, Tryptophan, and HPA profile in depressed 
patients. The depressed patients (n = 34) had significantly increased levels of (A) IL-6 
(t (62) = 2.69, p = 0.009) (B) IL-8 (t (61) = 2.37, p = 0.021) (C) TNF-α (t (49) = 2.36, p 
= 0.022) and (D) CRP (t (45) = 3.6, p = 0.001) compared to the healthy controls (n = 33). 
The depressed group had a significantly increased (E) Kynurenine/tryptophan ratio (t 
(61) = 2.01, p =0.049) and a greater cortisol output as measured by the (F) Area under 
the Curve with respect to ground (AUCg) (t (50) = 2.06, p = 0.045), though no significant 
difference in the (G) Cortisol Awakening Response (CAR) (p = 0.21).  
 
 
Altered Gut Microbiota Composition, Alpha Diversity & Richness in depressed 
patients  
Chao1 richness (U = 424, p = 0.005), total observed species (U = 441, p = 0.002) and 
phylogenetic diversity (U = 447.5, p = 0.001) were decreased in the depressed group (n 
= 23). There was no difference in Shannon diversity (U = 350, p = 0.197) (Figure 2.3A-
D). The difference of the global microbiota composition from the 16S rRNA data of the 
depressed and control groups (n = 25) was assessed by ordination. Statistics based on 
random permutations of the redundancy analysis (RDA) showed that the depressed group 
is significantly separated at genus level (p = 0.03) from the control group (Figure 2.3E). 
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At the phylum level, there were no statistically significant differences in the relative 
abundances between the depressed group and the healthy controls (data not shown). At 
the family level, the relative proportions of Prevotellaceae (U = 355, p = 0.007) were 
decreased, whereas Thermoanaerobacteriaceae were increased in the depressed group 
(U = 52.5, p = 0.021) (Figure 2.3F). At the genus level, the relative proportions of 
Eggerthella (U = 21.0, p = 0.009), Holdemania (U = 146.5, p=0.023), Gelria (U = 52.5, 
p = 0.021), Turicibacter (U = 89, p = 0.034), Paraprevotella (U = 119, p = 0.041), and 
Anaerofilum (U = 50.5, p = 0.021) were increased in the depressed group, whereas 
Prevotella (U = 324.5, p = 0.022) and Dialister (U = 153.5, p = 0.032) were decreased 
(Figure 2.3G). 
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Figure 2.3: Altered Gut Microbiota Composition, Alpha Diversity & Richness in 
depressed patients. There was a significant reduction in richness as measured by (A) 
Chao1, (U = 424, p = 0.005) and (B) Total observed species, (U = 441, p = 0.002). The 
depressed group (n = 23) showed reduced (C) phylogenetic Diversity, (U = 447.5, 
p = 0.001), but no significant differences in (D) Shannon diversity, (U = 350, p = 0.197). 
(E) The significant differences at genus level between the depressed group and the 
controls (n = 25) which cluster by group in a Redundancy analysis (RDA) plot (p = 0.03). 
(F) Significant Family level differences and (G) significant genus level differences 
between depressed patients and healthy controls in % relative abundances.  
 
Altered Beta Diversity in depressed patients  
There were significant differences in beta diversity between the healthy (n = 25) and 
depressed groups (n = 23) (Bray-Curtis (p = 0.014), unweighted unifrac (p = 0.002) and 
weighted unifrac (p = 0.018). However, PCoA analysis was unable to separate the groups 
(Figure 2.4A-C).  
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Figure 2.4: Beta Diversity in depressed patients (n = 23) PCoA plots representing (A) 
Bray-Curtis (R2 = 0.03444, p = 0.014), (B) unweighted (R2 = 0.05515, p = 0.018) and 
(C) weighted unifrac beta diversity (R2 = 0.05515, p = 0.018). Red represents healthy 
controls (n = 25) and black represents depressed patients. 
 
 
 
A. 
B. 
C.  
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Short chain Fatty Acids 
There were no significant differences between groups in the fecal SCFAs, acetate (t (49) 
= 0.457, p = 0.65), propionate (t (49) = 0.103, p = 0.918), iso-Butyrate (t (43) = 0.678, p 
= 0.501) or butyrate (t (49) = - 0.168, p = 0.867) (Figure 3A). 
 
 
Figure 2.5. Short chain Fatty Acids & Fibre. (A) There were no significant 
differences in fecal SCFAs. (B) There were no significant differences in the daily % 
fibre consumed between the groups (t (61) = 1.5, p = 0.134) (C) though within the 
depressed group (n = 34) the daily % fibre negatively correlated with the Beck 
Depression Scale (r = - 0.43, n = 31, p = 0.015). 
 
No alterations in Fecal Metabolites.  
A Principal Component Analysis (PCA) model did not reveal distinct grouping of the 
depression (n = 20) samples compared to the healthy control (n = 18) samples (Figure 
2.6). (A) Loading plot from PCA model calculated on the relative concentrations of the 
metabolites. (B) Score plot from PCA model calculated on the relative concentrations of 
the fecal metabolites. Red represents depressed patients and green represents healthy 
controls, blue triangles represents a mixed pooled sample (quality control sample). Data 
has been autoscaled. (C) Heat map demonstrating the change in concentration of fecal 
metabolites (log2) between depressed patients and healthy controls. 
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Figure 2.6. Fecal Metabolites. (A) Loading plot from PCA model calculated on the 
relative concentrations of the metabolites. (B) Score plot from PCA model calculated 
on the relative concentrations of fecal metabolites. Red represents depressed patients, 
green represents healthy controls and blue represents quality control samples. Data has 
(C) 
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been autoscaled. (C) Heat map demonstrating the change in concentration of fecal 
metabolites (log2) between depressed patients (n = 20) and healthy controls (n = 18).   
 
 
2.5 Discussion   
Our results confirm our main hypothesis and we have demonstrated that depression is 
associated with an altered gut microbiota composition, richness and diversity. It was 
possible to differentiate the depressed group from the healthy control group based on 
differences at the genus level using redundancy plot analysis (Figure 2.3E). The most 
pronounced difference was observed in the reduction of Prevotellaceae family and 
subsequently in the Prevotella genus, previously found to be decreased in Parkinson’s 
disease patients (Gustafsson et al., 2015, Scheperjans et al., 2015). A significant 
association has been noted between the Mediterranean diet, regarded as a preventive 
strategy in depression, and Prevotella (De Filippis et al., 2015, Opie et al., 2015). 
However, the differences in the gut microbiota profiles did not impact functional readouts 
as measured by SCFAs or in the fecal metabolomic profile between depressed patients 
and healthy controls.  
 
A significant increase in the order Bacteroidales and a decrease in Lachnospiraceae 
family compared to controls was previously shown in depressed patients (Naseribafrouei 
et al., 2014). The second study to investigate the gut microbiota in depression separated 
the depressed group into an actively depressed group and those that had responded to 
treatment (Jiang et al., 2015). Similar to our study, they demonstrated a decrease in 
Prevotellaceae and Prevotella in depressed patients. However, they found a significant 
increase in Shannon diversity in the actively depressed group compared to controls and 
no significant differences in richness. They reported no differences in circulating pro-
inflammatory cytokines in contrast to low grade inflammation described in depressed 
patients (Dinan, 2009b). The most recent study, found an increase in Actinobacteria and 
a decrease in Bacteroidetes in the depressed group at the phylum level and 54 differences 
in the operational taxonomic units (OTUs) between the groups. There were no significant 
differences in alpha diversity (Shannon, Simpson, phylogenetic diversity, observed 
species). Dietary factors, geography or methodological differences during sampling, 
processing or analysis may also account for discrepancies (Kelly et al., 2016c).  
 
90 
 
We show that depression is associated with dysregulated tryptophan metabolism as 
indicated by an increased plasma kynurenine: tryptophan ratio. Together with the 
potential impact on serotonin, increased microbiota-mediated degradation of tryptophan 
along this pathway has a broad range of implications for multiple neurotransmitter 
systems (Schwarcz et al., 2012). The rate of tryptophan metabolism along the kynurenine 
pathway is dependent on the activity of indoleamine-2, 3-dioxygenase (IDO), an enzyme 
induced by cytokines, and tryptophan-2,3-dioxygenase (TDO), the expression of which 
can be induced by circulating glucocorticoids (O'Connor et al., 2009) and has been 
reported to be regulated by the gut microbiota during colonization (El Aidy et al., 2014).  
 
The impact of stress on the gut microbiome might also be a factor and we have previously 
shown that early life stress can remodel the gut microbiota (O'Mahony et al., 2009). It is 
plausible that subtle alterations in microbiota acquisition or maintenance during this 
vulnerable early life period may act as to impact on (neuro)endocrine and (neuro)immune 
signalling pathways of the brain-gut-microbiota axis, disruption of which may 
subsequently predispose to stress-related disorders in adulthood (Sudo et al., 2004). The 
depressed group in our study did experience more stressful life events prior to the age of 
17 years and in the last 3 years compared to the healthy group (Figure 2.1A-B).  
 
Studies have demonstrated higher IgA- and IgM-mediated immune responses directed 
against LPS of certain commensal gram negative gut bacteria in depression (Maes, 2008, 
Maes et al., 2012b, Maes et al., 2013). Bacterial DNA has been detected in whole serum 
from depressed patients who also displayed increased TLR4 expression on peripheral 
mononuclear blood cells compared to healthy controls (Keri et al., 2014). Although we 
demonstrated dysregulated inflammatory (Figure 2.2A-D) and HPA axis function 
(Figure 2.2G) in the depressed group, we cannot rule out the possibility of glucocorticoid 
receptor resistance playing a role (Calfa et al., 2003, Pariante and Miller, 2001).  
 
We hypothesized that gut permeability could act as a conduit by which the gut microbiota 
may impact brain and behaviour. Using LBP as a marker of intestinal permeability 
(Forsyth et al., 2011) we found no statistically significant differences in intestinal 
permeability in the depressed patients. It is possible that gut permeability challenge 
studies or alternative markers to localise the barrier deficit may be required to resolve 
this uncertainty. 
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Our study was the first to record diet. Apart from trans-unsaturated fatty acids there were 
no significant differences in diet between the groups. Although the percentage of daily 
fibre consumed was the same between our depressed and healthy groups, we found a 
negative correlation with depressive symptoms in our depressed group suggesting an 
important role for fibre, and fermentation products of fibre in depression (Figure 2.5).  
 
Limitations 
Ideally, medication free patients would have been recruited. However, in this study, the 
majority of depressed patients in this study were prescribed antidepressant medication 
(Figure 2.1C) and there were significant differences in alcohol and cigarette 
consumption (Table 2.1). We acknowledge the possibility of an antidepressant-related 
and serotonin-driven contribution to the alteration in the gut microbiota. In addition, as 
this study was cross-sectional, only one time point was assessed.  
 
In conclusion, we confirm that depression is associated with neuroimmune and 
neuroendocrine dysfunction. Moreover, we show that depression is associated with an 
altered gut microbiota profile albeit in the absence of a compromised metabolic output 
or impacting on gut barrier integrity. Further studies exploring the mechanisms by which 
an altered gut microbiota profile may contribute to the pathophysiology of depression are 
required.  
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Chapter 3: Fecal Microbiota 
Transplantation induces behavioural & 
physiological changes in Antibiotic treated 
Rats 
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3.1 Abstract  
Background: Depression is associated with an altered gut microbiota composition, 
richness and diversity. However, it is not clear whether the gut microbiota plays a causal 
role in the pathophysiology of depression. A number of preclinical studies have shown 
that it is possible to transfer characteristics from donor to recipient via fecal microbiota 
transplantation (FMT). We aimed to further elucidate the mechanistic underpinnings 
explaining the interaction between depression and the microbiota using a FMT to 
microbiota-depleted rats. We tested the hypothesis that behavioural and physiological 
features of depression could be transferred via the gut microbiota. 
Methods: FMT was prepared from a sub group of depressed patients and matched 
healthy controls. The FMT was transferred by oral gavage to a microbiota-depleted rat 
model. A battery of behavioral tests and physiological measures were carried out post 
FMT. Plasma cytokines, CRP, cortisol and Lipopolysaccharide binding protein (LBP) 
were determined by ELISA. Plasma tryptophan and kynurenine were determined by 
HPLC. Hippocampal BDNF gene expression levels were determined by qRT-PCR. Fecal 
samples were collected for 16s rRNA sequencing. Fecal Short chain fatty acids (SCFAs) 
were determined by Gas Chromatography. 
Results: Rats that received the FMT from depressed patients demonstrated decreased 
sucrose intake (t (12) = 2.628, p = 0.022), decreased visits to the open arms (t (12) = 
2.471, p = 0.029) in the elevated plus maze, and a reduction in time spent in the centre in 
the open field (t (24) = 2.662, p = 0.013). There were no significant differences in the 
Forced swim test. In addition, they had increased plasma kynurenine levels (t (25) = 2.3, 
p = 0.029) and an increased plasma kynurenine/tryptophan ratio (t (25) = 2.9 p = 0.008) 
and a trend toward increased levels of plasma CRP (t (25) = 1.803, p = 0.083), though no 
differences in the levels of plasma IL-6, (t (23) = -0.173, p = 0.864), TNF-α, (t (24) = 
0.569, p = 0.574) or IL1b (t (24) = 1.716, p = 0.09). There were no significant differences 
in plasma LBP levels (t (22) = 0.15, p = 0.878) or plasma corticosterone levels (t (26) = 
0.063, p = 0.949) There were differences in the gut microbiota composition at the 
phylum, family and genus level and reduced richness as measured by Chao1 (p = 0.004), 
observed species (p = 0.006) and reduced diversity measured by phylogenetic diversity 
(p = 0.006) and Shannon index (p = 0.002). Fecal acetate and total SCFAs were increased 
(p= 0.011). There were no significant differences in hippocampal BDNF expression (t 
(26) = 0.312, p = 0.757).  
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Conclusions: FMT from depressed patients to microbiota-depleted rats induced 
behavioural and physiological features characteristic of depression in the recipient 
animals, including anhedonia and anxiety-like behaviours, as well as alterations in 
tryptophan metabolism. This data suggests that the gut microbiota may play a causal role 
in the development of features of depression and may provide a tractable target in the 
treatment and prevention of this disorder. 
 
3.2 Introduction  
The emerging links between our gut microbiome and the central nervous system are 
regarded as a paradigm shift in neuroscience with possible implications for not only our 
understanding of the pathophysiology of stress-related psychiatric disorders, but also 
their treatment. This narrative positions the gut microbiome and its influence on host 
barrier function as a critical node of the brain-gut axis. Mounting pre-clinical evidence 
broadly suggests that the gut microbiota can modulate brain development, function and 
behaviour by immune, endocrine and neural pathways of the brain-gut-axis. Moreover, 
we and other groups have shown that depression is associated with an altered gut 
microbiota profile, though the mechanisms underlying the interaction remain 
underdeveloped.  
 
A number of studies have shown that it is possible to transfer characteristics from donor 
to recipient via fecal microbiota transplantation (FMT). For example, the transfer of 
microbiota from obese mice to lean mice can result in weight gain and obesity associated 
metabolic profiles (Ridaura et al., 2013). Furthermore, transfer of the human maternal 
gut microbiota in pregnancy to GF rodents, induces metabolic changes such as greater 
adiposity and insulin insensitivity, resembling the metabolic changes that occur in 
pregnancy (Koren et al., 2012). This has been extended beyond metabolic system, as 
phenotype transfer via microbiota has also been demonstrated for behaviour.  
 
When the microbiota from BALB/c mice was transferred into adult GF NIH Swiss mice, 
the result was a decrease in exploratory behaviour and when the NIH Swiss microbiota 
was transferred into the BALB/c GF mice there was an increase in exploratory behaviour, 
associated with an increase in hippocampal BDNF levels (Bercik et al., 2011b). Thus, 
the anxiety-like behavioural phenotype could be transferred via the microbiota, 
independent of the autonomic nervous system, gastrointestinal specific neurotransmitters 
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or inflammation. Restoration of normal gut microbiota normalised anxiety like behaviour 
in GF mice (Clarke et al., 2013). It has been shown that mice that received an obesity 
associated microbiota exhibit more anxiety-like behaviours associated with increased 
evidence of neuroinflammation compared to controls (Bruce-Keller et al., 2015).  
 
More recently, a FMT from depressed patients to GF mice resulted in depression and 
anxiety like behaviours and disturbances of microbial genes and host metabolites 
involved in carbohydrate and amino acid metabolism (Zheng et al., 2016). While GF 
animals are an excellent proof-of principal tool, we and others have shown that these 
animals have some profound CNS abnormalities in adulthood as a consequence of GF 
status during critical neurodevelopmental windows, many of which are relevant for the 
depressive phenotype. The main advantage then of antibiotic-induced microbiota 
depletion during adulthood is that it avoids these potential confounding influences 
(Arrieta et al., 2016, Luczynski et al., 2016). 
 
Consequently, to confirm that an altered gut microbiota specifically influences aspects 
of depressive symptomatology, we carried out an FMT from depressed patients to a 
microbiota depleted antibiotic rat model to assess if a depressive-like phenotype emerged 
in the treated animals. In addition, using the same microbiota depleted antibiotic rat 
model we also determined the impact of the FMT on neurobiology.  
 
3.3 Methods 
Animals and Treatments 
Twenty-eight male Sprague-Dawley rats obtained from Harlan Laboratories UK, 
weighing an average of 350 g. Food and water was available ad libitum and animals were 
maintained on a 12:12-h dark–light cycle with temperature at 21 ± 1°C.  All experiments 
were in full accordance with the European Community Council Directive (86/609/EEC). 
The animals were acclimated to the environment and handling for 14 days. They were 
divided into control and depressed groups, matched for average body weight. Rats were 
then given a cocktail of ampicillin and metronidazole (both at 1g/L), vancomycin (500 
mg/L), ciprofloxacin HCl (200 mg/L) and imipenem (250 mg/L) once daily for 28 
consecutive days in drinking water. Seventy-two hours later, animals were colonized via 
daily oral gavage of donor microbiota (300 µL) for 3 days. Donor microbiota was 
acquired from pooled fecal samples from 3 of the most severely depressed male patients 
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and 3 age and sex matched healthy controls. To offset potential founder and/or cage 
effects and to reinforce the donor microbiota phenotype, booster inoculations were given 
biweekly throughout the study. Body weight was measured regularly, and all animals 
were euthanized following behavioural testing. 
 
Behaviour test battery 
Following the FMT and recolonization period, animals underwent a behavioural test 
battery. For all behavioural tests, animals were habituated to the testing room by placing 
home-cages in the test room for at least 30 min prior to testing. The same animals were 
assessed across all behavioural tests with at least 6-7 days of resting in between tests.  
 
Sucrose preference test 
Sucrose preference test assesses animal’s depressive like behaviour - anhedonia. Animals 
were single-housed 24 hours prior to and for the duration of the procedure. Twenty-four 
hours later, animals were presented with 2 bottles of water: one containing plain drinking 
water, and the second contains a 1% sucrose solution.  Animals were then given the free 
choice of either drinking the 1% sucrose solution or plain water for a period of 24hr 
hours. The positions of two bottles is switched every 12 hours to reduce any confound 
produced by a side bias. Water and sucrose solution intake was measured 24 hours after 
introducing sucrose solution by weighing the bottles. Sucrose preference was calculated 
as a percentage of the volume of sucrose intake over the total volume of fluid intake. At 
the end of the procedure, animals were group housed and returned to their home cage. 
 
Elevated plus maze 
The elevated plus maze is one of the most commonly used rodent tests of anxiety-like 
behaviours and was performed as previously described (Cryan et al., 2004). The maze 
consisted of two open arms (51 × 10 cm) and two enclosed arms (51 × 10 × 41 cm) that 
all extended from a common central platform (10 × 10 cm). The apparatus was elevated 
55 cm above the floor on a central pedestal. Animals were acclimatized to the testing 
room for 30 min prior experiment. At week 11, animals were placed in the centre of the 
maze facing an open arm to begin. Animal behaviour was videotaped for the duration of 
5 min test. Frequency of open and closed arms entries were scored and percentage visits 
to the open arms was calculated.  
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Open field test 
At week 12, rats were tested in the open field as described previously (O’Mahony et al., 
2014). At the beginning of each trial, animals were placed in the centre of a brightly 
illuminated white open field arena (1000 lux), measuring 0.9 m in diameter, and observed 
for 10 min. Animals were acclimatized to the testing room for 30 min prior experiment. 
The arena was cleaned with 70% ethanol to avoid cue smell between each trial. At the 
end of each trial, animals were returned to their cages. Total activity and time spent in 
inner zone were analyzed as recorded using a tracking system (Ethovision XT 8.5, 
Noldus). 
 
Forced swim test 
To assess depression-like behaviours at week 14, a modified rat forced swim test (FST) 
(Slattery and Cryan, 2012) was used. Briefly, on day one, rats were placed individually 
in Pyrex cylinders (46 cm tall × 21 cm in diameter) filled with water to 30 cm depth at 
25°C for habituation to the test. The rats were removed 15 min later, dried and placed in 
their home cage. On day two, 24 h after the first exposure, the rats were again placed in 
the swim apparatus for 5 min and behaviours were monitored from above by video 
camera for subsequent analysis. Three predominant behaviours were recorded in each 5 s 
period of the 300 s test. Climbing behaviour was defined as upward movements of the 
forepaws along the edge of the swim chamber. Swimming behaviour was identified as 
horizontal movements throughout the cylinder. Immobility was described when no 
additional activity was observed other than that required to keep the rat's head above the 
water. Latency to become immobile was defined as the time at which the rat first initiated 
a stationary posture that did not reflect attempts to escape from the water. In this 
characteristic posture, the forelimbs are motionless and tucked towards the body. To 
qualify as immobility, this posture had to be clearly visible and maintained for ≥ 2s. 
 
Rat Intestinal Transit time determination 
Animals were single-housed (with a thin layer of bedding) with food and water ad 
libitum. Three hours after being single-housed, animals were given 200 ul of 6% carmin 
red in 0.5% methylcellulose (in PBS) given by oral gavage.  After the gavage, the cages 
were inspected every 10 minutes, and the appearance of the first red fecal pellet was 
recorded. After the test, animals were group housed in their home cages. 
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Rat corticosterone determination 
On day one of the FST, blood samples via tail incision were collected 15 min after the 
test. Rats were restrained and the end of the tails was held with two fingers. Using a 
single edge razor blade a diagonal incision of 2 mm long was made at 15 mm from the 
end of the tail. Approximately 200 μl blood was collected in a collecting tube containing 
EDTA to avoid blood coagulation by increasing the pressure of the fingers on the tail 
above the incision. Blood was mixed with EDTA by gently inverting the tube and 
centrifuged at 3500 × g at room temperature for 15 min. Plasma was carefully aspirated 
and stored at −80°C. Corticosterone levels were assayed using a commercially-available 
ELISA kit (Corticosterone EIA Kit, ADI-900-097, Enzo®, Life Sciences) according to 
manufacturer instructions. Light absorbance was read with a multi-mode plate reader 
(Synergy HT, BioTek Instruments, Inc.) at 405 nm. Sensitivity: 27.0 pg/ml (range 32 - 
20,000 pg/ml). 
 
Rat CRP and cytokine determination 
Animals were sacrificed by decapitation and immediately after culling, trunk blood was 
collected in EDTA-coated tubes and centrifuged at 3500 × g for 15 min. Plasma 
supernatant was collected and stored on dry ice. All samples were frozen at −80°C for 
later analysis. CRP was determined using commercially available RayBio® Rat CRP 
ELISA Kit. Sensitivity 200 pg/ml. Detection Range 0.2 ng/ml - 60 ng/ml. TNF-α and IL-
6 were analyzed using a commercially available electrochemiluminescence multiplex 
system (MSD, Gaithersburg, MD, USA) according to the manufacturer protocol. The 
median lower limits of detection for; TNF-α; 0.72 pg/ml, IL-6; 13.8 pg/ml. 
 
Rat Lipopolysaccharide determination 
LBP concentrations were determined using the Enzyme Immunoassay Kit as per 
manufacturers’ instruction (Enzo®, Life Sciences). Detection Range 1-50ng/ml. 
 
Rat Short Chain Fatty Acid Caecal Content determination 
Caecal content was vortex-mixed with Milli-Q water, incubated at room temperature for 
10 min and centrifuged to pellet bacteria and other solids. The supernatant was filtered, 
transferred to a clear GC vial and 2-ethylbutyric acid (Sigma) was added as internal 
standard. The concentrations of SCFA were measured using a Varian 3800 GC flame-
ionization system, fitted with a ZB-FFAP column (30 m x 0.32 mm x 0.25 um; 
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Phenomenex, Macclesfield, Cheshire, UK). The initial oven temperature was set at 50oC 
for 0.5 min, raised to 140oC at 10oC/min and held for 0.5 min, then increased to 240oC at 
20oC/min, and finally held at this temperature for 12 min. The temperature of the injector 
and the detector were set at 240oC and 250oC, respectively. Helium was used as the 
carrier gas at a flow rate of 1.3 mL/min. A standard curve was built with different 
concentrations of a standard mix containing acetic acid, propionic acid, n-butyric acid 
and iso-butyric acid (Sigma). Peaks were integrated by using the Varian Star 
Chromatography Workstation version 6.0 software.  
 
Rat BDNF determination 
The hippocampus was rapidly hand-dissected and stored in RNAlater at 4°C for 24h 
followed by removal of RNAlater and storage at -80°C until tissues was processed for 
RNA extraction. RNA was isolated for the Hippocampus (healthy n=15 and depressed n 
= 13) using miRVanaTM miRNA Isolation Kit, with Phenol following (Thermo Fisher 
Scientific, AM1560) manufactures protocol for total RNA. Quantitative real-time PCR 
(qRT-PCR) reverse transcription was carried out on isolated RNA using the high capacity 
cDNA reverse transcription kit (Applied Biosystems, 4368814) in a G-storm 
thermocycler (G-storm, Surry, UK). Analyses of gene expression was carried out using 
TaqMan Gene Expression Assay for brain derived neurotrophic factor (BDNF) on a 
Roche LightCycler 480 instrument. Gene expression levels for BDNF was calculated as 
the average ct value of 3 replicates for each biological sample from both groups relative 
to Gapdh expression. Following this fold change was calculated using the ΔΔCt method 
(Livak and Schmittgen, 2001). For statistical analysis t-test was carried out. 
 
Statistical Analysis. Data that were normally distributed according to Shapiro-Wilk test 
were analyzed using unpaired t tests. Outliers were removed by Grubbs' test. Data that 
were not normally distributed were transformed by square root transformation. 
Microbiota data were analyzed using non parametric tests. Benjamini-Hochberg 
procedure was used to correct for multiple comparisons with a FDR-adjusted p-value ≤ 
0.1 considered significant. Statistical procedures were carried out using IBM SPSS 20.0. 
Graphs were generated using GraphPad Prism 5.  
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3.4 Results 
Adoptive transfer of depressive phenotype 
Behaviour 
Rats that received the FMT from the depressed pool demonstrated anhedonia-like 
behaviours as assessed in the sucrose preference test (t (12) = 2.628, p = 0.022) (Figure 
3.1B) with a significant decrease in sucrose intake without affecting fluid intake. Rats 
receiving FMT from depressed patients also exhibited anxiety-like behaviours as 
demonstrated by a significant decrease in visits to the open arms (t (12) = 2.471, p = 
0.029) in the elevated plus maze (Figure 3.1C) and a reduction in time spent in the centre 
in the open field (t (24) = 2.662, p = 0.013) (Figure 3.1D). Importantly, these changes 
occurred without alterations in overall activity as measured in the total visits to the closed 
and open arms in the EPM and total activity in the open field. In the forced swim test, 
there were no significant differences between the groups in immobility time (t (26) = - 
0.43, p = 0.966), swimming (t (26) = 1.164, p = 0.255) or climbing (t (26) 0.629, p = 
0.535) (Figure 3.1E). 
 
Physiology altered following FMT 
Rats that received the depression FMT had significantly increased plasma kynurenine 
levels (t (25) = 2.3, p = 0.029) and an increased plasma kynurenine/tryptophan ratio (t 
(25) = 2.9 p = 0.008) (Figure 3.1F) but no differences in plasma tryptophan levels (t (25) 
= 0.41, p = 0.686). There was a trend toward increased levels of plasma CRP in rats that 
received the depression FMT (t (25) = 1.803, p = 0.083) (Figure 3.1G) though no 
differences in the levels of plasma IL-6, (t (23) = -0.173, p = 0.864), TNF-α, (t (24) = 
0.569, p = 0.574) or IL1b (t (24) = 1.716, p = 0.09). There were no significant differences 
in plasma LBP levels (t (22) = 0.15, p = 0.878) (Figure 3.1H) or plasma corticosterone 
levels (t (26) = 0.063, p = 0.949) (Figure 3.1 I). Rats receiving the depression FMT 
demonstrated a significant increase in intestinal transit time (t (26) = 2.652, p = 0.013) 
(Figure 3.1J).  
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Figure 3.1: Behavioural and physiological changes following fecal transplantation  
(A) Experimental design (Sucrose preference; SP, Open field; OF, Elevated plus maze; 
EPM, Intestinal motility; IM, Forced swim test FST, Inoculation boost; IB (twice a 
week). The rats that received the depression FMT (n = 13) exhibited (B) anhedonia like 
behaviour, indicated by a decrease in the 24 hour 1% sucrose preference test (t (12) = 
2.628, p = 0.022) and an increase in anxiety like behaviour measured by (C) a decrease 
in open arm visits in the elevated plus maze (EPM) (t (12) = 2.471, p = 0.029) and (D) a 
decrease in time spent in the open field (t (24) = 2.662, p = 0.013) and compared to rats 
that received the healthy FMT (n = 15). (E) There were no differences in the immobility, 
swimming or climbing time in the Forced Swim Test (FST). (F) There was an increase 
in the plasma Kynurenine/Tryptophan ratio (t (25) = 2.9 p = 0.008) in the rats that 
received the FMT from depressed patients. (G) There was a trend for increased plasma 
CRP levels in the rats that received the FMT from depressed patients (t (25) = 1.803, p = 
0.083). There were no significant differences in (H) plasma Lipopolysaccharide binding 
protein (LBP) levels (t (22) = 0.15, p = 0.878) or (I) plasma corticosterone levels 15 
minutes post-acute FST stressor (t (26) = 0.063, p = 0.949). (J) Rats that received the 
FMT from depressed patients demonstrated a significant increase in intestinal transit time 
(t (26) = 2.652, p = 0.013).  
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Neurobiology following FMT 
There were no significant differences in hippocampal BDNF expression (t (26) = 0.312, 
p = 0.757) (Figure 3.2). 
 
Figure 3.2: Quantitative real-time PCR (qRT-PCR) of BDNF gene expression levels in 
the rat hippocampus. 15 rats received the healthy FMT and 13 rats received the 
depression FMT. There were no significant differences in hippocampal BDNF 
expression (t (26) = 0.312, p = 0.757). Bar graphs indicate average values after Gapdh 
normalization relative to average control levels.  
 
 
Altered Gut Microbiota Richness, Diversity, Composition & SCFAs following FMT 
Rats that received the FMT from depressed patients had reduced gut microbiota richness 
as measured by Chao1 (p = 0.004) and observed species (p = 0.006) and reduced diversity 
measured by phylogenetic diversity (p = 0.006) and Shannon index (p = 0.002) (Figure 
3.3A-D). 
 
At the phylum level, the relative abundances of Actinobacteria (U = 32, p = 0.013) and 
Candidate Division TM7 (U = 28.5, p = 0.006) were decreased in rats that received the 
depression transplantation (Figure 3.3E). At the family level, the relative proportions of 
Bifidobacteriaceae (U = 138.5, p = 0.001), Coriobacteriaceae (U = 129, p = 0.004), 
Porphyromonadaceae (U = 123, p = 0.012), Candidate division TM7 uncultured 
bacterium (U = 128, p = 0.005), Caldicoprobacteraceae (U = 126.5, p = 0.007), 
Alcaligenaceae (U = 144, p = < 0.000) were decreased in rats that received the depression 
FMT. Propionibacteriaceae (U = 27, p = 0.006) was increased in the rats that received 
the depression FMT (Figure 3.3F). 
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At the genus level, the relative abundances of Bifidobacterium uncultured (U = 136, p = 
0.001), Coriobacteriaceae uncultured (U = 128, p = 0.005), Caldicoprobacter (U = 124, 
p = 0.01), Roseburia (U = 132, p = 0.003), Allobaculum (U = 126, p = 0.004), 
Burkholderiales (U = 146, p = < 0.000) were decreased in rats that received the 
depression FMT. Freudenreichii (U = 26, p = 0.004), Staphyloccus (U = 37, p = 0.013), 
Peptococcus (U = 27.5, p = 0.006) were increased in rats that received the depression 
transplantation (Figure 3.3G).  
 
Fecal acetate and total SCFAs were increased in the rats that received the depression 
FMT (p= 0.011). There was a trend toward significant increases in the levels of 
propionate (p = 0.068) and butyrate (p = 0.06) following FMT from depressed patients 
(Figure 3.3H). 
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Figure 3.3:  Altered Gut Microbiota Richness, Alpha Diversity & SCFAs following 
fecal transplantation  
Rats that received the FMT from depressed patients (n = 13) had reduced gut microbiota 
richness as measured by (A) Chao1 (p = 0.004) and (B) observed species (p = 0.006) and 
reduced diversity measured by (C) phylogenetic diversity (p = 0.006) and (D) Shannon 
index (p = 0.002). Significant differences at the phylum level (E), the family level (F) 
and the (G) genus level between the rats that received the FMT from the depressed 
patients compared to the rats that received the healthy FMT (n = 15). (H) Levels of fecal 
acetate and total SCFAs were increased in the rats that received the depression FMT (p= 
0.011). There was a trend toward significant increases in the levels of propionate (p = 
0.068) and butyrate (p = 0.06) following FMT from depressed patients. 
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Figure 3.4:  Altered Beta Diversity following fecal transplantation 
(A) PCoA plot representing unweighted unifrac beta diversity in the rats. Red represents 
rats that received the healthy FMT (n = 15) and black represents the rats that received the 
FMT from depressed patients (n = 13).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
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3.5 Discussion   
The present findings represent definitive evidence that depression-associated alterations 
in the gut microbiome are sufficient to disrupt behavioural and physiological 
homeostasis. Specifically, transplantation of the perturbed microbiota signature from 
depressed patients to microbiota-depleted rats induced the development of some of the 
behavioural and physiological features of the depressive phenotype. Furthermore, this 
data indicates that a gut microbiota transfer from depressed patients could serve as a 
novel animal model of depression in the context of microbiome-gut-brain axis 
dysfunction. 
 
We have demonstrated, that transferring the gut microbiota from depressed patients to 
rats with a depleted gut microbiota can induce the development of some of the features 
of the depressive phenotype, such as anhedonia and anxiety-like behaviours, and produce 
a physiological profile similar to depressed individuals. In contrast to a recent FMT study 
from depressed patients using germ-free mice (Zheng et al., 2016a), we did not observe 
alterations in the FST. Our data is consistent with the view that the emergence of only 
some of the behavioural and neurobiological correlates of depression are contingent on 
the gut microbiota (De Palma et al., 2015).  
 
Similar to the depressed patients, the rats that received the depression FMT also had an 
increased kynurenine: tryptophan ratio. The pro-inflammatory profile was also partially 
transferred, with a trend towards an increase in plasma CRP in the rats that received the 
depressed FMT. However, there were no differences in the levels of plasma IL-6, TNF-
α, or IL1b in the rats that received the depression FMT. A dysregulated HPA axis 
function was not observed following the FMT, at least in terms of corticosterone output 
following an acute stressor. However, single time point analysis of HPA axis function 
can be unreliable (Allen et al., 2014b).  
 
Rats that received the depression FMT demonstrated increased intestinal transit, 
suggestive of colonic motility dysfunction. Altered gastro-intestinal function is a well-
established but often neglected characteristic of depression (Gorard et al., 1996, Haug et 
al., 2002). Importantly, there were also comparable significant differences in gut 
microbiota richness and diversity following FMT as between the clinical depression and 
control groups (Figure 3.3A-D). The rats that received the FMT from depressed patients 
107 
 
had altered levels of caecal SCFAs (Figure 3.3H) despite this not being noted in the 
clinical fecal samples (Figure 2.5A) suggesting that a depression-associated microbiota 
can impact SCFA production. Microbial metabolites such as SCFAs can reach the 
circulation, cross the BBB (Frost et al., 2014, Vijay and Morris, 2014) and activate 
specific receptors in relevant brain regions underpinning the neurocircuitry pertinent to 
the expression of depression and anxiety-related behaviours (Schroeder et al., 2007, Wei 
et al., 2015).  
 
We acknowledge that antidepressant use in the depressed group is a limitation of our 
study, and that we cannot exclude the possibility of an antidepressant-related serotonin-
driven contribution to the alteration in the gut microbiota. However, antidepressants 
would be expected to reduce the kynurenine/tryptophan ratio rather than increase it via, 
for example, activity on TDO (Badawy and Morgan, 1991, Badawy et al., 1991) making 
it unlikely that residual medication in the fecal transplantation from the depressed 
patients would increase depressive and anxiety like behaviours in the rats that received 
the depressed FMT. Regardless of the origins of the gut microbiota differences in the 
transplant, the preclinical data confirms that when a depression-associated microbiota is 
transferred, neurobiological and behavioural consequences can ensue. Although the gut 
microbiota can impact transcriptional regulation (Stilling et al., 2015) we found no 
significant differences in hippocampal BDNF expression in the rats that received the 
FMT.  
 
In conclusion, we have demonstrated that it is possible to reproduce aspects of depressed 
behaviour and physiology via a gut microbiota transfer. This suggests that the gut 
microbiota could play a causal role in the complex mechanisms underlying the 
development of depression. The profile of depression-like behaviours and physiological 
alterations noted following FMT suggests that this represents a novel paradigm in 
behavioural pharmacology to investigate microbiota-associated depression. Ultimately, 
findings from this study advance the concept that targeting the gut microbiota may be a 
viable therapeutic strategy for novel antidepressant development in sub groups of 
depressed patients and may augment depression prevention strategies.  
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Chapter 4: Targeting the Microbiota-gut-
brain axis with Lactobacillus Rhamnosus 
(JB-1): Evaluation of a Candidate 
Psychobiotic in healthy male volunteers 
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4.1 Abstract  
Background: Preclinical studies have identified certain probiotics as psychobiotics - live 
microorganisms with a potential mental health benefit. Lactobacillus rhamnosus (JB-1) 
has been shown to reduce stress-related behaviour, corticosterone release and alter central 
expression of GABA receptors in an anxious mouse strain. However, it is unclear if this 
single putative psychobiotic strain has psychotropic activity in humans. Consequently, 
we aimed to examine if these promising preclinical findings could be translated to healthy 
human volunteers. 
Objectives: To determine the impact of L. rhamnosus on stress-related behaviours, 
physiology, inflammatory response, cognitive performance and brain activity patterns in 
healthy male participants. 
Methods: An 8 week, randomized, placebo-controlled, cross-over design was employed. 
Twenty-nine healthy male volunteers participated. Participants completed self-report 
stress measures, cognitive assessments and resting electroencephalography (EEG). 
Plasma IL10, IL1β, IL6, IL8 and TNFα levels and whole blood Toll-like 4 (TLR4) 
agonist cytokine release were determined by multiplex ELISA. Salivary cortisol was 
determined by ELISA and subjective stress measures were assessed before, during and 
after a socially evaluated cold pressor test (SECPT).  
Results: There was no overall effect of probiotic treatment on measures of mood, 
anxiety, stress or sleep quality and no significant effect of probiotic over placebo on 
subjective stress measures, or the HPA response to the SECPT. Visuospatial memory 
performance, attention switching, rapid visual information processing, emotion 
recognition and associated EEG measures did not show improvement over placebo. No 
significant anti-inflammatory effects were seen as assessed by basal and stimulated 
cytokine levels. 
Conclusions: L. rhamnosus was not superior to placebo in modifying stress-related 
measures, HPA response, inflammation or cognitive performance in healthy male 
participants. These findings highlight the challenges associated with moving promising 
preclinical studies, conducted in an anxious mouse strain, to healthy human participants. 
Future interventional studies investigating the effect of this psychobiotic in populations 
with stress-related disorders are required. 
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4.2 Introduction 
An abundance of preclinical studies have shown that probiotics acting via the brain-gut-
axis can affect brain development, function and behaviour (Cryan and Dinan, 2015b, 
Desbonnet et al., 2014, Desbonnet et al., 2010, Hsiao et al., 2013). This has prompted a 
growing interest in the possibility of targeting the gut microbiome to beneficially impact 
human brain and behaviour. Psychobiotics have been defined as bacteria that ingested in 
adequate amounts produce a positive mental health benefit (Dinan et al., 2013).  
 
Considering the potential impact of putative psychobiotics upon central nervous system 
processes, especially stress, mood, anxiety and cognition (Cryan and Dinan, 2012c, 
Dinan et al., 2015), the prospect of targeting the gut microbiota as a potential modifiable 
risk factor for stress-related disorders is appealing (Kelly et al., 2015). Preclinical 
research has indicated that chronic probiotic administration can reduce anxiety-like and 
depressive-like behaviour, and can normalise associated physiological outputs such as 
corticosterone, noradrenaline, brain-derived neurotrophic factor (BDNF) and immune 
function (Bercik et al., 2011a, Bravo et al., 2011, Desbonnet et al., 2010, Janik et al., 
2016, Messaoudi et al., 2011). There is a growing appreciation of the need to translate 
this promising preclinical work to the clinic while at the same time  recognising the 
challenges inherent in this process (Kelly et al., 2016c).  
 
To date, there are indications from a number of sources that highlight the opportunities 
in this regard, for example, probiotic use in irritable bowel syndrome (IBS) (O’Mahony 
et al., 2005, Whorwell et al., 2006), a stress-related brain-gut axis disorder associated 
with high rates of psychopathology (Whitehead et al., 2002) as well as altered 
hypothalamic-pituitary-adrenal (HPA) axis activity (Kennedy et al., 2014c) and 
cognition (Kennedy et al., 2015, Kennedy et al., 2014b). A number of proof-of-principle 
studies in healthy human volunteers have demonstrated that multi-strain probiotics, 
fermented drinks containing probiotics, or prebiotics, can alter resting brain activity, 
cognitive performance, baseline physiological stress outputs and self-reported 
psychological variables (Benton et al., 2007, Chung et al., 2014, Messaoudi et al., 2011, 
Schmidt et al., 2015, Steenbergen et al., 2015a, Tillisch et al., 2013b). More recently, 
Bifidobacterium longum 1714, selected based on pre-clinical evidence (Savignac et al., 
2014, Savignac et al., 2015a), reported reduce stress levels and a neurocognitive profile 
associated with enhanced memory in healthy volunteers (Allen et al., 2016).  
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By utilizing a well-validated preclinical screening platform, developed to inform efficient 
selection of prospective psychobiotic strains, we identified L. rhamnosus (JB-1). In these 
studies, which were carried out in the stress-sensitive BALB/c mice, ingestion of the JB-
1 strain reduced anxiety in the elevated plus maze and despair-like behaviour in the 
forced swim test. Moreover, there was enhanced learning in a fear conditioning paradigm 
and reduced stress-induced corticosterone levels. At a brain level there were marked 
alterations in central GABAA and GABAB receptor levels (Bravo et al., 2011). 
Furthermore, a magnetic resonance spectroscopy study, also conducted in BALB/c mice 
showed that treatment with the JB-1 strain significantly elevated central GABA levels by 
25% after four weeks of treatment (Janik et al., 2016). In addition, L. rhamnosus 
treatment modulates the immune system (Forsythe et al., 2012, Karimi et al., 2009, 
Kozakova et al., 2016, Ma et al., 2004), intestinal motility (Wang et al., 2010), gut barrier 
function (Patel et al., 2012b, Wang et al., 2012b) and enteric nervous system (Kamiya et 
al., 2006, Ma et al., 2009). Taken together, these preclinical studies identify L. 
rhamnosus as the candidate psychobiotic with the most comprehensive behavioural, 
physiological and neurobiological profile. 
 
We employed a randomized, placebo-controlled, cross-over, repeated measures design 
to examine the effects of the JB-1 strain compared to placebo on the psychobiological 
response to an acute, controlled stressor (Schwabe et al., 2008, Schwabe and Wolf, 2010) 
and assessed cognitive performance on tests assessing memory, sustained attention, 
social cognition and emotional processing. In addition, we measured the immune 
response to this candidate psychobiotic by measuring a panel of cytokines and TLR4 
induced cytokine release. 
 
Finally, to ascertain if the JB-1 strain effected brain activity patterns, we assessed brain 
activity in frontal, parietal and central regions using EEG following 4-week 
supplementation with the JB-1 strain in comparison to placebo, as these regions have 
been associated with memory and sustained attention (Coull et al., 1996, Hales et al., 
2009) and are sensitive to anxiolytics (Fukami et al., 2010).  
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4.3 Methods  
Subjects 
Approval of the study protocol was granted by the Cork University Hospital ethics 
committee (Protocol Number: APC057) and conducted in accordance with the ICH 
Guidelines on Good Clinical Practice, and the Declaration of Helsinki. Written informed 
consent was obtained from all subjects before any study procedures were conducted.  
 
Participants were aged between 20 and 33 years of age. Inclusion criteria were as follows: 
aged between 18 - 40 years, able to speak English, in good health as determined by the 
investigator. Male participants were selected to avoid the need to control for menstrual 
cycle, which can impact upon cortisol output and other readouts. Exclusion criteria were 
as follows: having a significant acute or chronic illness, following a diet or taking a 
medication that would interfere with the objectives of the study, pose a safety risk or 
confound the interpretation of the study results, to include, probiotics, antibiotics, 
antipsychotics, anxiolytics, laxatives, enemas, anti-coagulants and over-the counter non-
steroidal anti-inflammatorys (NSAIDS), antidepressants or any other psychotropic 
medication, Evidence of immunodeficiency, bleeding disorder or coagulopathy, colour 
blindness, dyslexia or dyscalculia, or receiving any treatment involving experimental 
drugs.  
 
Design 
A repeated measures crossover design was employed. Participants were screened at an 
initial visit for psychiatric disorder using the MINI International Neuropsychiatric 
Interview (MINI)(Sheehan et al., 1998) and demographic and baseline psychological 
information was collected. Following screening, participants completed neurocognitive 
visits and acute stress visits utilizing the socially evaluated cold pressor test (SECPT) at 
baseline, at 4 weeks and at 8 weeks. Participants were administered placebo capsules for 
four weeks or L. Rhamnosus capsules for four weeks in a randomized single blind 
placebo controlled cross over trial. (See Table 4.1 for detailed participant 
characteristics).  
 
Materials  
Both active and placebo capsules contained corn starch, magnesium stearate and silicon 
dioxide. The count for L. Rhamnosus (JB-1) in the active capsules was 1x109 colony-
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forming units (CFU). Participants were instructed to take one capsule each morning. 
Compliance was assessed by self-report at each study visit.  
 
Tests from the CANTAB Battery  
Tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) 
were presented on a touch-screen monitor, Sahara i440D Slate Tablet PC (Sand Dune 
Ventures, Tablet Kiosk) running CANTABeclipse™ software (Cambridge, UK). The 
researcher provided verbal instructions to participants from a standardised script, and had 
full control of a keyboard used to start, pause or abort each test. As a test battery of 
multiple cognitive tests was employed, test order was counterbalanced, using a Latin 
square design, to avoid effects of fatigue for tests completed later in the session. The test 
battery lasted approximately 45 minutes in total. Participants were assessed on the 
following tests from the battery: 
 
Motor Screening Test (MOT)  
The MOT is a screening test and allows participants to get familiar with using the 
touchscreen. It screens for difficulty with movement, comprehension and vision. 
Participants are presented with a series of crosses in different locations on the screen and 
instructed to touch them in turn. The administration time was approximately 2 minutes. 
 
Paired Associates Learning (PAL)  
PAL test was used to assess conditional learning of pattern-location associations. Paired 
associate performance has shown sensitivity to functional changes in the hippocampus 
(de Rover et al., 2011) and frontal lobes (Hales et al., 2009). The parallel mode (which 
presents different shapes at each visit) was used in order to avoid practice effects. White 
boxes are presented on-screen and each opens in a randomized order; in some boxes a 
pattern is shown. Participants must remember patterns associated with different 
locations. In the practice phase 2 patterns are presented and after this presentation the 
participant must touch the boxes the patterns appeared in. Participants then have to 
remember 2 patterns for 1 trial, 3 for 1 trial, 6 for 1 trial and 8 for 1 trial. If the participant 
makes an error the patterns are presented again to remind the participant of their 
locations. When all pattern locations are correctly identified the test proceeds to the next 
stage. If participants do not correctly identify the pattern locations within 10 trials the 
test terminates. The administration time was approximately 10 minutes. Outcomes 
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assessed: Total errors per stage (8 shapes), mean trials required to locate all patterns 
correctly, first trial memory score. 
 
Attention Switching Task (AST) 
AST was used to measure the subject’s ability to switch attention between the direction 
of an arrow and its location on the screen and to ignore task-irrelevant information. This 
test has been designed to measure top-down cognitive control processes involving the 
prefrontal cortex. The test displays an arrow which can appear on either side of the screen 
(right or left) and can point in either direction (to the right or to the left). Each trial 
displays a cue at the top of the screen that indicates to the participant whether they have 
to press the right or left button according to the “side on which the arrow appeared” or 
the “direction in which the arrow was pointing”. Some trials display congruent stimuli 
(e.g. arrow on the right side of the screen pointing to the right) whereas other trials display 
incongruent stimuli which require a higher cognitive demand (e.g. arrow on the right side 
of the screen pointing to the left). The administration time was approximately 8 minutes. 
Outcomes assessed: Reaction latency, Reaction latency congruent, Reaction latency 
incongruent, congruency cost, switching cost, percent correct. 
 
Rapid visual information processing (RVP)  
RVP was used to assess sustained attention. Performance on this task activates a fronto-
parietal network of brain regions (Coull et al., 1996), and a modified version of this task 
is sensitive to changes in frontal EEG (Allen et al., 2014a). Subjects are presented with 
digits appearing on screen one at a time. Participants are required to press the button on 
the press pad as soon as they detect target sequences of digits (e.g. 3-5-7). The test 
consists of a practice phase followed by a four-minute testing phase. The administration 
time was approximately 7 minutes. Outcomes assessed: Targets correctly detected, false 
alarms and reaction time. 
 
Emotion Recognition Task (ERT)  
ERT was used to assess social cognition. fMRI has previously demonstrated probiotic 
effects on a network of brain regions involved in emotional and viscerosensory 
processing in healthy controls (Tillisch et al., 2013b). The participant is briefly shown 
faces displaying distinct emotions; happiness, anger, sadness, fear, surprise and disgust. 
The participant is then required to identify the emotion as quickly as possible from a list 
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of possible options. The administration time was approximately 8 minutes. Outcomes 
assessed: Total correct, total errors, mean speed of response. 
 
Other cognitive tests 
Emotional Stroop  
In addition to tests from the CANTAB battery, we assessed emotional processing using 
an Emotional Stroop (Strauss et al., 2006). The Stroop test was presented on the same 
high-resolution touch screen monitor used with the CANTAB battery. The emotional 
Stroop is associated with activation in the anterior cingulate cortex (Bush et al., 2000, 
Etkin et al., 2006). Positively, negatively and neutrally valenced words were presented, 
matched for length in letters, orthographic neighbourhood size (i.e. the number of words 
which differ from a given word by only one letter) and frequency of use (Larsen et al., 
2008). Participants were asked to name the colour the word was printed in. 
Administration time was approximately 10 minutes. Outcomes assessed: Positive percent 
correct, Positive reaction time, Negative percent correct, Negative reaction time, Neutral 
percent correct, Neutral reaction time.  
 
Acute Stress Procedure  
We employed the socially evaluated cold pressor test (SECPT) (Schwabe et al., 2008) as 
a combined psychological and physiological stressor procedure, which has been shown 
not to induce HPA axis habituation across repeated exposures (Minkley et al., 2014). 
Participants were required to avoid alcohol for 24 hours prior to the visit, as well as 
caffeinated beverages on the day of the stress procedure and strenuous exercise from 2pm 
the day before, and to fast for 2 hours prior to testing.  
 
After the participant completed the state items from the state-trait anxiety inventory 
(Spielberger et al., 1970) a baseline saliva sample was taken. The baseline measures were 
followed by a 5-minute resting phase. Following the 5-minute resting phase, another 
saliva sample was taken. The participant read the instructions for the SECPT and the 
experimenter answered any questions. The participant was then lead into a second room 
in which a confederate, who was dressed in a white lab coat and maintained a neutral 
demeanour throughout, was seated at a table with a container of ice water (at 0-4°C), and 
a camera which was directed towards the participant’s face during completion of the 
SECPT. Paper towels were kept beside the container. The experimenter said: 
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“Researcher, this is subject number xxx. Subject xxx, remember that your task is to keep 
your hand submerged in cold water, that your facial expressions will be video recorded 
for later analysis, and that the researcher is specially trained to monitor non-verbal 
behaviour. Do you have any questions?” After answering any questions the experimenter 
left. The confederate instructed the participant to complete the cold pressor test and 
started the timer; during the entire procedure the confederate maintained a neutral 
demeanour. After withdrawing their hand from the water, the participant returned to the 
previous room, and completed the post-stress state anxiety questionnaire. Further saliva 
samples were taken 1 minute after the cessation of the stressor, as well as, 10, 20, 30, and 
60 minutes post-stressor cessation.  
 
Neurocognitive assessment 
Prior to EEG testing participants were asked to refrain from caffeine on the morning of 
their experimental session, as well as ensuring they got a good night’s sleep, to remove 
any piercings and avoid wearing hair gel. All EEG measurements were made using a 
Neuroscan®, SynAmps 2 Amplifier and Neuroscan 4.3.1 acquisition software. EEG was 
recorded at a sampling rate of 1,000Hz. Scalp electrodes were attached at midline 
positions Fz, Pz, Cz, (see Figure 4.1) and F1, F2, F3, F4, F5, F6, F7, F8, according to 
the international 10/20 system, as well as mastoid electrodes and a reference electrode 
on the nose. Vertical eye movements were detected using electrodes attached above and 
below the orbit of the left eye, simultaneously horizontal eye movements were monitored 
by electrodes at the right and left outer canthi. EEG recordings were made using 
Neuroscan ® Quick-Cap (containing AgCl sintered electrodes and Neuroscan Quick-Cell 
technology) therefore ensuring reduced impedance levels for optimized recordings at 
each electrode. Following a resting EEG recording, the cognitive tasks were completed 
(see Cognitive tasks).  
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Figure 4.1: Electrode position of Fz, Cz and Pz. Scalp electrodes were attached at 
midline positions Fz, Pz, Cz according to the international 10/20 system.  
 
Resting EEG 
EEG measures of absolute power in the delta (2-4Hz), theta1 (4-6Hz), theta2 (6-8 Hz) 
alpha1 (8-10Hz), alpha2 (10-12Hz), beta (15-30Hz) frequency bands were taken for five 
minutes with eyes closed. Participants were requested to relax and sit still with their eyes 
closed while resting EEG was recorded.  
 
EEG analysis  
The EEG signal was down sampled from 1000Hz to 256Hz with an antialiasing filter set 
at 128Hz. The filtered EEG signal was segmented into 1s windows without overlap. 
Curve length, root mean squared amplitude, Hjorth parameters (activity, mobility, 
complexity) (Hjorth, 1970), zero crossings (raw epoch, first and second derivative), 
autoregressive modelling error (model order 1-9), nonlinear energy, variance (first and 
second derivative), entropy (Shannon entropy, spectral entropy, singular value 
decomposition entropy), Fisher information, and wavelet energy (Daubechy 4) were 
calculated using MATLAB. EEG measures of absolute power were extracted in the delta 
(2-4Hz), theta1 (4-6Hz), theta2 (6-8 Hz) alpha1 (8-10Hz), alpha2 (10-12Hz), beta (15-
30Hz) frequency bands. 
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Sample analysis 
Cortisol sampling & analysis 
Salivettes were centrifuged at 1000 g for 5 min and aliquoted and stored at -80oC until 
analysis. Cortisol concentrations were determined using the Cortisol Enzyme 
Immunoassay Kit as per manufacturers’ instruction (Enzo®, Life Sciences). Assay 
detection limit was 0.16 nmol/L. Inter and intra-assay % C.Vs were 11.24% and 8.2% 
respectively. 
 
Cytokine sampling & analysis 
10ml of whole blood was collected in an EDTA tube. Samples were centrifuged at 1000 
g for 15 minutes and then aliquoted and stored at -80oC until analysis. Plasma levels of 
IL1β, IL6, IL8, IL10 and TNFα were assayed in duplicate using high sensitivity 
commercially available electrochemiluminescence MULTI-SPOT® Meso Scale 
Discovery kits (MSD, Rockville, MD, 75USA) as per manufacturer’s instructions. The 
median lower limits of detection for each cytokine are; IL-1β; 0.04 pg/ml, IL-6; 0.06 
pg/ml, IL-8; 0.04 pg/ml, IL-10; 0.03 pg/ml, TNF-α 0.04 pg/ml.  
 
TLR4 cytokine release 
TLR cytokine release was determined as previously described (McKernan et al., 2011). 
Whole blood was collected in lithium heparin tubes and diluted 1:10 with Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS) 
and 5% penicillin streptomycin. Each blood sample was cultured with and without the 
TLR4 receptor ligand - lipopolysaccharide (LPS), from the Human TLR agonist kit 
(InvivoGen, San Diego, CA, USA) for 24 hours. After the 24 hour culture period the 
supernatant from both untreated and stimulated cells was aspirated and stored at -80°C. 
Levels of IL1β, IL6, IL8, I-10 and TNFα were assayed in duplicate using high sensitivity 
commercially available electrochemiluminescence MULTI-SPOT® Meso Scale 
Discovery kits (MSD, Rockville, MD, 75USA) as per manufacturer’s instructions. 
 
Statistical analysis 
With a power of 0.8 for a one-way ANOVA, a minimum sample size of 20 was required 
to demonstrate an effect sized f = 0.3 at alpha = 0.05 (Buchner et al., 1997) (Allen et al., 
2016). Data were analysed using SPSS 21. Repeated measures ANOVA and pairwise t-
tests using post-hoc Fisher's least significant difference (LSD) were used to examine 
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differences between conditions, and non-parametric equivalents (Friedman and 
Wilcoxon respectively) were used where parametric assumptions were violated. Areas 
under the curve with respect to ground (AUCg) were also calculated (Pruessner et al., 
2003), and analysed in the same manner.  
 
4.3 Results 
Demographic data  
See (Table 4.1) for Participant characteristics. 
 
Table 4.1: Participant characteristics. Means and Standard errors of the mean in 
parentheses 
Participant characteristics Total sample 
(n=29) 
Placebo / Probiotic  
(n=15) 
Probiotic / placebo 
(n=14) 
p-value 
Age (mean) 24.59 (0.75) 23.6 (0.97) 25.64 (1.14) 0.22 
Ethnicity         
Caucasian 25 13 12   
Asian 4 2 2 1.00 
BMI 24.55 (0.58) 24.8 (0.69) 24.29 (0.96) 0.66 
Alcohol (units per week) 10.14 (1.85) 11.85 (2.68) 8.42 (2.56) 0.36 
Years of Education 18.45 (0.49) 17.87 (0.71) 19.07 (0.65) 0.22 
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Subjective stress measures 
A repeated measures ANOVA with a Greenhouse-Geisser correction determined that 
there was no overall effect of treatment phase on the Beck Depression Inventory (p = 
0.75), the Beck Anxiety Inventory (p = 0.95), the Perceived Stress Scale (p = 0.053), 
the State Anxiety Inventory (p = 0.09), the Trait Anxiety Inventory (p = 0.72), the 
Symptom Checklist-90 (p = 0.87) or the Pittsburgh sleep quality index (p = 0.07). In the 
coping checklist, there was a reduction in wishful thinking (p = 0.03) in the placebo (p 
= 0.04) and probiotic phase (p = 0.02), see (Figure 4.1). For pairwise comparisons see 
(Table 4.2). 
 
 
Figure 4.1: Subjective Stress Measures 
There was no overall effect of treatment phase in the (A) Beck Depression Inventory (F 
1.93, 50.36 = 0.27, p = 0.75), (B) the Beck Anxiety Inventory (F 1.53, 43.00 = 0.02, p = 
0.95) (C) the Perceived Stress Scale (F 1.80, 50.38 = 3.23, p = 0.053) (D), the State 
Anxiety Inventory (F 1.72, 48.18 = 2.57, p = 0.09), (E) the Trait Anxiety Inventory (F 
1.97, 55.19 = 0.31, p = 0.72, (F) the Symptom Checklist-90 (F 1.93, 52.11 = 0.12, p = 
0.87) or (G) the Pittsburgh sleep quality index (F 1.74, 47.16 = 2.80, p = 0.07). (H) In 
the coping checklist, there was a reduction in wishful thinking (F 1.74, 47.08 = 3.96, p = 
0.03) in the placebo (p = 0.04) and probiotic phase (p = 0.02).  
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Table 4.2: Subjective Stress Measures. Means and Standard errors of the mean in parentheses. 
 
  Baseline  Placebo  Probiotic 
Baseline V 
Placebo 
Placebo V 
Probiotic 
Baseline V 
Probiotic 
Treatment Effect (Repeated 
Measures ANOVA) 
        (p value)  (p value)  (p value)    
Beck Depression 
Inventory 3.92 (0.76) 4.33 (0.72) 3.88 (0.67) 0.57 0.95 0.51 F (1.93, 50.36) = 0.27, p = 0.75 
Beck Anxiety Inventory 4.31 (0.88) 4.17 (1.04) 4.17 (0.67) 0.88 1.00 0.84 F (1.53, 43.00) = 0.02, p = 0.95 
Perceived Stress Scale 10.75 (0.98) 12.96 (1.12) 11.72 (0.94) 0.03 0.10 0.26 F (1.80, 50.38) = 3.23, p = 0.053 
Symptom Checklist                
Total (global severity 
index) 24.28 (3.47) 25.57 (4.05) 24.35 (3.68) 0.65 0.69 0.97 F (1.93, 52.11) = 0.12, p = 0.87 
State Trait Anxiety 
Inventory               
Trait 31.69 (1.50) 30.96 (1.50) 31.58 (1.36) 0.47 0.54 0.91 F (1.97, 55.19) = 0.31, p = 0.72 
State 24.58 (0.95) 26.10 (1.18) 27.20 (1.13) 0.26 0.36 0.008 F (1.72, 48.18) = 2.57, p = 0.09 
Pittsburgh Sleep 
Quality Index (PSQI) 4.57 (0.47) 5.50 (0.62) 4.96 (0.47) 0.008 0.25 0.32 F (1.74, 47.16) = 2.80, p = 0.07 
Coping Checklist                
Wish % 44.19 (4.62) 37.50 (3.99) 35.56 (4.45) 0.04 0.48 0.02 F (1.74, 47.08) = 3.96, p = 0.03 
Positive % 56.98 (2.24) 56.34 (2.98) 52.54 (3.11) 0.78 0.30 0.18 F (1.63, 44.08) = 1.17, p = 0.30 
Escape % 22.09 (3.72) 23.01 (3.13) 19.04 (3.02) 0.74 0.08 0.43 F (1.41, 38.28) = 0.95, p = 0.36 
Advice (%) 46.03 (3.15) 46.82 (3.96) 43.45 (3.91) 0.83 0.46 0.47 F (1.84, 49.80) = 0.38, p = 0.66 
Blame % 36.60 (4.33) 32.14 (4.10) 32.73 (4.34) 0.22 0.87 0.37 F (1.92, 51.91) = 0.75, p = 0.47 
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Acute Stress response to the Socially Evaluated Cold Pressor Test (SECPT) 
There was no overall effect of treatment phase on subjective stress measures pre or post 
the SECPT (see Figure 4.2A-H), and no significant overall effect of probiotic over 
placebo in HPA response to the SECPT (Figure 4.2I-J). See (Table 4.3) for pairwise 
comparisons.   
 
 
Figure 4.2: Acute Stress response to the Socially Evaluated Cold Pressor Test 
(SECPT) 
In the primary appraisal/secondary appraisal scale, there was no significant effect of 
probiotic the (A) primary appraisal (F 1.52, 42.70 = 0.23, p = 0.73), (B) secondary 
appraisal (F 1.69, 47.56 = 2.10, p = 0.14) in (C) control expectancy (F 1.58, 44.39 = 1.91, 
p = 0.16), (D) self-control (F 1.80, 50.62 = 2.21, p = 0.12), (E) threat (F 1.45, 40.70) = 
1.28, p = 0.27), (F) challenge (F 1.83, 51.48 = 0.64, p = 0.51), (G) or stress index (F 1.54, 
41.65 = 1.01, p = 0.35). (H) There was no significant effect of treatment in pre-stress (F 
1.66, 46.58 = 2.59, p = 0.09), post-stress, (F 1.89, 52.92 = 0.65, p = 0.51), difficulty (F 
1.83, 51.38 = 1.23, p = 0.29), unpleasantness (F 1.91, 53.55 = 2.16, p = 0.12), or pain 
reports (F 1.60, 45.04 = 1.27, p = 0.28). (I) There were no significant differences in the 
HPA response to the SECPT (F 4.53, 104.22 = 0.80, p = 0.54), the (J) Area under the 
curve with respect to ground (AUCg) (F 1.60, 38.52 = 1.03, p = 0.35) or the (K) delta 
cortisol response (p = 0.28). 
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Table 4.3:  Subjective Stress Measures in the SECPT. Means and Standard errors of the mean in parentheses. 
  Baseline Placebo  Probiotic  
Baseline V 
Placebo 
Placebo V 
Probiotic 
Baseline V 
Probiotic 
Treatment Effect (Repeated 
Measures ANOVA) 
        (p value)  (p value)  (p value)    
Primary Appraisal/Secondary 
Appraisal               
Threat 1.87 (0.14) 1.67 (0.10) 1.66 (0.12) 0.26 0.92 0.20 F (1.45, 40.70) = 1.28, p = 0.27 
Challenge 3.32 (0.12) 3.48 (0.16) 3.39 (0.18) 0.29 0.46 0.64 F (1.83, 51.48) = 0.64, p = 0.51 
Self-Control 4.36 (0.13) 4.41 (0.11) 4.58 (0.10) 0.68 0.08 0.04 F (1.80, 50.62) = 2.21, p = 0.12 
Control Expectancy 3.81 (0.17) 4.11 (0.19) 3.94 (0.17) 0.11 0.12 0.43 F (1.58, 44.39) = 1.91, p = 0.16 
Primary appraisal 2.60 (0.09) 2.57 (0.11) 2.53 (0.11) 0.83 0.51 0.55 F (1.52, 42.70) = 0.23, p = 0.73 
Secondary appraisal 4.09 (0.12) 4.26 (0.12) 4.26 (0.11) 0.14 1.00 0.07 F (1.69, 47.56) = 2.10, p = 0.14 
Stress index -2.89 (0.12) -3.20 (0.29) -3.30 (0.19) 0.39 0.65 0.18 F (1.54, 41.65) = 1.01, p = 0.35 
Socially Evaluated Cold Pressor 
(SPECT) %               
Prestress 12.50 (2.33) 17.14 (4.04) 18.57 (3.59) 0.16 0.70 0.02 F (1.66, 46.58) = 2.59, p = 0.09 
Difficulty 34.82 (4.31) 36.89 (4.86) 41.72 (5.15) 0.63 0.35 0.09 F (1.83, 51.38) = 1.23, p = 0.29 
Unpleasantness 40.69 (4.88) 36.55 (4.92) 46.55 (4.94) 0.41 0.06 0.18 F (1.91, 53.55) = 2.16, p = 0.12 
Post stress 25.51 (3.27) 21.03 (3.62) 24.13 (3.92) 0.31 0.45 0.69 F (1.89, 52.92) = 0.65, p = 0.51 
Painful 43.10 (5.08) 37.93 (4.53) 45.17 (4.64) 0.37 0.09 0.60 F (1.60, 45.04) = 1.27, p = 0.28 
 
 
 
 
124 
 
Immune response 
There was no overall treatment effect on the concentrations of IL10 (p = 0.32), IL1β (p 
= 0.08), IL6 (p = 0.13) or IL8 (p = 0.16) (Figure 4.3A-D). The concentration of TNFα 
increased from baseline during the placebo phase (p = 0.02), but there was no 
significant change in baseline versus probiotic (p = 0.08) or placebo versus probiotic (p 
= 0.18) (Figure 4.3E). There was no overall treatment effect on the IL1β:IL10 (p = 
0.68), IL6:IL10 (p = 0.12), IL8:IL10 (p = 0.97), or TNFα:IL10 (p = 0.99) ratios (Figure 
4.3F-I). Inspection of IL6:IL10 data suggested differences during the probiotic phase so 
we carried out exploratory analysis by using pairwise comparisons (Table 4.4) which 
indicated a lower IL6:IL10 ratio from baseline (p = 0.03) (Figure 4.3G), however this 
was non-significantly lower than placebo levels (p = 0.13). 
 
TLR4 cytokine release 
In the TLR4 stimulated cytokines, there was an increase in the level of IL1β (p = 0.02) 
(Figure 4.3J) and TNFα (p = 0.01) (Figure 4.3K) during the placebo phase compared 
to baseline (p = 0.01) but no effect of probiotic (p = 0.03). There was no effect of either 
treatment phase on TLR4 stimulated IL10 (p = 0.12), IL6 (p = 0.22) or IL8 (p = 0.25) 
cytokine release (Figure 4.3L-M).  
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Figure 4.3: Immune response 
There was no overall treatment effect on the plasma concentrations of (A) IL10 (F 1.64, 
34.57 = 1.12, p = 0.32) (B) IL1β (F 1.69, 47.46 = 2.72, p = 0.08), (C) IL6 (F 1.97, 51.38 
= 2.11, p = 0.13) or (D) IL8 (F 1.78, 50.00) = 1.87, p = 0.16). (E) The concentration of 
TNFα increased from baseline during the placebo phase (p = 0.02), but there was no 
significant change in baseline versus probiotic (p = 0.08) or placebo versus probiotic (p 
= 0.18). There was no overall treatment effect on the (F) IL1β:IL10 (F 1.91, 51.81 = 0.36, 
p = 0.68), (G) IL6:IL10 (F 1.84, 48.00 = 2.165, p = 0.12) (H) IL8:IL10 (F 1.91, 51.56 = 
0.02, p = 0.97), or (I) TNFα:IL10 (F 1.96, 54.90 = 0.006, p = 0.99) ratios. Pairwise 
comparisons showed that the probiotic decreased the IL6:IL10 ratio (p = 0.03), though 
not significantly over placebo (p = 0.13). In the TLR4 stimulated cytokines, there was an 
increase in the level of (J) IL1β (F 1.77, 40.77 = 4.46, p = 0.02) and (K) TNFα (p = 0.01) 
during the placebo phase compared to baseline (p = 0.01). There was no effect of either 
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treatment phase on (L) IL10 (F 1.68, 42.04 = 2.30, p = 0.12) (M) IL6 (F 1.72, 43.02 = 
1.57, p = 0.22) or (N) IL8 (F 1.17, 29.24 = 1.409, p = 0.25) cytokine release.  
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Table 4.4: Inflammatory Measures. Means and Standard errors of the mean in parentheses. 
  Baseline  Placebo  Active  
Baseline V 
Placebo 
Placebo V 
Probiotic 
Baseline V 
Probiotic 
Treatment Effect (Repeated 
Measures ANOVA) 
        (p value)  (p value)  (p value)    
IL10 0.35 (0.10) 0.36 (0.07) 0.39 (0.13) 0.80 0.30 0.22 F (1.64, 34.57) = 1.12, p = 0.32 
IL1b 0.09 (0.01) 0.10 (0.01) 0.11 (0.01) 0.25 0.62 0.11 F (1.69, 47.46) = 2.72, p = 0.08 
IL6 0.38(0.03) 0.49 (0.05) 0.44 (0.05) 0.05 0.31 0.31 F (1.97, 51.38) = 2.11, p = 0.13 
IL8 2.45 (1.22) 2.84 (1.25) 2.61 (0.96) 0.10 0.25 0.37 F (1.78, 50.00) = 1.87, p = 0.16 
TNFα 1.23 (0.07) 1.42 (0.11) 1.31 (0.08) 0.02 0.18 0.08 F (1.50, 42.00) =  3.79, p = 0.04 
IL1b:10  0.24 (0.03) 0.24 (0.03) 0.26 (0.03) 0.91 0.52 0.39 F (1.91, 51.81) = 0.36, p = 0.68 
IL6:10  1.07 (0.09) 1.05 (0.11) 0.90 (0.09) 0.84 0.13 0.03 F (1.84, 48.00) = 2.165, p = 0.12 
IL8:10  5.99 (0.63) 6.12 (0.62) 5.99 (0.57) 0.85 0.87 0.99 F (1.91, 51.56) = 0.02, p = 0.97 
TNFα:10  3.10 (0.22) 3.08 (0.22) 3.09 (0.22) 0.91 0.97 0.95 F (1.96, 54.90) = 0.006, p = 0.99 
TLR4 IL10 185.26 (18.55) 160.83 (12.16) 161.14 (14.10) 0.09 0.98 0.12 F (1.68, 42.04) = 2.30, p = 0.12 
TLR4 IL1b 669.17 (58.91) 903.14 (89.57) 763.95 (59.51) 0.01 0.12 0.15 F (1.77, 40.77) = 4.46, p = 0.02 
TLR4 IL6 2002.99 (119.85) 
1960.94 
(121.74) 1821.67 (92.86) 0.62 0.25 0.13 F (1.72, 43.02) = 1.57, p = 0.22 
TLR4 IL8 7781.87 (625.10) 
7043.81 
(575.93) 
7739.74 
(644.47) 0.22 0.25 0.83 F (1.17, 29.24) = 1.409, p = 0.25 
TLR4   
TNFα 612.12 (66.22) 909.65 (124.17) 637.77 (75.06) 0.00 0.03 0.64 F (1.29, 31.04) = 6.717, p = 0.009 
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Cognitive Measures  
Paired Associates Learning (PAL) 
There was no overall treatment effect on the total errors made (p = 0.06) (Figure 4.4A), 
however at the 8 shape stage (Figure 4.4B), there was a significant reduction in errors 
from baseline in the placebo (p = 0.04) and probiotic phases (p = 0.04), but no significant 
difference between the placebo and probiotic. There was no significant difference in the 
mean trials to success (p = 0.13) (Figure 4.4AC).  
 
Attention Switching Task (AST) 
There was an increase in the correct response in the placebo (p = 0.03) (Figure 4.4D) 
and probiotic phases (p = 0.01) compared to baseline, and a decrease in the reaction time 
to correct response (Figure 4.4E) in the probiotic phase compared to baseline (p = 0.006), 
however the differences between placebo and probiotic were not significant.  
 
Rapid visual information processing (RVP)  
The placebo and probiotic improved the total correct hits (p = < 0.001) (Figure 4.4F), 
but there was no overall effect in the total false alarms (p = 0.53) (Figure 4.4F), or the 
reaction time (p = 0.48) (Figure 4.4H). 
 
Emotional Stroop 
There was an increase in the percentage of correctly identified neutral words in the 
probiotic phase of treatment (p = 0.03) (Figure 4.4I), but this was not significantly 
greater than baseline (p = 0.54). There was no difference in reaction time to identify 
neutral words (p = 0.85) (Figure 4.4J). There were no significant differences in positive 
percent correct, positive reaction time, negative percent correct, negative reaction time 
(data not shown).  
 
Emotion Recognition task 
The total correctly identified emotions increased in the placebo and probiotic phase 
compared to baseline (p = < 0.001) (Figure 4.4K), manifest in the disgust (p = 0.02) and 
fear (p = < 0.001) categories, but no differences between placebo and probiotic. In 
addition, there was a non-significant decrease in time taken to correctly identify emotions 
in the placebo and probiotic phases (Figure 4.4L).    
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Figure 4.4: Cognitive Measures  
In the paired associates learning task, there was no overall treatment effect on the (A) 
total errors made (F 1.71, 48.05 = 3.09, p = 0.06), however at the (B) 8 shape stage, there 
was a significant reduction in errors from baseline in the placebo (p = 0.04) and probiotic 
group (p = 0.04), but no significant difference between the placebo and probiotic. There 
was no significant difference in the (C) mean trials to success (F 1.55 , 42.10 = 2.21, p = 
0.13). (D) In the attention switching task, there was an increase in the correct responses 
in the placebo (p = 0.03) and probiotic phases (p = 0.01) compared to baseline, and a 
decrease in the (E) reaction time to correct response in the probiotic phase compared to 
baseline (p = 0.006), however the differences between placebo and probiotic were not 
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significant. In the rapid visual information processing task, the placebo and probiotic 
improved the (F) total correct hits (p = < 0.001), but there was no overall effect in the 
(G) total false alarms (F 1.57, 44.06 = 0.55, p = 0.53) or the (H) reaction time (F 1.65, 
44.55 = 0.68, p = 0.48). In the emotional stroop task there was an increase in the 
percentage of correctly identified neutral words in the probiotic phase of treatment (I) (p 
= 0.03), but this was not significantly greater than baseline (p = 0.54). There was no 
difference in (J) reaction time to identify neutral words (F 1.93, 54.09 = 0.15, p = 0.85). 
In the emotion recognition task, the (K) total correctly identified emotions increased in 
the placebo and probiotic phase compared to baseline (p = < 0.001), manifest in the 
disgust (p = 0.02) and fear (p = < 0.001) emotion sub-categories. (L) In addition, there 
was a non-significant decrease in time taken to correctly identify emotions in the placebo 
and probiotic phases.  
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Table 4.5: Cognitive Measures. Means and Standard errors of the mean in parentheses 
 Baseline  Placebo  Active  
Baseline V 
Placebo 
Placebo V 
Probiotic 
Baseline V 
Probiotic 
Treatment Effect (Repeated 
Measures ANOVA) 
        (p value)  (p value)  (p value)    
Paired associate learning 
(PAL)               
Total errors 5.58 (0.82) 4.00 (0.59) 3.82 (0.57) 0.08 0.78 0.04 F (1.71, 48.05) = 3.09, p = 0.06 
Total errors (8 shape) 4.93 (0.74) 3.17 (0.49) 3.44 (0.50) 0.05 0.58 0.04 F (1.51, 42.47) = 3.73, p = 0.04 
First trial memory score 17.27 (0.47) 18.10 (0.40) 18.13 (0.37) 0.12 0.94 0.11 F (1.87, 50.653 = 2.47, p = 0.09 
Mean trials to success 1.42 (0.06) 1.33 (0.040 1.30 (0.04) 0.22 0.49 0.06 F (1.55 , 42.10) = 2.21, p = 0.13 
Attention Switching Task 
(AST)               
Mean correct latency 472.10 (13.87) 455.39 (13.36) 
437.41 
(12.740 0.13 0.05 0.00 F (1.90, 53.36) = 6.40, p = 0.004 
Correct % 96.75 (0.57) 98.22 (0.34) 98.10 (0.33) 0.03 0.74 0.01 F (1.34, 32.22) = 5.25, p = 0.02 
Rapid visual information 
processing (RVP)               
Total hits 21.17 (0.62) 23.53 (0.60) 23.50 (0.47) <0.001 0.93 <0.001 F (1.97, 55.19) = 15.21, p = <0.001 
Total false alarms 1.27 (0.22) 1.41 (0.27) 1.13 (0.19) 0.67 0.29 0.49 F (1.57, 44.06) = 0.55, p = 0.53 
Mean reaction time (ms) 344.69 (9.77) 338.21 (8.68) 
334.03 
(7.32) 0.55 0.56 0.26 F (1.65, 44.55) = 0.68, p = 0.48 
Emotional Stroop               
% correct (positive) 99.04 (0.29) 98.61 (0.37) 99.30 (0.21) 0.35 0.12 0.42 F (1.72, 48.40) = 1.50, p = 0.23 
Mean RT (positive) 943.00 (22.72) 944.77 (21.46) 
933.77 
(20.13) 0.91 0.36 0.56 F (1.81, 49.09) = 0.34, p =  0.69 
% correct (negative) 98.70 (0.39) 98.95 (0.27) 98.78 (0.27) 0.57 0.65 0.84 F (1.92, 53.97) = 0.19, p = 0.81 
Mean RT (negative) 957.07 (28.42) 952.15 (22.43) 
958.02 
(22.22) 0.79 0.67 0.96 F (1.81, 50.78) = 0.07, p = 0.91 
% correct (neutral) 92.06 (0.87) 90.00 (0.67) 92.75 (0.65) 0.07 0.00 0.54  F (1.86, 52.25) = 3.82, p = 0.03 
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Mean RT (neutral) 948.86 (25.19) 956.45 (24.04) 
953.71 
(21.66) 0.55 0.85 0.75 F (1.93, 54.09) = 0.15, p = 0.85 
Emotion recognition test 
(ERT)               
Tot % correct 71.01 (1.37) 74.19 (1.03) 74.84 (1.32) 0.01 0.48 <0.001 F (1.75, 49.22) = 9.90, p =  <0.001 
Tot latency 1011.50 (44.13) 976.05 (47.91) 
930.58 
(40.97) 0.40 0.15 0.08 F (1.74, 48.71) = 2.15, p = 0.13 
Happiness % correct 90.92 (1.64) 90.00 (1.82) 91.26 (1.34) 0.55 0.39 0.79 F (1.94, 54.33) = 0.42, p = 0.65 
Happiness latency 726.16 (43.26) 732.21 (45.98) 
680.12 
(42.39) 0.88 0.18 0.26 F (1.98, 55.45) = 1.02, p = 0.36 
Sadness % correct 76.09 (2.11) 78.62 (1.79) 79.65 (2.40) 0.14 0.48 0.08 F (1.78, 50.07) = 2.31, p = 0.11 
Sadness latency 1064.43 (53.11) 957.13 (50.14) 
932.41 
(50.56) 0.03 0.58 0.02 F (1.87, 52.54) = 4.19, p = 0.02 
Anger % correct 64.94 (1.54) 67.12 (1.96) 67.58 (1.89) 0.14 0.82 0.14 F (1.72, 48.39) = 1.30, p = 0.27 
Anger latency 1121.31 (68.90) 1039.89 (57.12) 
975.70 
(54.96) 0.21 0.11 0.04 F (1.53, 43.03) = 3.14, p = 0.06 
Disgust % correct 68.69 (1.97) 74.64 (1.87) 74.99 (1.60) 0.04 0.86 0.01 F (1.73, 46.76) = 4.53, p = 0.02 
Disgust latency 1125.91 (56.6) 1019.41 (60.29) 
1003.65 
(49.46) 0.14 0.73 0.04 F (1.61, 45.31) = 2.62, p = 0.09 
Fear % correct 47.01 (3.66) 57.12 (2.87) 57.24 (4.21) 0.00 0.97 0.00 F (1.97, 55.39) = 9.47, p = <0.001 
Fear latency 1098.88 (62.36) 1096.51 (57.85) 
1092.25 
(57.53) 0.97 0.90 0.91 F (1.92, 53.77) = 0.28, p = 0.74 
Surprise % correct 81.54 (1.38) 78.92 (2.04) 79.64 (1.60) 0.27 0.73 0.33 F (1.90, 51.41) = 0.84, p = 0.43 
Surprise latency 914.41 (43.160 970.46 (47.000 
897.11 
(43.54) 0.30 0.09 0.77 F (1.78, 49.83) = 1.12, p = 0.32 
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EEG 
There was a significant difference between placebo and probiotic for F3 zero crossings 
(second derivative) (p = 0.015), however, there was no significant difference in this index 
between baseline and placebo (p = 0.693) or between baseline and probiotic (p = 0.058). 
There were no significant differences between placebo and probiotic in any of the other 
measures. See (Table 4.6) for pairwise comparisons.   
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  Baseline  Placebo  Probiotic 
Baseline V 
Placebo 
Placebo V 
Probiotic 
Baseline 
V 
Probiotic 
Treatment Effect (Repeated 
Measures ANOVA) 
        (p value)  (p value)  (p value)    
F3 Normalised Power (delta) 0.074 (0.005) 0.083 (.006) 0.093 (0.006) 0.202 0.194 
 
0.023 F (2, 48) = 3.29, p = 0.046 
Fz Normalised Power (theta 2) 0.037 (0.005) 0.028 (0.004) 0.031 (0.004) 0.017 0.278 
 
0.069 F (1,.45, 34.69) = 4.57, p = 0.027 
Fz Normalised Power (alpha 1) 0.041 (0.005) 0.031 (0.005) 0.033 (0.005) 0.043 0.56 
 
0.041 F (2, 48) = 3.52, p = 0.037 
Pz Normalised Power (alpha 2) 0.084 (0.016) 0.052 (0.014) 0.05 (0.012) 0.03 0.84 
 
0.02 F (2, 48) = 4.67, p = 0.014 
Pz Normalised Power (Beta) 0.078 (0.012) 0.047 (0.004) 0.051 (0.006) 0.034 0.43 
 
0.065 F (1.23, 29.46) = 4.14, p = 0.044 
Fz Shannon Entropy 4 (0.05) 4.13 (0.07) 4.07 (0.06) 0.019 0.22 
 
0.064 F (2.48) = 4.07, p = 0.023 
        
Fz Root mean square amplitude 16.45 (1.22) 19.57 (1.53) 18.13 (1.19) 0.005 0.157 
 
0.053 F (2, 48) = 5.42, p = 0.008 
Pz Peak Frequency of spectrum 5.45 (0.75) 3.4 (0.53) 3.36 (0.48) 0.004 0.903 
 
0.01 F (1.35, 32.29) = 7.86, p = 0.005 
Fz Activity 318.33 (60.4) 444.57 (75.56) 376.58 (53.93) 0.01 0.122 
 
0.141 F (2, 48) = 4.55, p = 0.016 
Pz Complexity 3.93 (0.26) 4.75 (0.36) 4.7 (0.31) 0.05 0.88 
 
0.04 F (2, 48) = 3.28, p = 0.046 
Pz Non-linear energy 85.29 (29.24) 46.98 (16.72) 48.66 (18.92) 0.046 0.717 
 
0.05 F (1.01, 26.33) = 4.22, p = 0.047 
Pz Spectral entropy 5.63 (0.16)| 5.14 (0.14) 5.24 (0.14) 0.019 0.476 
 
0.02 F (2, 48) = 4.92, p = 0.01 
Pz Wavelet Energy 22.58 (1.91) 19.5 (1.36) 20.29 (1.55) 0.016 0.491 
 
0.055 F (2, 48) = 3.87, p = 0.03 
Pz Fisher information 0.15 (0.01) 0.21 (0.02) 0.2 (0.01) 0.006 0.420 
 
0.005 F (2, 48) = 7.34, p = 0.002 
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Table 4.6: Pairwise Comparisons of EEG indices. Mean values (standard errors of the mean in parentheses) 
Cz Zero crossings (first 
derivative) 
1056.68 
(26.04) 
1112.53 
(21.81) 
1089.64 
(19.88) 0.006 0.291 
 
0.212 F (2, 48) = 3.26, p = 0.47 
Pz Zero crossings (first 
derivative) 
1015.28 
(32.26) 
1099.23 
(26.07) 
1074.44 
(21.48) < 0.001 0.305 
 
0.047 F (2,48) = 6.4, p = 0.003 
F3 Zero crossings (second 
derivative) 1385.68 (7.22) 1388.55 (6.18) 1368.56 (7.56) 0.693 0.015 
 
0.058 F (2, 48) = 3.82, p = 0.03 
Fz total power 303423.9 
(59749) 
430219.4 
(74428.2) 
359577.3 
(51091.7) 0.008 0.1 
 
0.14 F (2, 48) = 4.85, p = 0.012 
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4.5 Discussion 
Preclinical data strongly supports the view that L. rhamnosus (JB-1) has the capacity to 
alter central GABA transmission by acting through the vagus nerve (Bravo et al., 2011) 
and in so doing impact significantly on stress responses and behaviour. In this 
translational study conducted in healthy volunteers we failed to replicate the preclinical 
findings, which were conducted in an anxious mouse strain. In contrast to the preclinical 
data, this cross-over study found that L. rhamnosus treatment was not superior to placebo 
in improving cognitive performance and did not attenuate reported stress in healthy male 
subjects. Furthermore, probiotic treatment did not have a clear anti-inflammatory effect 
and did not attenuate the subjective stress response or HPA axis response during an acute 
stress procedure. This study highlights the challenges in translating the findings from 
candidate psychobiotics in stress-susceptible animals, to healthy human populations. 
 
The candidate psychobiotic used in this study displayed a strong behavioural signal 
across multiple aspect of behaviour in well-validated screening assays in an anxious 
mouse strain (Bravo et al., 2011). However, over the eight week period of this trial, self-
reported mood, anxiety, stress and sleep were constant and not significantly altered from 
baseline during the placebo or probiotic phases (Figure 1A-H). The data from other 
studies is mixed. For example, our results are consistent with a study by (Benton et al., 
2007), albeit in an older age group, that showed no overall effect of Lactobacillus casei 
Shirota on mood and only a small improvement when post-hoc analysis of the lowest 
tertile mood scores were considered. After a 6 week, randomized, double-blind, placebo-
controlled trial in petrochemical workers, there was a significant improvement in the 
general health questionnaire score in the probiotic yogurt group (L. acidophilus LA5 and 
B. lactis BB12) and in the probiotic capsule group (Actobacillus casei, L. acidophilus, L. 
rhamnosus, L. bulgaricus, B. breve, B. longum, S. thermophiles), as well as a significant 
improvement in the depression anxiety and stress scale score in the probiotic yogurt and 
the multispecies probiotic capsule group. The improvement in scores in these scales were 
not seen in the conventional yogurt group (containing the starter cultures of 
S.thermophilus and L. bulgaricus). The probiotic did not alter HPA axis function or the 
kynurenine/tryptophan ratio (Mohammadi et al., 2015c). The same group did not observe 
a significant effect between the groups in oxidative stress markers (Mohammadi et al., 
2015b).   
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A more recent study, using a multi-species probiotic (B. bifidum W23, B. lactis W52, L. 
acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, and Lactococcus lactis 
(W19 and W58), did not find significant changes in mood or anxiety as measured by the 
Beck Depression Inventory or Beck Anxiety Inventory, but reported a reduction on 
subscales of the Leiden index of depression for rumination and aggressive thoughts 
(Steenbergen et al., 2015a). Another study in healthy controls, using L. helveticus R0052 
and B. Longum R0175 found no change in stress, as measured by the perceived stress 
scale, but did report a reduction in anxiety scores using the Hospital Anxiety and 
Depression Scale and a reduction in the global severity index, somatisation, depression 
and anger–hostility scores in the Hopkins Symptoms Checklist (HSCL-90) (Messaoudi 
et al., 2011). Interestingly, we have recently shown that a B. Longum which also had anti-
stress and precognitive effects in BALB/c mice (Savignac et al., 2014, Savignac et al., 
2015a), also was able to modulate behaviour and stress responses in healthy volunteers. 
 
From a physiological perspective, L. rhamnosus (JB-1) also exhibited the capacity to 
reduce acute stress responses in mice (Bravo et al., 2011). Our participants exhibited an 
increased cortisol output in response to the acute stressor (Figure 2I). However, probiotic 
treatment did not attenuate cortisol output and there were no differences in subjective 
stress reports (Figure A-H). Although not utilizing an acute stress procedure, Messaoudi 
and colleagues found a significant difference in urinary cortisol levels between the L. 
helveticus R0052 and B. longum R0175 group and placebo groups (Messaoudi et al., 
2011). In a study administering a prebiotic (galactooligosaccharide) to healthy controls 
for three weeks a significant decrease in the salivary cortisol awakening response 
compared to placebo was found (Schmidt et al., 2015).  
 
Our results suggest that L. rhamnosus (JB-1) treatment doesn’t affect either basal or 
stimulated immune responses. In contract to our findings, both preclinical and clinical 
studies have previously shown that L. rhamnosus has anti-inflammatory effects (Forsythe 
et al., 2012, Mortaz et al., 2015, Pessi et al., 2000). Thus, two key pillars of brain-gut 
axis signalling were not modified following psychobiotic treatment. In terms of 
cognition, the parallel mode of the PAL test (which presents different shapes at each 
visit) was used in order to avoid practice effects, and to assess conditional learning of 
pattern-location associations. PAL test performance is dependent upon the hippocampus 
(de Rover et al., 2011, Eichenbaum and Bunsey, 1995), which has a high proportion of 
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glucocorticoid receptors (McEwen, 1999). A deficit in visuospatial memory 
performance, evident in PAL test performance, has been demonstrated in stress-related 
brain-gut axis disorders with a cognitive component such as IBS (Kennedy et al., 2015, 
Kennedy et al., 2014b). In this study, the probiotic was not superior to placebo across 
multiple cognitive domains including memory, attention, executive function and emotion 
recognition. Similarly, there were no significant differences of relevance in EEG 
measures between the probiotic and the placebo.  
 
We employed a rigorous cross-over trial with a repeated measures design to control for 
potential effects of individual differences. Given that our study consisted of young 
healthy males, with low baseline mood, stress and anxiety scores and no deficits in HPA, 
inflammatory or cognitive function, demonstrating a clear probiotic effect over placebo 
in this population may be challenging. This inability to demonstrate superiority of 
treatment over placebo is not unusual, either in the assessment of psychotropics in general 
or in microbiota-directed interventions. For example, a novel and initially promising 
spore based microbiome therapy (SER-109) in Clostridium difficile infection (Khanna et 
al., 2016), was shown not to be statistically superior to placebo in a larger phase II trial 
(Seres, 2016). At each study visit, participants were asked whether they experienced any 
side effects from consumption of the capsules. Side effects were negligible, however, 
formal assessment of gastrointestinal function, was not carried out and is thus a limitation 
of the study. 
 
There is an important difference in vulnerability between the anxious mouse strain used 
in the preclinical study and the healthy human volunteers that make up the clinical 
sample. It is worth noting that probiotics may be of limited benefit in healthy populations. 
Comparably, antidepressants also have a limited beneficial effect in healthy controls 
(Serretti et al., 2010). Moreover, antidepressants have a delayed onset of action (Taylor 
et al., 2006) and we acknowledge that more than four weeks of psychobiotic treatment 
may be required in future studies in populations with stress-related psychiatric 
disorders.A recent systematic review indicated that the impact of probiotic 
supplementation on gut microbiota structure, including an assessment across features 
such as α-diversity, richness and evenness, in healthy controls was minimal (Kristensen 
et al., 2016). However, it is important to consider that probiotics may impact the function 
of colonizing microbes or promote homeostasis of the gut microbiota, rather than change 
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its composition (Sanders, 2016). A more defined role for probiotic intervention may be 
in populations with some degree of pathology, for example IBS (Didari et al., 2015). 
Recently, several studies have demonstrated altered gut microbiota composition in 
depression (Jiang et al., 2015, Kelly et al., 2016b, Naseribafrouei et al., 2014) and 
suggest that this altered gut microbiota composition may play a causal role in the 
development of certain features of depression (Kelly et al., 2016b, Zheng et al., 2016b), 
though the precise mechanisms have yet to be elucidated. To date, only one small study 
has investigated a probiotic intervention in depressed patients (Akkasheh et al., 2016). 
In this study, eight weeks of a multispecies probiotic containing L. acidophilus, L. casei 
and B. bifidum, reportedly reduced depressive symptoms in moderately depressed 
patients compared to placebo. Although, microbiota analysis was not completed in this 
study and it was not clear what other forms of treatment patients were undergoing.  
 
Despite the momentum provided by preclinical microbiome studies, there is a growing 
appreciation of the challenges in moving this work from bench to bedside (Arrieta et al., 
2016, Dinan and Cryan, 2016). This includes the fact that the rodent gastrointestinal tract 
and microbiota composition differs from the human equivalent (Nguyen et al., 2015). It 
is worth noting that the effects of L. rhamnosus were dependent on the vagus nerve 
(Bravo et al., 2011). The precise mediators between the gut microbiota and the vagus 
nerve have not been defined and could not therefore be assessed in this study. Moreover, 
it is important to note that the preclinical analysis of L. rhamnosus was carried out in 
BALB/c mice which are innately anxious and have different brain and gut responses to 
stress (Browne et al., 2011, Julio-Pieper et al., 2012, O'Mahony et al., 2010, Savignac et 
al., 2011).  
 
Moreover, Bercik and colleagues have shown alterations in microbiota composition in 
this strain compared with strains with normal stress responses. Further, when these mice 
were transplanted with microbiota from a normo-anxious mouse their behaviour 
normalised suggesting a strong connection between host microbiota and behaviour 
(Collins et al., 2013). Recently, B. longum 1714, an alternative candidate psychobiotic 
selected following a similar preclinical screening battery in BALB/c mice, has been 
reported to reduce stress and improve memory (Allen et al., 2016), although a detailed 
mechanistic understanding of its effects in this regard is currently lacking. These 
diverging outcomes highlight the issue of different putative psychobiotics likely 
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exhibiting different mechanisms of action. Ultimately, this study, together with the SER-
109 study illustrate the need to better understand the mechanisms, for effective 
translation. Whether the JB-1 strain has potential in the treatment of stress-related 
psychiatric disorders, either as a single agent, or in combination with other potential 
psychobiotics, remains an open question and further investigations are warranted. 
 
Conclusions 
This eight week randomized cross-over trial did not show that L. rhamnosus (JB-1) was 
superior to placebo in modifying stress-related measures, HPA responses, inflammation 
or cognitive performance in healthy male participants. These results suggest that some 
caution is required regarding expectations of targeting the gut microbiome in healthy 
populations and that there may be challenges in translating candidate psychobiotics 
with promising preclinical signals in anxious mouse strains into healthy human 
subjects. Future interventional studies investigating the effect of this probiotic in 
populations with stress-related disorders are required. 
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Chapter 5: General Discussion 
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5.1 Overview and summary 
A growing body of literature suggests a role for the gut microbiota in stress-related 
disorders but the clinical implications of these findings lags behind this promising 
research. In this thesis, we assessed this hypothesis using a translational approach. We 
have demonstrated that depression is associated with an altered gut microbiota. Further, 
this altered gut microbiota contributes to the complex underlying pathophysiology of 
depression. These findings can be incorporated within a neurobiological model of 
depression, and together with the existing literature, these results support the possibility 
of therapeutic targeting of the gut microbiota in stress-related disorders such as 
depression.  
 
In Chapter 2, we demonstrated that depression is associated with altered gut microbiota 
composition, including decreased richness and diversity. In addition, we affirmed that 
depression is associated with increased levels of inflammatory markers, altered 
tryptophan metabolism along the kynurenine pathway and HPA axis dysfunction – all 
factors which have been linked to gut microbiota alterations in preclinical studies. In 
Chapter 3, we showed that transferring the gut microbiota from depressed patients to 
microbiota-depleted rats can induce behavioural and physiological features characteristic 
of depression in the recipient animals, including anhedonia and anxiety-like behaviours, 
as well as alterations in tryptophan metabolism. In Chapter 4, we conducted an 
interventional study in a healthy male cohort to attempt to translate a candidate 
psychobiotic identified from our preclinical screening platform. Although we provide 
evidence that the gut microbiota is altered in depression and that this alteration could 
have a role in prominent features of depression, therapeutic targeting of the gut 
microbiota in healthy males using L. Rhamnosus (JB-1) was not superior to placebo in 
modifying self-reported stress, HPA axis response to an acute stressor, inflammation, 
cognition or neurophysiological measures.  
 
5.2 The Gut Microbiota as a Neurobiological factor in Depression 
As we have highlighted throughout, depression is a heterogeneous disorder and the 
pathophysiology is complex. The factors contributing to the onset of this condition will 
vary widely from person to person but the interaction of genetic predisposition with 
environmental factors, such as significant psychosocial stress, particularly in early life, 
and biological systems such as the neuroendocrine and neuroimmune pathways are 
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cardinal. To this complex model, we now propose that the gut microbiota be added. In 
this thesis, we have demonstrated that a depression-associated gut microbiota can induce 
common features of depression such as anhedonia and anxiety and as well as altered 
tryptophan metabolism. By incorporating the gut microbiota into existing concepts of 
depression a more comprehensive model has been developed (Figure 5.1). 
 
 
Figure 5.1: Neurobiological model of depression. Genetic and environmental factors 
interact to predispose the individual to the risk of depression. Due to these gene-
environment interactions, alterations in the gut microbiome, acting via the brain-gut-axis, 
function as an additional biological vulnerability factor. Psychosocial stressors can 
precipitate depression symptom expression and can result in gut microbiome alterations. 
At this stage, gut microbiome alterations both increase the biological vulnerability to 
subsequent stressors and may act as a perpetuating factor for depressive symptom 
expression.  
 
5.3 The Microbiome as a Stratification tool  
What exactly constitutes a “healthy microbiome” has not yet been clearly defined 
(Backhed et al., 2012), and there are considerable interpersonal differences in healthy 
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individuals (Falony et al., 2016, Zhernakova et al., 2016). Consequently, there are 
multiple possible configurations for a healthy gut microbiome and it is also likely that 
some stable configurations are associated with disease (Relman, 2015). It is important 
also to appreciate that the functional output of multiple microbiome configurations may 
in fact be equivalent, given that concepts of redundancy and pleiotropy can also be 
applied to specific microbial members of the overall consortium. Indeed, our 
metabolomics analysis indicated that even though the gut microbiome was less diverse 
in depression, it was not associated with differential microbial metabolite production. 
 
 
Despite the considerable and complex challenges of defining a healthy gut microbiome, 
and the relevant features that might be implicated in stress-related disorders, we 
anticipate that successful translation of our work to date on pathological microbiomes 
could lead, for example, to stratification based on gut microbiome composition profiles, 
which in turn could identify sub-groups of patients that may be more likely to respond to 
a microbiome-based therapeutic approach. A major, as yet unfulfilled objective in 
psychiatry is the identification of biomarkers. Due to the complexity of the brain, it is 
perhaps no surprise that psychiatry is the only medical speciality that has no robust 
biomarker to assist in diagnosis or treatment, and unfortunately the dogma of trial and 
error prevails. Considerable effort has been invested into rectifying this situation. For 
example, studies utilizing a range of techniques, including, but not limited to 
neuroimaging (McGrath et al., 2013), microRNAs (Gururajan et al., 2016b) and 
inflammatory profiles (Cattaneo et al., 2013, Raison et al., 2013, Uher et al., 2014) have 
reported to be of benefit. However, none of these approaches are near the stage of 
benefitting decision making in routine clinical practice.   
 
It is likely that a constellation of biomarkers will be necessary. Thus, the addition of gut 
microbiota profiling may deliver further diagnostic accuracy and potentially extend 
personalized medicine. For example, Irritable bowel syndrome (IBS) subtypes have been 
stratified according to their gut microbiota profiles, specifically those with an increased 
Firmicutes: Bacteroidetes ratio (Jeffery et al., 2012a). Furthermore, depression was the 
most robust clinical discriminator between a high Firmicutes: Bacteroidetes ratio in IBS 
patients relative to IBS patients with a healthy-like microbiota signature (Jeffery et al., 
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2012a). In addition, the order Actinomycetales and the family Actinomycetaceae were 
inversely associated with clinically significant depression (Jeffery et al., 2012a).  
 
Although, microbiome-based biomarkers in depression have not yet been developed, the 
current study identified some interesting candidate microbiota signatures which could be 
considered in this regard. In the depressed group, the most pronounced difference was 
observed in the reduction of the relative abundance of prevotellaceae at the family level 
and in the prevotella at the genus level, whereas the thermoanaerobacteriaceae family 
were increased. At the genus level, the relative proportions of eggerthella, holdemania, 
gelria, turicibacter, paraprevotella, and anaerofilum were increased in the depressed 
group, whereas dialister was decreased. We also observed more general markers which 
might have utility, including reductions in richness and diversity. However, given our 
limited sample size, we did not note any marked correlations between specific alterations 
and symptoms. Future large scale studies that focus on the possible links between gut 
microbiota signatures and components of depression are necessary to address this issue. 
We speculate that in conjunction with a range of other biomarkers (Gururajan et al., 
2016a) gut microbiota signatures will be of increasing importance in psychiatry.  
 
 
It is interesting to note that the emergence of the gut microbiome as a key player in brain 
and behaviour parallels another major development: The Research Domain Criteria 
(RDoC) (Glannon, 2015, Morris and Cuthbert, 2012). This research initiative, although 
the subject of much debate (Frances, 2014, Kraemer, 2015, Weinberger et al., 2015, Yee 
et al., 2015) presents an exciting opportunity to advance psychiatric research (Casey et 
al., 2014, Cuthbert and Insel, 2013, Insel, 2014). Rather than using the traditional 
restricted categorical diagnostic approaches to psychiatric diagnosis, the RDoC matrix of 
functional dimensions, grouped into broad domains such as cognition and reward-related 
systems, examined across units of analysis ranging from genetic, molecular, and circuit 
activity to psychology and behaviour. Furthermore, by removing the constraints of 
classical psychiatric disease diagnosis, the RDoC leads to a better alignment of pre-
clinical and clinical studies to build a common framework of comparable neurobiological 
abnormalities, for example, based on microbiome alterations, to help form subgroups of 
patients on the basis of similar pathophysiology (Kaiser and Feng, 2015). For example, 
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in our study, anhedonia and anxiety emerged in our preclinical model and this may be a 
useful starting point for stratification across other psychiatric diagnoses.   
 
5.4 The Microbiome as a therapeutic target in Depression 
Novel psychiatric drug development is in a state of stagnation (Nutt and Goodwin, 2011). 
In the last 40 years, very few therapeutics with novel mechanisms have progressed to 
phase III clinical trials or regulatory approval. In this context, targeting the gut 
microbiome is an appealing option and potentially represents a major advance. Our 
results with a potential psychobiotic, which failed to demonstrate an impact in healthy 
human subjects despite a strong preclinical profile, suggest that the development of 
microbiome-based therapeutics will also be challenging. It is not immediately obvious 
why our current psychobiotic exhibited a limited impact while a previous and recent 
study in our laboratory using B. longum 1714, was translatable (Allen et al., 2016). It is 
important to note that the preclinical analysis in both studies was carried out in BALB/c 
mice which are innately anxious and have different brain and gut responses to stress 
(Browne et al., 2011, Julio-Pieper et al., 2012, O'Mahony et al., 2010, Savignac et al., 
2011). These diverging outcomes highlight the issue of different putative psychobiotics 
likely exhibiting different mechanisms of action. 
 
The overall probability of success of bringing any new drug, through preclinical stages 
and clinical trial stages I through III to market is approximately 8% (DiMasi et al., 2003). 
The glycine reuptake inhibitor Bitopertin, serves as a recent example. After an initially 
promising proof-of-concept study, for the treatment of negative symptoms of 
schizophrenia (Umbricht et al., 2014), Roche announced that it was not going to proceed 
with further development of the drug. Indeed, major pharmaceutical companies have 
shifted drug discovery efforts away from psychiatric toward non-psychiatric disorders 
with identified biological targets (Cressey, 2010, Miller, 2010, Munos, 2013). A 
multitude of factors may account for this, including the high levels of heterogeneity and 
co-morbidity in psychiatry, the absence of molecular targets, the increasing cost and 
average duration of treatment discovery (Morgan et al., 2011), together with the 
increasing placebo response rate and failure rates in clinical trials. 
 
Given the stasis in psychiatric drug development, expanding potential therapeutic targets 
is an essential endeavour. The gut microbiome, acting via the brain-gut-axis, is an easily 
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accessible and druggable target. Our results show that there is reduced gut microbiota 
richness and diversity in depressed patients and this was sufficient to produce anhedonia 
and anxiety-like behaviour in a rodent model. This concept of an entire ecosystem as a 
potential pathogen is a somewhat unfamiliar concept in clinical psychiatry, but the 
concept of diversity and stability as key indices in healthy ecosystems is generally 
accepted (Guarner et al., 2006, Hidaka, 2012, Klerman and Weissman, 1989, Lozupone 
et al., 2012b, Rook and Lowry, 2008, Rook et al., 2013, Rook et al., 2014, Turnbaugh et 
al., 2009a, Weissman, 1992). Clearly, gut microbiota alterations are just one of many 
potential vulnerability factors that may lead to symptom expression in depression (see 
Figure 5.1).  
 
The formidable challenges of developing an effective drug also applies to microbiome-
based therapies. This has recently been highlighted in a study using a spore based 
microbiome therapy (SER-109) in Clostridium difficile infection. After, an initially 
promising Phase Ib trial of a spore based microbiome therapy (SER-109) for C. difficile 
infection (Khanna et al., 2016), was shown not to be statistically superior to placebo in a 
larger phase II trial (Seres, 2016). This interim failure, which cost at least 120 million 
dollars, emphasizes the significant challenges in developing new effective therapies. 
Considering this failure to achieve the primary efficacy endpoint was in a gastro-
intestinal infection, for which FMT is of proven clinical benefit (Kelly et al., 2015, van 
Nood et al., 2013), it emphasizes the significant challenges for the development of a 
microbiome based therapy in psychiatric disorders.  
 
To date, only one small study has investigated a probiotic intervention in depressed 
patients (Akkasheh et al., 2016). In this study, eight weeks of a multispecies probiotic 
containing L. acidophilus, L. casei and B. bifidum, reportedly reduced depressive 
symptoms in moderately depressed patients compared to placebo. Although, microbiota 
analysis was not completed in this study and it was not clear what other forms of 
treatment patients were undergoing, it does provide a platform for larger and more 
detailed clinical probiotic trials. This suggests that a revision of current preclinical 
screening platforms to include an assessment of psychobiotics under pathological 
conditions may be a necessary refinement. 
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5.5 A new animal model of depression 
As is the case in our study, animal models will never recapitulate all the disease 
symptoms of a psychiatric diagnosis. But many of the questions we have raised will 
require evaluation in reliable preclinical models. However, most currently used 
behavioural models do not include the gut microbiota as a factor (relying instead on 
stressors, for example). The humanized FMT model is an integral component to 
demonstrate cause and effect in gut microbiota studies involving psychiatric populations. 
While GF animals are an excellent proof-of principal tool, we and others have shown that 
these animals have some profound CNS abnormalities in adulthood as a consequence of 
GF status during critical neurodevelopmental windows, many of which are relevant for 
the depressive phenotype. The main advantage of antibiotic-induced microbiota 
depletion during adulthood is that it avoids these potential confounding influences 
(Arrieta et al., 2016, Luczynski et al., 2016).  
 
The profile of depression-like behaviours and physiological alterations noted following 
FMT from depressed patients suggest that this model may be a useful paradigm in 
behavioural pharmacology to investigate microbiota-associated depression. Of course, as 
with any potential novel model, further rigorous validation is imperative, especially given 
the well described issues of reproducibility (Baker, 2016, Omary et al., 2016). While, 
humanized non germ-free mice using antibiotic treatment and human fecal transfer has 
been performed previously (Hintze et al., 2014), it is also important to acknowledge that 
some antibiotics act directly on the brain (Nau et al., 2010) to impact behaviour, anatomy, 
and physiology (Desbonnet et al., 2015, Frohlich et al., 2016, Mohle et al., 2016). 
 
A key question that must be addressed is, why were only some features of depression 
transferred? We can speculate that different donor profiles may account for this, but to 
answer this question, we need to investigate whether different donor symptom profiles 
can be transferred via FMT. For example, would it be possible to further disentangle the 
contribution of the gut microbiota to the pathophysiology of depression, by attempting 
to transfer sub-categories of depressed subjects with different levels of severity or 
different co-morbidities. As an extension, could other domains from other psychiatric 
disorders, for example anxiety disorders be transferred via FMT? Another question, to 
be addressed, is the precise temporal dynamics of the emergence and possible persistence 
of the behavioural alterations post FMT.  
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Further validation of the model developed in this thesis would provide the opportunity to 
further dissect the mechanistic properties of potential psychobiotics and expedite the 
screening process for translation into clinical populations. The current pre-clinical 
screening process does not include pathological models of depression, and thus the 
development of this new model could facilitate a superior platform to evaluate potential 
psychobiotics and delineate further, what the optimal combination of synergistic strains 
would be for the treatment of stress-related disorders. Furthermore, prebiotics, short 
chained fatty acids, antibiotics, and indeed currently available antidepressants could also 
be tested and compared.  
 
5.6 Limitations of the reported studies 
Although, the studies reported in this thesis have generated some novel and exciting 
insights into how the gut microbiota acting via the brain-gut axis contributes to the 
underlying neurobiological mechanisms of depression, there are a number of limitations 
which must be accounted for when interpreting our findings. In Chapter 2, the study was 
cross-sectional in design, thus precluding longitudinal assessment of changes in the gut 
microbiota as they related to changes in depressive symptoms. Our depressed group 
consisted of more males than females, whereas epidemiological studies show that 
females have higher rates of depression (Kessler, 2003, Weich et al., 2001, WHO, 2008). 
However, it is interesting to point out that this sex difference may partially be attributed 
to different manifestations of depressive symptoms in males (Martin et al., 2013). 
Regardless, the unbalanced sex profile in our study was due to the fact that more males 
than females were willing to provide fecal samples. Although our depressed group and 
healthy control group were matched on sex, age and body mass index, there were 
significant differences in alcohol and cigarette consumption. In terms of gut microbiota 
collection and DNA extraction, a mixture of fresh and frozen samples were used. 
However, this has been shown to have minimal impact on the integrity of the gut 
microbiota (Fouhy et al., 2015).  
 
In recent years, there has been a focus on the complex interaction between the gut 
microbiota and drug metabolism (Clayton et al., 2009, Saad et al., 2012, Swanson, 2015). 
For example, the gut microbiota can modulate the effects of oncology drugs (Viaud et 
al., 2013), cardiac drugs (Haiser et al., 2013, Saha et al., 1983), proton pump inhibitors 
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(Imhann et al., 2015) and statins (Kaddurah-Daouk et al., 2011). In a recent well powered 
cross-sectional microbiome study, medication had the largest explanatory power on 
microbiome composition, accounting for 10% of community variation (Falony 2016). Of 
the medications reported in this study the anti-depressant venlafaxine and the 
benzodiazepine clonazepam were the psychiatric medications included in the analysis, 
though a thorough investigation of the effects of anti-depressants on the gut microbiota 
has not yet been conducted. It is well established that recruiting medication free 
depressed patients is a significant challenge, and in our study, the majority of the 
depressed patients, who were at least moderately depressed, were prescribed anti-
depressant medication. We acknowledge the possibility of an antidepressant-related and 
serotonin-driven contribution to the alteration in the gut microbiota. However, 
antidepressants would be expected to reduce the kynurenine/tryptophan ratio rather than 
increase it via, for example, activity on TDO (Badawy and Morgan, 1991, Badawy et al., 
1991) making it unlikely that residual medication in the fecal transplantation from the 
depressed patients would increase depressive and anxiety like behaviours in the rats that 
received the depressed FMT.  
 
The full impact of the effect of psychotropic medication on the gut microbiota has yet to 
be established, but several pre-clinical and clinical studies have started to examine the 
bidirectional relationship between the gut microbiota and antipsychotic medication. 
Antipsychotics result in metabolic dysregulation and weight gain (Bak et al., 2014). In a 
preclinical study chronic olanzapine treatment altered gut microbiota composition and 
induced significant body weight gain in the female rats, while both males and females 
had olanzapine-induced increases in adiposity (Davey et al., 2012). Pre-treatment with 
an antibiotic cocktail attenuated this weight gain (Davey et al., 2013). Another preclinical 
study using GF mice, demonstrated that the gut microbiota are necessary and sufficient 
for weight gain caused by oral olanzapine, which shifted the microbiota profile towards 
an "obesogenic" bacterial profile (Morgan et al., 2014). Similarly risperidone, alters gut 
microbiota in mice and a FMT from risperidone-treated mice to naive recipients resulted 
in a 16% reduction in total resting metabolic rate (Bahra et al., 2015). The same group 
translated the findings into an adolescent clinical cohort to show that chronic risperidone 
treatment was associated with an increase in body mass index and a significantly lower 
ratio of Bacteroidetes:Firmicutes compared to antipsychotic-naive psychiatric controls 
(Bahr et al., 2015).  
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In Chapter 3, given that rodent and human microbiota are different and the inherent 
translational challenges in moving from rodent to man, it is perhaps not surprising that 
overlap of specific taxa were not reflected in the rat microbiota following the FMT. In 
addition, the microbiota composition was determined using fecal samples in the human 
study and from cecal samples in the rodent study. Considering, not all behavioural 
readouts of relevance to depression were recapitulated in our preclinical study, this 
suggests that those domains which were impacted relate to the missing taxa which are a 
feature of the rodent microbiota following the transfer. In addition, as mentioned above, 
our depressed patients were on anti-depressant medication and it would be important to 
determine the effects of a FMT from medication free depressed patients in future studies.   
 
In Chapter 4, male participants were selected to avoid the need to control for menstrual 
cycle, which can impact upon cortisol output and other readouts. Future studies will need 
to assess the impact of probiotic interventions in female participants and may need to 
consider the incorporation of a washout period into the study design. Given that our study 
population consisted of young healthy males, with low baseline mood, stress and anxiety 
scores and no deficits in HPA, inflammatory or cognitive function, this finding does not 
necessarily preclude the exploration of this probiotic or a combination, in stress-related 
disorders.  
 
5.7 What Future Studies are needed? 
The investigation of the role of the gut microbiota in clinical psychiatric populations is 
in its infancy and the few clinical studies conducted thus far are cross-sectional. The 
failure to find a robust and consistent gut microbiota signature in depression thus far is 
not surprising given the small sample sizes and lack of a standardized approach (Jiang et 
al., 2015, Naseribafrouei et al., 2014, Zheng et al., 2016a). This is not confined to 
depression studies and there are also considerable variation in the results reported in IBS. 
Two recent large scale cross-sectional microbiome studies, with a combined sample size 
of 3948, have highlighted some of the major challenges in the field of microbiome 
research (Falony et al., 2016, Zhernakova et al., 2016). These studies re-iterate the 
problems in defining a “normal” microbiome and the importance of large sample sizes 
and the need to consider confounding variables, such as stool consistency, medication 
use, and diet.  
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Interestingly, and contrary to some studies, early-life events such as birth mode were not 
reflected in adult microbiota composition. With a strikingly low cumulative, 
nonredundant effect size of 7.63%, the study emphasizes the influence of additional, 
currently unknown covariates as well as intrinsic microbial ecological processes such as 
founder effects, species interactions, and dynamics. Most studies of the gut microbiome 
in specific disorders have sample numbers well below the impressive size of these studies 
and have not even taken into account many of the known confounding variables. It is 
nonetheless striking that we and others have been able to pick up a narrowing of 
microbiota diversity under various pathologies in much smaller populations, suggesting 
that some of these factors may be subservient under certain disease-associated conditions. 
 
With these issues in mind, identification and validation of specific microbiome-based 
biomarkers in psychiatric disorders will require large scale longitudinal studies that 
assess the trajectory of the gut microbiota and its relationship to neuropsychiatric 
symptom development across the lifespan. There are already some examples from 
epidemiological research, focused on the impact of various insults to the microbiome, for 
example, following different modes of birth (Curran et al., 2016, Curran et al., 2015, 
Curran et al., 2014, O'Neill et al., 2015) and antibiotic use (Lurie et al., 2015). And large 
scale studies, such as The American Gut (Goedert et al., 2014) and associated British Gut 
projects (http://www.britishgut.org/) are ongoing in healthy volunteers and may assist in 
providing an appreciation of what is meant by a healthy microbiome and a template for 
future studies in psychiatry.  
 
In order to establish solid clinical relevance in psychiatric populations, microbiome based 
interventional studies, will also need to assess the functional consequences of microbiota 
shifts, as well as the impact on central markers of brain activity, before, during and after 
the intervention. Clinical trials of probiotic interventions in depressed patients at different 
levels of severity, and in comparison to other treatment modalities including 
antidepressants would be an interesting prospect. Consideration should also be given to 
investigation of pharmacokinetic, toxicological and dose-responses, to precisely 
determine optimal concentration and frequency of probiotic dosing (Marteau and 
Shanahan, 2003a).  
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5.8 Perspectives and conclusions 
The fusion of neuroscience and the microbiome is a new frontier in psychiatric research. 
This thesis, together with existing data demonstrates that the contemporary 
neurobiological models of depression should be extended to incorporate the gut 
microbiome. This data provides a platform to further delineate the precise gut microbiota 
signatures and functional outputs of relevance to depression in large scale longitudinal 
studies. Exploration of the role of the microbiome in other psychiatric disorders is now 
warranted. We propose that this process should involve breaking down psychiatric 
diagnoses into biological dimensions using an evolving RDoC framework which 
includes the microbiome as an additional dimensional construct. Merging the 
microbiome project and the brain connectome project (Toga et al., 2012) using the RDoC 
framework, although a significant multi-disciplinary endeavour, provides an important 
opportunity to advance the understanding of the pathophysiology of these complex brain 
disorders.  
 
It is an unanswered question whether sub-groups of depressed patients with specific gut 
microbiome profiles would respond better to microbiome based therapies than other 
treatments. And although, a promising approach, we acknowledge that targeting the gut 
microbiome in depression needs to be put into current clinical context. This will depend 
on many factors, but primarily on level of severity. Probiotics will be of negligible utility 
in the treatment of severe depression, however, in depression of mild to moderate 
severity, they may prove useful augmenting agents to other treatment modalities. Perhaps 
the strongest indication of probiotic intervention may be as part of a pre-emptive strategy, 
either in those in remission or with other vulnerability factors.  
 
Of course, in clinical practice, probiotic supplementation, would form only one 
component in the overall multimodal treatment strategy for depressed patients, which 
includes, but is not limited to, recommendations regarding healthy diet and exercise. A 
key question is whether probiotic supplementation is superior to dietary alteration. The 
immediacy of probiotic supplementation, in patient populations with potential 
motivational issues offers one potential advantage over dietary alteration, and thus this 
could be the first step for a further and more sustained transition to a healthier diet. Our 
results certainly highlight the role of the gut microbiome in depression and indicate that 
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further studies that extend across neurobiological and symptom domains in psychiatric 
populations, with implications for patient management strategies are now warranted.  
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Appendix 
 
Subject information sheet 
Study title:  The gut microbiome in major depression  
 
Principal Investigators: 
Professor Ted Dinan 
Professor John Cryan 
Professor Catherine Stanton 
Professor Paul Ross 
 
Site of Investigation: 
Cork University Hospital, Mercy University Hospital and University College Cork.  
 
Site of Laboratory: 
Alimentary Pharmabiotic Centre, University College Cork 
 
Why is this study being run? 
Depression is the most common mental disorder. It will affect up to 15% of the 
population during their lifetime. It can have a profound negative impact on the 
sufferer’s quality of life and it can incur significant health care costs. 
We do not have a complete understanding of the mechanism underlying depression, 
however it is well established that exposure to stress, particularly at an early age, is an 
important factor for the development of depression later in life. Stress can result in 
changes in the bacterial composition of the gut (microbiota). There is now increasing 
evidence that this communication pathway works in both directions and it has been 
shown that bacteria within the gut may influence brain function and behaviour. This 
study aims to investigate whether the gut microbiota is altered in people with 
depression. 
 
Study Proceedure 
Depending on your location the visits will take place at Cork University Hospital, 
Mercy University Hospital, University College Cork, or outpatients departments. 
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Thirty male and female patients diagnosed with major depressive disorder between the 
ages of 18 and 65 years will be enrolled.  
 
You will be advised of the purpose of the study and the procedures which will be 
undertaken. You will be given a copy of the subject information sheet, which will 
explain what is required from you. If interested, you will then be requested to read and 
sign the informed consent form and will receive a signed copy. 
 
Your suitability to participate in the study will be checked. You will be asked questions 
about your mood both now and in the past and will be asked about alcohol and drug 
use. You will also be asked questions about your current medical health, previous 
medical problems. You will be asked whether anybody in your family suffers from 
medical or mental health problems. You will be asked about your medications and 
allergies. 
 
Your height and weight will be measured and your body mass index (BMI) will be 
calculated. A urine sample will be taken for a HCG pregnancy test if you are a woman 
of childbearing age. 
 
A blood sample (nine millilitres) will be collected to measure inflammatory markers 
and a nine millilitre sample for haematology and biochemistry analysis performed as 
per standard of care.  
 
Three early morning saliva samples will be collected. You will be provided with 
containers and instructed how to do this. 
 
A faecal (stool) sample will be collected (which has been collected at home, within 12 
hours of your visit to the clinic). You will be provided with a container and an 
information sheet. You will be instructed how to do this. 
 
What happens if I start the study and change my mind later? 
You do not have to take part in the study, participation is entirely voluntary. Refusal to 
participate, or discontinuing participation at any time, will involve no penalty, loss of 
benefits or denial of treatment or services by the Cork teaching hospital or the 
participating doctor. 
 
Who is funding the trial? 
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There are no cost implications for the Health Service Executive (HSE) or to you. The 
management of patients and investigative tests will comply with current standards of 
care. Cost of research tests will be incurred by the Alimentary Pharmabiotic Centre, 
University College Cork. 
 
Is the information confidential? 
All information which is collected about you during the course of the research 
programme will be kept strictly confidential.  Any information about you which leaves 
the hospital will have your name and address removed so that you cannot be recognised 
from it. To protect your privacy, your sample and any medical information that is 
transferred to our collaborators, will be labelled (or “coded”) only with a study subject 
number, not your name. Only your doctor at the hospital and his or her staff will keep 
the link between your subject number and your name. In the event of any publication 
regarding this study, your identity will not be disclosed. 
 
Blood samples may be sent to third party service providers for specialised analyses or 
to collaborators in other Universities. In all instances, anonymity will be preserved and 
the samples will not be used for commercial purposes. 
 
What will happen to the results of the research study? 
It is intended that the data will be combined with data obtained using material from 
several different patients. We hope to publish the results so that as many of our findings 
as possible will be made available to the medical and scientific community. You will 
not be personally identified in any publication. Because of the exploratory nature of the 
work, none of the results will be provided to you or to the physicians who are treating 
you or may treat you in the future. The timing of any publication will depend mostly on 
the speed with which we collect the data and cannot be predicted with certainty. 
 
What happens if there is anything I do not understand? 
If there is anything you are not sure about, the Doctor will be happy to explain in more 
detail to yourself or your relatives, guardians (or legal representative if required). The 
study will be fully explained to you before you decide if you want to take part.  
 
Who has reviewed the study? 
This study has been checked and approved by the Clinical Research Ethics Committee 
of the Cork Teaching Hospitals, Lancaster Hall, 6 Little Hanover Street, Cork. 
 
Professor Ted Dinan 
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Professor of Psychiatry, Cork University Hospital (CUH), and Alimentary 
Pharmabiotic Centre, University College Cork. 
 
 
Dr John Kelly, Lecturer in Psychiatry, University College Cork  
Telephone number: 021 4901224 
 
Informed Consent Form by subject for participation in a human intervention 
study 
 
Protocol Number:  APC045 
 
Patient Name:  ________________________________ 
 
Title of protocol: 
The gut microbiome in major depression and response to treatment 
 
Principal Investigator(s): 
Professor Ted Dinan (021-4901224) 
 
Participation in this study is voluntary and you may withdraw at any time for any 
reason. 
 
The research project and procedure associated with it have been fully explained to me. 
All experimental procedures have been identified and no guarantees have been given 
about the possible results. I have had the opportunity to ask questions concerning any 
and all aspects of the project and any procedures involved. I am aware that participation 
is voluntary and I may withdraw my consent at any time. I am aware that my decision 
not to participate or to withdraw will not restrict my access to heath care services 
normally available to me. Confidentiality of records concerning my involvement in this 
project will be maintained in an appropriate manner. I understand that the investigators 
have such insurance as is required by law in the event of injury resulting form this 
research. 
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I, the undersigned, hereby consent to participation as a subject in the above described 
project conducted at Cork University Hospital, Mercy University Hospital and 
University College Cork.  
 
I have received a copy of this consent form for my records. 
I understand that if I have any questions concerning this research, I can contact the 
Doctor listed below. 
 
If I have further queries concerning my rights in connection with the research, I can 
contact the Clinical Research Ethics Committee of the Cork Teaching Hospitals, 
Lancaster Hall, 6 Little Hanover Street, Cork. 
 
After reading the entire consent form, if you have no further questions about giving 
consent, please sign where indicated. 
 
Informed Consent Form by subject for participation in a human intervention 
study 
 
Name (Block letters):_________________ 
 
 
Subject’s Signature:__________________  Date:_____________ 
        dd.mm.yy 
 
 
Name (Block letters):_________________ 
 
 
Investigator’s Signature:_______________  Date;______________ 
        dd.mm.yy 
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SUBJECT INFORMATION SHEET 
 
Study Title: The effect of probiotics on stress and cognition. 
 
Protocol No.:   APC057 
 
Principal Investigator: Professor Ted Dinan 
                                                 
Co-Investigators:  Professor John Cryan, Professor Paul Ross,  
Professor Catherine Stanton, Prof Geraldine Boylan 
Dr Gerard Clarke, Dr Paul Kennedy  
Dr Andrew Allen, Dr Fahmi Ismail, Dr John Kelly 
  
Site of Investigation:             Cork University Hospital, 
Wilton, Cork. 
 
Brookfield Health Sciences Complex, Human Nutrition Studies Unit and Alimentary 
Pharmabiotic Centre, 
University College Cork, Cork.  
 
Alimentary Pharmabiotic Centre, UCC  
 
Why is this study being run?  
You are invited to participate in a research study to determine how the consumption of 
probiotics influences cognitive function and stress in healthy individuals. This study 
will also assess the role that the immune system plays in the effect of probiotics on 
cognitive function and stress, as well as the role of recent and early life traumatic 
experiences and sleep patterns.  
 
Study procedures 
This study will involve up to 20 – 30 healthy subjects, aged between 18 and 40 years.  
In total, participation will involve five main study visits, including one screening visit 
prior to the first main study visit. If you agree to participate in the study you will first 
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be asked to visit the Alimentary Pharmabiotic Centre UCC for a short screening visit 
lasting around one hour. You will be asked to visit the study site for collection of blood 
and will be asked to provide saliva and stool samples at home. You will be provided 
with probiotic or placebo capsules but you will not be aware of which capsule you are 
receiving. You will be required to take the capsule once a day every day for four weeks. 
At the end of the four-week period you will return for another study visit, this time 
looking at cognitive performance with EEG measures. You will then complete another 
period of consuming the probiotic/placebo capsule, which will be followed by another 
cognitive performance/EEG test.  
 
Screening Visit Outline 
You will be advised of the purpose of the study and the procedures which will be 
undertaken. You will be given a copy of the Subject Information Sheet, which will 
explain what is required from you. If interested, you will then be requested to read and 
sign the Informed Consent form, and receive a signed copy. 
 
You will be asked some general questions concerning your health and personal details, 
including your medical history, your family medical history and current medical status. 
Details of your current and/or past medications will also be collected. Your height and 
weight will be taken to determine your body mass index (BMI). You will be asked to 
complete questionnaires regarding recent and early life traumatic experiences, general 
stress levels and how you respond to stress, your general health and activity levels, 
sleeping habits, diet and current levels of depression and anxiety. You will complete a 
brief verbal IQ test. In addition, you will be given containers to collect saliva and stool 
samples to bring along to the later visits, and specific instructions on how to collect 
these samples. 
 
Pre-supplementation visit outline 
You will be asked to bring a stool sample to this visit. You will fill in a number of 
questionnaires assessing stress, anxiety and depression, as well as sleep disturbances, 
and gastrointestinal symptoms. Five venous blood samples (10mls each) will be 
obtained and assessed for levels of tryptophan (an amino acid) and immune system 
measurements in the blood. During the collection of blood samples, you may 
experience a slight scratch, which may be uncomfortable for a moment but quickly 
passes. Probiotic or placebo capsules will be provided, with instructions for when to 
take them.  
 
Baseline cognitive performance 
You will visit the research centre for assessment of cognitive performance. You will be 
asked to refrain from strenuous exercise and alcohol for 24 hours prior to the 
experimental session and from caffeine for two hours prior to testing. Sensors will be 
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attached to the scalp to measure brain activity (EEG). During this visit you will 
complete a handedness scale and a number of cognitive tests using a touch screen 
computer apparatus. 
 
Supplementation phase 
During this period you will be required to take the capsule once a day, every day for 
four weeks. You are requested not to make any major changes to your diet during this 
phase, and to avoid taking any probiotics or antibiotics.  
Pre-experimental Day Outline 
On the morning of this day you will be required to take a number of saliva samples 
after awakening. You will be asked to provide these saliva samples, as well as stool 
samples at this visit. The stool samples are taken to ensure that probiotics have entered 
the digestive system in the probiotic condition. A blood sample will also be obtained 
during this visit, to assess effects of the probiotic supplementation on tryptophan and 
immune factors.  
 
Experimental Study Day Outline: Cognitive performance 
At the end of the supplementation phase, you will visit the research centre for 
assessment of cognitive performance, similar to the baseline cognitive performance 
visit.  
 
Second supplementation phase 
This will follow the same procedure as the first supplementation phase; you will be 
consuming the capsule you did not consume during the first consumption phase. 
 
Cognitive performance test 
At the end of the second supplementation phase you will complete one more 
assessment of cognitive performance and EEG as before. 
 
What happens if I start the study and change my mind later?   
You do not have to take part in the study, participation is entirely voluntary. Refusal to 
participate, or discontinuing participation at any time, will involve no penalty, loss of 
benefits or denial of treatment or services by the Cork Teaching Hospital or the 
participating doctor. 
Will I experience any unpleasant side effects?    
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During the collection of your blood sample, you may experience a slight scratch, which 
may be uncomfortable for a moment but quickly passes.  
 
Funding of trial 
There are no cost implications for the Health Board or to you. The management of 
patients and investigative tests will comply with current standards of care. Cost of 
research tests will be incurred by the Alimentary Pharmabiotic Centre, University 
College Cork. Upon completion of the study, you will receive €200 on completion of 
the study to cover your costs and expenses.  
 
Confidentiality  
All the information gathered from this study will be stored on a computer and paper 
files and will be treated confidentially. You will be identified only by a subject number. 
In the event of any publication regarding this study, your identity will not be disclosed.  
 
What happens if there is anything I do not understand?   
The study will be fully explained to you before you decide if you want to take part. If 
there is anything you are not sure about, the investigators will be happy to explain in 
more detail. If you have any problems or questions after the study has started you may 
call: 
 
Dr John Kelly 
GF Unit        
Cork University Hospital                                       
Wilton Cork                                       
Telephone Number:  +353 (0)21 4901224 
 
Professor Ted Dinan                                                     
GF Unit        
Cork University Hospital                                       
Wilton Cork                                      
Telephone Number:  +353 (0)21 4901224 
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CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH PROTOCOL 
           Section A 
Protocol Number:                  Patient Name:   
  
 
 Title of Protocol: The effects of probiotics on stress and cognition 
       
Doctor(s) Directing Research:  Professor Ted Dinan   Phone: +353(0)21 
4901224                                   Dr John Kelly    Phone: 
+353(0)21 4901224                                  
     
 
You are being asked to participate in a research study. The doctors at University College Cork 
study the nature of disease and attempt to develop improved methods of diagnosis and 
treatment. In order to decide whether or not you want to be a part of this research study, you 
should understand enough about its risks and benefits to make an informed judgment. This 
process is known as informed consent. This consent form gives detailed information about the 
research study, which will be discussed with you.  Once you understand the study, you will be 
asked to sign this form if you wish to participate. 
Section B 
I. NATURE AND DURATION OF PROCEDURE(S): Studies suggest that probiotics are 
associated with reduced stress and improved cognitive function, but few have actually 
investigated physiological factors associated with cognitive performance and stress. We 
hypothesise that probiotic consumption will lead to effects on physiological measurements of 
the stress response system and changes in cognitive functioning. By carrying out a clinical 
assessment of factors such as early life trauma and sleep quality we can further characterize 
the role these factors may play in the stress response and their relationship to cognitive 
functioning following probiotic administration. Understanding the interactions between probiotic 
consumption, the physiological response to stress and the subsequent effects on cognitive 
functioning may potentially aid in developing new products which can aid in the reduction of 
stress and the improvement of cognitive function. 
 
II. POTENTIAL RISKS AND BENEFITS: 
1. Collection of blood samples (in amounts not exceeding 50 millilitres - 4 tablespoons) by 
venipuncture might cause hematoma, a bruise at the site of vein puncture, inflammation of the 
vein and possible infection. Care will be taken to avoid these complications.  
2. While there is no immediate direct benefit to you from this study, more research like this 
may ultimately lead to new treatments for stress. 
 
III. POSSIBLE ALTERNATIVES: 
 You may choose not to participate, or participate voluntarily. 
 
Confidentiality and Anonymisation  
Your medical history will be used in the research. To preserve confidentiality, full 
anonymisation applies to all participants. Your personal data will be stored, processed and 
analysed in a form that does not allow individuals to be identified. Identifiable data (name, 
address) should only be accessible to staff who have a formal duty of confidence to the 
participant. 
 
Section C                                                                    AGREEMENT TO CONSENT 
The research project and the treatment procedures associated with it have been fully explained 
to me.  All experimental procedures have been identified and no guarantee has been given about 
the possible results.  I have had the opportunity to ask questions concerning any and all aspects 
of the project and any procedures involved.  I am aware that participation is voluntary and that 
I may withdraw my consent at any time.  I am aware that my decision not to participate or to 
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withdraw will not restrict my access to health care services normally available to me.  
Confidentiality of records concerning my involvement in this project will be maintained in an 
appropriate manner.  When required by law, the records of this research may be reviewed by 
government agencies and sponsors of the research. 
 I understand that the sponsors and investigators have such insurance as is required by law in 
the event of injury resulting from this research. 
 I, the undersigned, hereby consent to participate as a subject in the above described project 
conducted at the Cork Teaching Hospitals.  I have received a copy of this consent form for my 
records.  I understand that if I have any questions concerning this research, I can contact the 
doctor(s) listed above.  If I have further queries concerning my rights in connection with the 
research, I can contact the Clinical Research Ethics Committee of the Cork Teaching Hospitals, 
Lancaster Hall, 6 Little Hanover Street, Cork. 
 After reading the entire consent form, if you have no further questions about giving consent, 
please sign where indicated. 
 
 
 
Subject’s Signature: ________________________  Date: __________________ 
        dd          mm    yy                        
NAME (BLOCK LETTERS):  ________________   Time: 
__________________         
 
Investigator’s Signature:  ____________________ Date: __________________ 
        dd          mm    yy     
NAME (BLOCK LETTERS)  _________________ 
        
 
 
 
 
 
 
 
 
 
